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Abstract
Hepatitis C virus (HCV) is a medically important RNA virus in the Flaviviridae family. It persists in
chronically infected individuals by replicating in hepatocytes and by evolving as a genetically diverse
"quasispecies" that evades host immune pressures. However, transmission, with its attendant population
bottlenecking, represents a period of relative vulnerability and is of particular importance with respect to viral
natural history, immunopathogenesis, treatment intervention, and vaccine development. A precise molecular
characterization of HCV transmission and early diversification has not previously been possible. In this
dissertation work, it was hypothesized that HCV genomes that are transmitted from one individual to the next
giving rise to productive clinical infection (termed transmitted/founder or T/F genomes) could be
unambiguously identified by single genome sequencing (SGS), mathematical modeling, and phylogenetic
inference. This hypothesis was tested in cohorts of acutely infected human subjects with community acquired
HCV infection and in human-to-human and human-to-chimpanzee HCV transmission pairs. The resulting
data showed that HCV transmission was generally associated with a stringent population bottleneck and that
early virus evolution was characterized by diversification of discrete, low diversity sequence lineages. These
findings enabled an unambiguous phylogenetic inference of T/F genomes, a precise characterization of early
molecular pathways of viral sequence evolution, and a refined estimate of the in vivo mutation rate of HCV,
which was at least 5-fold lower than previously reported. These efforts further allowed for the molecular
identification, cloning, and analysis of full-length T/F viral genomes, which like most HCV clones, were
restricted in their in vitro replication capacity. Altogether, our findings provide a substantially enhanced
molecular view of HCV transmission and early diversification in natural human infection and illustrate a novel
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MOLECULAR CHARACTERIZATION OF THE TRANSMISSION AND EARLY 
DIVERSIFICATION OF HCV 
Mark B. Stoddard 
George M. Shaw 
 Hepatitis C virus (HCV) is a medically important RNA virus in the Flaviviridae family. It 
persists in chronically infected individuals by replicating in hepatocytes and by evolving as a 
genetically diverse "quasispecies" that evades host immune pressures. However, transmission, 
with its attendant population bottlenecking, represents a period of relative vulnerability and is of 
particular importance with respect to viral natural history, immunopathogenesis, treatment 
intervention, and vaccine development. A precise molecular characterization of HCV transmission 
and early diversification has not previously been possible. In this dissertation work, it was 
hypothesized that HCV genomes that are transmitted from one individual to the next giving rise to 
productive clinical infection (termed transmitted/founder or T/F genomes) could be 
unambiguously identified by single genome sequencing (SGS), mathematical modeling, and 
phylogenetic inference. This hypothesis was tested in cohorts of acutely infected human subjects 
with community acquired HCV infection and in human-to-human and human-to-chimpanzee HCV 
transmission pairs. The resulting data showed that HCV transmission was generally associated 
with a stringent population bottleneck and that early virus evolution was characterized by 
diversification of discrete, low diversity sequence lineages. These findings enabled an 
unambiguous phylogenetic inference of T/F genomes, a precise characterization of early 
molecular pathways of viral sequence evolution, and a refined estimate of the in vivo mutation 
rate of HCV, which was at least 5-fold lower than previously reported. These efforts further 
allowed for the molecular identification, cloning, and analysis of full-length T/F viral genomes, 
which like most HCV clones, were restricted in their in vitro replication capacity. Altogether, our 
findings provide a substantially enhanced molecular view of HCV transmission and early 
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diversification in natural human infection and illustrate a novel experimental approach to the 
proteome-wide analysis of HCV that may aid future vaccine development efforts. 
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CHAPTER 1: OVERVIEW OF HEPATITIS C VIRUS TRANSMISSION AND EARLY 
PATHOGENESIS 
 
Mark B. Stoddard 
 






The Importance of Understanding HCV Transmission and Diversification 
Hepatitis C virus (HCV) is a non-segmented, single-stranded, positive-sense RNA virus in the 
Flaviviridiae family (161) and is of substantial medical importance. An estimated 2% - 3% of the 
world population is chronically infected with HCV, and it is a major cause of hepatitis, cirrhosis, 
liver failure leading to transplantation, and hepatocellular carcinoma (8, 235). Most individuals 
who are acutely infected with HCV will fail to clear the virus and go on to become chronically 
infected (190). HCV demonstrates high genetic diversity at a global level, with at least seven 
major genotypes differing by 30% at the nucleotide level (279). Within chronically infected 
individuals, the virus persists as a swarm of related but genetically distinct viruses termed a 
“quasispecies” capable of swiftly evolving in response to selective pressures (228). 
Despite infecting approximately 150 million people worldwide, the global burden of HCV infection 
represents a largely "silent epidemic" (139), in part because acute infection is generally 
asymptomatic and morbidity and mortality arise only after years of infection (235). However, 
greater social awareness to HCV infection has begun to develop as HCV has surpassed HIV as a 
cause of death in the United States (172) and as advances in therapy have greatly altered the 
prospects for HCV infected individuals (240). Within the last five years the release of first-in-class 
anti-HCV direct acting antivirals (DAAs) (9, 117), the testing and release of more-broadly active 
and effective generations of DAAs (116), and the first successful efforts to develop highly-
tolerable, all-oral antiviral treatment regimens (292) have been achieved. 
Despite these therapeutic successes, major obstacles to the eradication of HCV remain: an 
effective vaccine is not available despite substantial efforts (159, 291), and current therapeutics 
are not likely to be cost effective beyond wealthy nations with advanced medical systems (240). 
Historical attempts to prevent or eradicate other infectious diseases emphasize the importance of 
understanding disease transmission and the early phases of infection for developing and 
deploying effective treatment and prevention strategies. For example, studies of therapeutic 
intervention during the early phases of hepatitis A, B, and C infection indicate this a period of 
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relative vulnerability and prophylactic antiviral therapy is a highly effective mainstay of treatment 
for needle stick injuries or other exposures (331). Successful programs to eradicate infectious 
diseases, such as small pox or rinderpest, have relied on broadly available approaches (e.g., 
vaccines) that target the transmission event (132). Therefore, a strong argument can still be 
made for studying HCV transmission and early diversification despite recent therapeutic 
advances. 
 One important area of investigation is in characterizing the "bottleneck," or viral 
population restriction, associated with transmission (32, 34, 48, 104, 162, 229, 325). While the 
quasispecies nature of HCV in chronic infection is well described (71), less is known about 
molecular features of virus transmission and subsequent virus evolution prior to the onset of the 
immune response. Previous studies of HCV transmission and early evolution generally used 
qualitative or semi-quantitative methodologies including heteroduplex mobility assays (148, 166), 
bulk PCR amplification and cloning (104, 142, 164, 234, 285, 309, 311), and 454/Roche 
pyrosequencing (32, 325). Data regarding the stringency of the transmission bottleneck and the 
genetic composition and complexity of transmitted and early evolving sequences has been 
conflicting and largely dependant on the methodologies used. For example, studies relying on 
heteroduplex assays were qualitative at best and described what appeared to be quasispecies 
complexity even in acute infection (148, 166). Other approaches using PCR to bulk amplify HCV 
sequences, with or without prior cloning, lead to a homogenization of sequences reported, either 
because of the poor sensitivity of bulk sequencing, the error prone nature of Taq polymerase, or 
the artifactual template switching in vitro that is associated with Taq polymerization. The most 
precise analysis of acute infection sequences was performed using next generation deep 
sequencing with these studies suggested a very limited number of founder genomes spawned 
new infections but they were limited to few subjects studied by non-SGS approaches (32, 325). 
The evolution of HCV genomes immediately after transmission and before the onset of the 
adaptive immune response has also been characterized imprecisely, leading to strikingly different 
interpretations. Reversion towards prototypical (142, 164, 234) or actual (311) replication 
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competent genomes, early rapid shifts in the dominance of transmitted lineages, and the random 
accumulation of mutations (32, 325) have been variously described as major factors affecting 
early HCV evolution. The most definitive description of reversion towards a more robust genotype 
was described by Timm and colleagues where they characterized a case of transmission from a 
HLA-B8 positive to a HLA-B8 negative subject that resulted in reversion of epitopes associated 
with escape in the donor (311). Other studies that describe the accumulation of “reversion” 
mutations describe this as reversion towards genotype consensus sequences (such as towards 
the genotype 1b Con1 sequence), but were not able to show a mechanism for this activity (142, 
164, 234). Rapid shifts in the dominance of lineages after infection have been described by a few 
reports and were typified by complete turnover of lineages in as little as 7 to 30 days (285, 309). 
This was hypothesized to be due to different interactions with the host innate immunity (285) or 
compartmentalization (310) but alternative explanations for these findings including frequent 
reinfection or superinfection of the studied subjects were suggested by other authors (320). 
Random accumulation of mutations proposes that with the exception of purifying selection (which 
removes lethal or strongly attenuating mutations from the viral population) that other mutations 
accrue in an essentially random fashion throughout the genome (32, 325). 
A novel way to analyze the transmission bottleneck and early evolution of HCV would be to adapt 
Single Genome Sequencing (SGS) strategies to generate accurate genetic information from 
recently infected subjects. SGS is an approach that combines limiting dilution PCR with stringent 
quality control and mathematical or phylogenetic analysis originally developed, and still widely 
used, in Human Immunodeficiency Virus type 1 (HIV-1) and Simian Immunodeficiency Virus 
(SIV) studies (82, 128, 151, 257). SGS is a powerful approach for multiple reasons. First, it is 
capable of distinguishing lineages by as little as a single nucleotide difference across ~5-9 kb 
genome fragments while accounting for PCR introduced artifacts (257). Second, the 
mathematical models developed for SGS studies of HIV have been empirically shown to permit 
the correct inference of the actual viral genomes responsible for transmission and founding the 
productive infection (termed Transmitted/Founder or T/F viruses) (129). Third, the mathematical 
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and phylogentic tools that support SGS make specific predictions (namely, that early mutations 
will accumulate according to a Poisson distribution and that star-like phylogenies will describe the 
intra-lineage relationships) that can be tested for validity before T/F sequence inferences are 
made (82, 151). Perhaps due to these advantages, SGS has been extensively used to study 
evolution, viral transmission, immunopathogenesis, and candidate vaccine development for HIV 
and SIV (11, 88, 154, 244, 245, 258, 289, 318). 
HIV-1 shares many features of its replication cycle and biology with HCV. These include a single 
stranded RNA genome, an error prone replication process, transmission via blood or sexual 
contact, the capacity produce large number of infectious virions on the plasma, and a natural 
history that involves rapid adaptation of a viral quasispecies to immune pressures (73, 84, 161, 
177, 209). Therefore, SGS might be expected to be a similarly enabling approach for studying 
HCV transmission and early evolution. However, adaptation of this approach would both be novel 
and would require substantial technical and theoretical efforts because of major differences in the 
HCV, genome organization, RNA structure, replication cycle, and replication machinery from HIV-
1. Therefore, the HCV replication cycle and as must be carefully considered and compared with 
HIV-1 for the potential impact of these differences on generating or interpreting SGS data. 
 
Features of the HCV Replication Cycle and Early Natural History Relevant to SGS 
Analysis and Modeling Viral Transmission and Early Evolution 
 There are many aspects of the HCV viral replication cycle that differs from the HIV-1 
replication cycle where the approach of SGS followed by mathematical modeling and 
phylogenetic inference were first developed. An overview of the HCV replication cycle and 
immune responses to viral infection in comparison with HIV-1 is discussed below with emphasis 
on elements that might be important for the adaptation of the HIV-1 models to HCV transmission 
and evolution. 
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 HCV is a blood-borne infection that is typically transmitted by IV drug abuse in developed 
nations and by unsafe medical procedures involving non-sterile equipment in developing 
countries (270, 327). It is transmitted sexually less commonly, although there are recent reports 
of an emerging “mini-epidemic” in men who have sex with men (MSM) (70, 319). Given these 
diverse routes of transmission, some of which could included substantial exposure to plasma and 
other bodily fluids, one might expect the virus inoculum to be large compared with that of HIV-1. 
 After HCV-containing material is introduced into a new host, HCV lipoviral particles 
(LVPs) are thought to circulate until binding and entering liver cells through interactions between 
proteins extruding from the LVP with target cell binding factors and receptors (5, 37, 224, 345). 
An exact quantification of how many HCV viral genomes may be contained per LVP has not been 
achieved, but measurements of viral RNA and proteins in comparison with host-derived proteins 
in LVPs suggest that these very rarely, if ever, contain more than one HCV genome (37). This is 
a major difference from HIV-1, where each infectious particle contains two complete genomes 
and both may contribute (via early recombination) to progeny produced from infected cells (36). 
 Following attachment, HCV is internalized via clathrin-mediated endocytosis, the 
endosome is acidified, the viral membrane fuses with the endosomal membrane in a pH-
dependent fashion, and the viral genome is released into the cytoplasm (111, 315). The infecting 
vRNA template is used to generate the first viral proteins by IRES-mediated translation initiation 
in the rough endoplasmic reticulum. The resulting polyprotein is processed by cellular and viral 
proteases yielding the canonical viral structural (Core, E1, E2) and non-structural (p7, NS2, NS3, 
NS4A/B, SN5A/B) proteins (161). These viral proteins will promote the formation of a 
“membranous web” intracellular structure closely associated with the endoplasmic reticulum 
where viral replication, coating, and biogenesis of the immature LVP occurs (247). The HCV 
genome itself is replicated through the activity of NS5B protein, an RNA-dependent RNA 
polymerase (RdRp). The intrinsic error rate of the HCV RdRp is thought to be high with previous 
estimates based on in vitro purified proteins approximating 1 x 10-3 errors per nucleotide (226) 
and an in vivo error rate estimated to be at 1.15 x 10-4 mutations per nucleotide per replication 
7	  
cycle (51). However, approximately 30 to 40% of mutations introduced by the RdRp would be 
expected to be lethal and would not contribute to the viral population diversity from generation to 
generation since the HCV genome very rarely undergoes recombination (259). The HCV RdRp 
generates minus strand genomes that accumulate and serve as the templates for the positive 
stranded RNAs; in turn positive strand RNAs are either packaged end exported or used to 
generate additional viral proteins and minus strand templates. Specifically, the negative strand 
templates are likely first generated during an initial phase of geometric growth (whereby newly 
generated positive strand RNAs are used to synthesize additional negative strand templates) that 
begins shortly after entry into the target cell and culminates in the generation of approximately 7 
to 64 replication complexes per cell (40, 230). Replication complexes consist of a negative strand 
genome with at the least the viral NS5B, SN5A, NS4B, and SN3 proteins in association (27). 
Following the generation of these replication complexes, a “stamping machine” model is likely 
favored whereby large numbers of positive strand RNA genomes are generated from a limited 
number of long-lived complexes (262, 263). Viral variation is ultimately introduced by the error-
prone RdRp (66); however, the accumulation of mutations in viral progeny is also affected by the 
balance of early phase geometric replication versus later phase “stamping machine” replication 
(186). In turn, additional factors might enhance the proportion of geometric replication of viral 
genomes including the high turnover of infected cells or replication complexes that may occur 
during robust adaptive or cell-intrinsic immune responses. All of these aspects of early and viral 
replication for HCV are substantially different from HIV-1 where, after integration as a provirus, 
vRNA generated from a relatively stable genomic DNA intermediate is used to generate viral 
mRNA, proteins, and genomes for packaging (73). The HIV-1 replication cycle does not involve 
continuously maintaining pool of (-) RNA cytosolic replication complexes that may switch 
between "stamping machine" or geometric phase replication with attendant alterations in mutation 
rates (73). 
 The next aspect of the HCV replication cycle, particle assembly and egress, is closely 
associated with cellular lipid metabolism and specifically VLDL secretion (5, 38, 78, 112, 188). 
8	  
The half-life of infectious LVPs in the serum is approximately 45 minutes, which is broadly similar 
to that of HIV (95, 143). The presence of neutralizing antibodies would represent an additional 
evolutionary pressure on the viral population by binding to LVP components necessary for 
maintaining infectivity. Direct cell-cell transmission has also been described for HCV and may be 
a major route of viral spread throughout the liver (333, 334). Direct cell-cell spread may be a 
means by which the virus can minimize exposure to neutralizing antibody activity (29). However, 
while this process would likely have an important effect on early viral diversification and evasion 
of immune pressures, it would not likely play a role in the transmission event to a naïve host. In 
summary, while the assembly and egress of HCV and HIV-1 is markedly different, the short half-
life of HCV, the cell-free nature of transmission, and susceptibility of some of the population of 
circulating virions to neutralizing antibodies is similar between HIV-1 and HCV (143). 
 A final aspect of the HCV replication cycle that could play an important role in 
transmission and early diversification of the virus is the non-cytolytic nature of HCV infection. 
Hepatocytes are long-lived cells with life spans ranging from 200 to 450 days in animal models 
(174, 176), and studies suggest that HCV infection may actually promote the survival of infected 
cells (179) despite the stresses imposed by viral replication (150, 199, 242). As a result, long-
lived infected hepatocytes containing stable replication complexes with a potentially slow rate of 
turnover would be expected to contribute to the viral population observed in the serum until 
sufficient time has passed for degradation and turnover of early replication complexes or the host 
has mounted a cytolytic immune response to the initially infected cells. This is substantially 
different from retroviruses, such as SIV, where infected cells have a half-life approximating 1 day 
(43). 
 The interaction between HCV and the host innate and adaptive immune system is 
another important factor affecting the evolution of the viral quasispecies and potentially the 
transmission and evolution of early viral genomes. The first pressure that the virus faces is the 
cell-intrinsic innate immune system (109). Specific viral pathogen-associated molecular patterns 
(PAMPS), such as the viral 5’ triphosphate and the 3’ poly(U/UC) tract, may be detected by host 
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factors including retinoic acid-inducible gene 1 (RIG-I) (256), Toll-like receptor 3 (256), and 
protein kinase R (7). In turn, HCV has evolved countermeasures to target these sensors, and the 
signaling cascades they elicit, for example through direct cleavage of the downstream signaling 
proteins TRIF and MAVS by NS3/4A (13). The consequence of the detection of viral PAMPs is 
that the host cell begins to manufacture anti-viral factors that promote synthesis of anti-viral 
genes and alert other uninfected cells to do the same. Factors intrinsic to the host innate 
response have been shown to have an impact on the outcome of infection and the response to 
medical therapy with interferons. Most notably, a favorable interferon lambda-3 (IFNL3 or IL28B) 
genotype strongly associates with both clearing the virus instead of progressing to chronic 
infection in the absence of therapy (13) and with responding well to interferon therapy during 
chronic infection (79, 294, 299). These immune forces exert evolutionary pressure on HCV and 
there is evidence that viral genetics (ie. genotype) makes an important contribution to how well 
the virus manages these forces. For example, HCV genotypes 1 and 4 are known to be 
comparatively more resistant to treatment with IFN therapy than genotypes 2 and 3 (107, 185, 
213, 266). Another genetic factor that may play an important role is the composition of the 
poly(U/UC) PAMP since differences in this region are known to yield antiviral responses of 
differing magnitudes (267). 
Natural killer (NK) cells are another arm of the innate response that may impact on viral evolution 
prior to the emergence of the adaptive immune response. Intriguingly, homozygosity for certain 
favorable NK receptor and cognate human leukocyte antigen genotypes promotes spontaneous 
resolution (130) and uninhibited expression of interferon gamma by naturally hyper-active NK 
cells appears to confer enhanced resistance to acute HCV infection (306). NK cells may also play 
a role in bridging the transition from an innate-immune predominated response to the adaptive 
response found later in the course of disease (214). The innate response, including cell-intrinsic 
immunity, is evidently capable of exerting substantial evolutionary pressure on replicating HCV 
genomes (13, 256, 267). However, this is less clearly the case for HIV-1, where spontaneous 
clearance due to IFN mediated responses, for example, have not been described (143). 
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Importantly, this suggests that very early population bottlenecking due to an increasingly 
exuberant innate responses might occur in the context of HCV infection and lead to early 
selective pressures, for example, on the poly(U/UC) PAMP structure, whereas this would not be 
expected for early HIV-1 diversification. 
 The antigen-specific adaptive immune response to HCV exerts a profound influence on 
the viral population with spontaneous clearance of the virus after acute infection achieved in one-
third of cases (190). Both the T-cell and B-cell responses typically arise in response to infection 
at 4 – 10 (190, 305) and 8 – 40 (167) weeks post infection, respectively, and generally coincide 
with spikes of liver alanine transaminases into the blood. This responses is delayed compared to 
HIV-1, for example the first T and B responses to infection for HIV-1 occurs in approximately 3 - 7 
(317) weeks and 2 - 4 (313) weeks respectively. This observation may be explained by defective 
T or B cell priming, blunting of the innate response, or preferential replication in the relatively 
tolerogenic liver environment (65, 272, 303). Regardless, these delayed mechanics suggest that 
it may be possible to track HCV evolution for slightly longer prior to the adaptive immune 
response than is the case for HIV-1. 
 There is strong evidence that the primary pressure associated with elimination of HCV is 
a potent, broad, sustained CD8 and CD4 T cell response (46, 191, 296, 305). Depletion of CD8 T 
cells in the chimpanzee model of HCV results in ablation of any acquired capacity to resist 
second challenges (274). CD8 T cells serve an effector role mediated by cytolytic activity and the 
secretion of IFN-gamma in close proximity to infected hepatocytes (120, 304). On the other hand, 
CD4 cells play a coordinating role. This is demonstratedin CD4 depletion studies where second 
challenges results in persistence of viral escape variants even in when the animal previously 
cleared the infection with an effective epitope-specific CD8 T cell responses (92). Emergence 
and fixation of T-cell resistant escape mutants is a key aspect of viral persistence (97). 
 The development of neutralizing antibodies appears to exert significant evolutionary 
pressure. The HCV glycoproteins E1 and E2 are particularly targeted since they are exposed to 
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host antibodies and neutralizing antibodies have been discovered in chronically infected patients 
that target E1 or E2 linear (206) and conformational epitopes (81). Because these proteins play a 
functional role in mediating entry, they must both contain conserved structural regions (85, 184, 
207) as well as “decoy” regions, such as hypervariable regions 1 and 2, that are tolerant to 
genetic variation (126) despite evolutionary pressures exerted by neutralizing antibodies (67, 68, 
323). Hypervariation in the E1 and E2 glycoproteins has been attributed to viral evasion of the 
antibody response (67, 164, 323) and the development of early neutralizing antibodies responses 
does appear to correlate with viral clearance (61, 205, 217). Neutralizing antibodies continue to 
play a role in chronic infection, as evidenced by an increase in viral load observed in patients 
treated with the anti-CD20 monoclonal rituximab (205), and the severity and progression of liver 
disease is worse in patients with hypogammaglobulinemia (20, 249) However, the role of the 
humoral response in clearing HCV infection does not appear to be absolutely critical since 
hypogammaglobulinemic individuals are nevertheless able to occasionally clear infection (44) 
and viral clearance has been reported in the absence of antibody seroconversion. 
The net combined pressures on the viral quasispecies in the form of innate immunity, neutralizing 
antibodies, and cell-mediated responses in the context of ineffective evasion by the virus likely 
explains why some individuals spontaneous resolve whereas others do not (233). In comparison 
with HIV-1, the innate response may exert an earlier and more potent selective pressure. On the 
other hand, the later B and T-cell adaptive responses appear to be similar between HCV and 
HIV-1 in that selective sweeps likely playing an important role on shaping the viral quasispecies 
for both these viruses (143, 282). 
 In summary, there are several aspects of the HCV replication cycle which differ 
substantially from the HIV-1 replication cycle and might need to be accounted for in the 
development of an SGS approach for analyzing HCV tranmission and early diverisification. These 
include differences in how viral genomes replicate and persist in infected cells and the degree to 
which cell intrinsic or innate responses might exert selective pressure on expanding viral 
populations. On the other hand, the interaction between the adaptive immune system and the 
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emerging and chronic viral quasispecies share similarities in that it is typified by sequential 
bottlenecks and the emergence and fixation of escape mutations. 
 In the studies described below, SGS was utilized to query serial samples from source 
plasma donors with community acquired HCV infection. The primary aim was to analyze the 
nature of the HCV transmission and early evolution, develop or adapt models to describe these 
events, and to study the properties of these founding viral genomes. The first hypothesis tested 
postulated that despite the differences in replication cycle and the expected impact of the innate 
response, that HCV diversification would generally fit a model of early random diversification 
similar to HIV-1 transmission. Figure 1.1 shows a general conceptual model of HCV transmission 
with early random diversification. Notably, this model predicts that the phylogeny of the early 
offspring of any T/F virus would be star-like, and that mutations would accumulate in the genome 
according to a Poisson distribution. After these initial studies produced promising results (ie. that 
diversification was sufficiently similar to permit adaptation of the HIV-1 models for the majority of 
transmission cases investigated), the SGS data was used to study the in vivo mutation rate. 
An additional study was pursued to empirically validate that prediction of HCV T/F viruses could 
be inferred was performed in human-to-human and human-to-chimpanzee paired transmission 
subjects. This study also further investigated a subset of cases that had been found to violate 
some of the mathematical and phylogenetic predictions important for the identification of T/F 
genomes. 
Finally, these efforts permitted the examination of a further hypothesis that SGS could be used to 
determine the sequences of complete HCV genomes. Molecular clones of these genomes were 
chemical synthesized and these unadapted, full-length T/F genomes were utilized to test key 
HCV in vitro systems for their capacity to support viral replication. Together, these studies 
illuminated key molecular aspects of the transmission and early evolution of HCV. These findings 
are relevant to the current understanding of HCV immunopathogenesis and natural history and 





Figure 1.1. Conceptual model of HCV transmission and diversification. Viral genomes are 
depicted as colored rectangles and blue or grey circles represent virions. Mutations are 
represented as colored tic marks on the genomes. Two genomes, a major and a minor lineage, 
are productively transmitted whereas other defective or poorly replication competent genomes 
are quickly extinguished. If the subject becomes chronically infected, the viral population will 
generally increase in diversity over time as it weathers adaptive immune sweeps and progress to 
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 A precise molecular identification of transmitted hepatitis C virus (HCV) genomes could 
illuminate key aspects of transmission biology, immunopathogenesis and natural history. We 
used single genome sequencing of 2,922 half or quarter genomes from plasma viral RNA to 
identify transmitted/founder (T/F) viruses in 17 subjects with acute community-acquired HCV 
infection. Sequences from 13 of 17 acute subjects, but none of 14 chronic controls, exhibited one 
or more discrete low diversity viral lineages. Sequences within each lineage generally revealed a 
star-like phylogeny of mutations that coalesced to unambiguous T/F viral genomes. Numbers of 
transmitted viruses leading to productive clinical infection were estimated to range from 1 to 37 or 
more (median = 4). Four acutely infected subjects showed a distinctly different pattern of virus 
diversity that deviated from a star-like phylogeny. In these cases, empirical analysis and 
mathematical modeling suggested high multiplicity virus transmission from individuals who 
themselves were acutely infected or had experienced a virus population bottleneck due to 
antiviral drug therapy. These results provide new quantitative and qualitative insights into HCV 
transmission, revealing for the first time virus-host interactions that successful vaccines or 
treatment interventions will need to overcome. Our findings further suggest a novel experimental 
strategy for identifying full-length T/F genomes for proteome-wide analyses of HCV biology and 




 Hepatitis C virus infects as many as 170 million people worldwide. Globally, there are 
seven major genotypes of HCV that differ by approximately 30% in nucleotide sequence. 
Importantly, the natural history of HCV infection is variable, ranging from spontaneous resolution 
to persistent viremia and chronic disease. Factors responsible for this variability in clinical 
outcome are unknown but likely involve a combination of viral and host determinants. To this end, 
a precise molecular identification of transmitted HCV genomes could illuminate key aspects of 
transmission biology, immunopathogenesis and natural history. We used single genome 
sequencing of plasma viral RNA to identify transmitted viral genomes and their progeny in 17 
subjects with acute infection. Numbers of transmitted viruses leading to productive clinical 
infection ranged from 1 to 37 or more (median = 4). Surprisingly, we found evidence of high 
multiplicity acute-to-acute HCV transmission in 3 of 17 subjects, which suggests that clinical 
transmission of HCV, like that of HIV-1, may be enhanced in early infection when virus titers are 
highest and neutralizing antibodies are absent. These results provide novel insight into HCV 
transmission and early virus diversification key to our understanding of virus natural history and 




 Hepatitis C virus (HCV) infects as many as 170 million people or nearly 3% of the world’s 
population. The virus causes a wide variety of pathologic outcomes, the most significant being 
chronic liver disease, cirrhosis and hepatocellular carcinoma, which is nearly always fatal. HCV 
infection is the leading indication for liver transplantation in the United States (235). 
 HCV is a positive strand, non-segmented, enveloped RNA virus of approximately 9.6 kb 
in length. The virus is classified in the genus Hepacivirus within the larger family of Flavivirus, 
which includes the human pathogens West Nile virus, yellow fever virus and dengue fever virus 
among others (161). A common feature among the Flaviviridae is their dependence on a virally-
encoded RNA-dependent RNA polymerase (RdRp) for replication (196). RdRp is error-prone, and 
HCV is notable for its extensive diversity within and among individuals. Globally, there are seven 
major genotypes of HCV that differ by approximately 30% in nucleotide sequence (198, 235, 
277). 
 The extraordinary diversity of HCV complicates studies of virus biology, pathogenesis 
and susceptibility to novel therapeutics. Clinically, the different HCV genotypes exhibit variable 
natural history and responsiveness to interferon, ribavirin and the newer direct acting antiviral 
(DAA) agents (107, 161, 213). HCV variation poses similar challenges to the development of 
effective vaccines and to the elucidation of viral immunopathogenesis (25, 198, 236, 344). It is of 
interest then that the extraordinary diversity of HCV is similar to that of HIV-1 and that a novel 
experimental strategy to identify transmitted/founder (T/F) HIV-1 genomes has led to new insights 
into virus transmission and persistence (2, 11, 88, 100, 128, 154, 210, 258). 
 Acute HCV infection isconventionally defined as the initial 6 months of infection and sets 
into motion virus-host interactions that to a large extent dictate the natural history of the disease 
(25, 32, 48, 67, 84, 104, 114, 142, 177, 209, 236, 285, 305, 309). Depending on viral genotype 
and host immunogenetic factors, most importantly IL28B alleles, a proportion of newly infected 
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individuals spontaneously controls or eliminates virus (10, 25, 130, 236, 307). A greater number 
can be cured if the infection is treated with interferon and ribavirin alone or in combination with 
DAA drugs (107, 117, 119, 225). Mechanistically, how this occurs is incompletely understood. 
From a vaccine perspective, the acute infection period is critical, since transmitted viruses are the 
obvious targets of a vaccine and early stages of infection when viral diversity is lowest represent 
a period when the virus may be most vulnerable to elimination by vaccine-elicited immune 
responses (110, 177). For all these reasons, there is considerable interest in the molecular 
features of the initial virus population ‘bottleneck’ associated with virus transmission and the 
subsequent pathways of virus evolution that lead to persistence (32, 48, 67, 84, 104, 114, 142, 
285, 302, 305, 326). 
 Previous reports have described different experimental approaches to the analysis of the 
HCV transmission bottleneck. These include studies that employed a DNA heteroduplex gel shift 
method to estimate viral diversity (166, 326), conventional polymerase chain reaction (PCR) 
methods to bulk amplify, sequence, or clone and sequence fragments of HCV genomes (48, 61, 
67, 104, 142, 164, 285, 302), and 454 pyrosequencing to interrogate early viral sequences more 
deeply but narrowly (32, 325). These reports documented a restriction in viral diversity associated 
with virus transmission, but despite the use of increasingly sensitive methods, a precise 
quantitative, molecular description of HCV transmission and early diversification has remained 
elusive. In the current study, we hypothesized that T/F HCV genomes could be identified 
unambiguously and their early pathways of diversification mapped precisely by single genome 
amplification (SGA) followed by direct amplicon sequencing, otherwise known as single genome 
sequencing (210), an approach we used previously to gain insight into HIV-1 transmission (128, 
258). This strategy differs from previous methods applied to HCV by providing gene-wide or 
genome-wide viral sequences that are proportional to their representation in human plasma and 
are not confounded by template resampling or by Taq polymerase errors of nucleotide 
misincorporation or recombination (129, 165, 189, 210, 258, 275, 278). We amplified and 
sequenced HCV core, E1, E2, P7, NS2 and NS3 genes and analyzed them by adapting a model 
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of random HIV-1 evolution (82, 128, 151) to account for differences in the biology of replication 
between the HIV-1 and HCV. In an accompanying report, Ribeiro and colleagues (238) used 
these sequences together with plasma viral load kinetic data to develop an agent based 
stochastic model of acute HCV replication dynamics resulting in new estimates of the HCV 




 Study subjects, viral load measurements and single genome sequencing. One 
hundred fifty-four plasma specimens from 17 subjects with acute HCV infection and 14 subjects 
with chronic HCV infection were analyzed for viral RNA (vRNA) load (Figure 2.1; Table 2.1). 
Acute infection subjects were source plasma donors who had undergone once or twice weekly 
plasmapheresis for months, and in some cases years, with persistently negative testing for HCV, 
HBV and HIV antibody or RNA before becoming acutely infected by HCV. Chronically infected 
subjects were patients at the University of Alabama at Birmingham who were known to have been 
HCV infected for approximately 3 to >20 years. All subjects were untreated with anti-HCV 
medications. A median of 8 (range 5–11) sequential specimens per acutely infected subject was 
analyzed for vRNA load spanning the period of plasma vRNA negativity through exponential 
increase to an early plateau (Figure 2.1), and a subset of these was analyzed for sequence 
diversity. The median peak plasma viral load in acute infection subjects was 2,850,000 IU/ml 
(range = 527,000–10,300,000 IU/ml). Five of 17 acutely infected subjects developed HCV 
antibodies by the last sampling time point. Chronic subjects had a median vRNA load of 
2,081,138 IU/ml (range = 24,000–7,690,001 IU/ml), all were HCV antibody positive, and all were 
sampled once for vRNA sequence diversity. A total of 2003 5' half genomes and 919 5' quarter 





Figure 2.1. HCV plasma viral RNA kinetics in acute infection subjects. Plasma vRNA was 
quantified by Roche COBAS AmpliPrep/Taqman HCV assay. Circled values indicate samples 
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Table 2.1. Diversity analysis of HCV 5' half genome sequences from 14 chronically infected 
subjects. 





Viral load (IU/ml) 
 
Genotype 




Range of  
diversity 
WIMI4025 10/3/08 7,690,001 1a 36 4887 1.21% 0.12 - 3.83% 
SLRO5563 9/16/09 1,000,000 1a 29 4902 0.63% 0.24 - 3.22% 
KNPH3730 4/22/09 1,300,000 1a 13 4887 0.82% 0.12 - 2.01% 
ROMI6847 9/2/08 1,444,000 1a 18 4902 0.94% 0.08 - 1.31% 
BLMI6862 10/3/08 1,830,000 1a 22 4880 0.59% 0.08 - 2.50% 
BRRO6924 7/9/09 2,400,000 1b 35 4904 0.55% 0.08 - 2.96% 
ARJA6267 3/19/09 4,000,000 1a 43 4875 0.64% 0.06 - 2.46% 
WEPA5774 5/11/09 6,400,000 1a 44 4902 2.41% 0.10 - 3.00% 
WHRO3882 11/2/05 146,000 1a 22 4889 0.33% 0.12 - 1.01% 
JOTO6422 7/31/07 2,850,000 1a 21 4887 1.38% 0.24 - 2.27% 
RUVI5913 10/10/08 1,870,000 1b 29 4902 1.37% 0.14 - 3.00% 
LAST90001 1/25/11 24,000 1a 19 4839 0.23% 0.08 - 1.49% 
GOTO90002 1/25/11 2,435,764 1b 20 4842 0.29% 0.12 - 0.56% 






   
Range 
 
24,000 - 7,690,001 
 
13-44 
   !!
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 Phylogenetic analysis of acute and chronic sequences. Sequences corresponding to 
core antigen and envelope E1 and E2 genes (2.2 kb) from the initial HCV RNA positive sample 
from acute and chronic subjects were subjected to maximum-likelihood (ML) phylogenetic 
analysis (Figure 2.2). Sequences formed subject- specific clades (bootstraps 93–100%) and 
represented HCV genotypes 1a (n=23), 1b (n=4), 2b (n=2) or 3a (n=2). No subject was infected 
by more than one virus genotype and there was no intermixing of sequences between subjects in 
the phylogenetic tree. Sequences from acute and chronic subjects revealed widely varying 
degrees of maximum within-subject diversity ranging from 0.14% to 6.40% (Tables 2.1 and 2.2), 
which was not different between the two groups (p>0.05, Mann-Whitney test). Acute sequences 
were, however, distinctly different from chronic sequences in having one or more discrete 
lineages characterized by extremely low diversity. This was true for sequences from each acutely 
infected subject but from none of the chronically infected subjects. Maximum diversity of 
sequences within these discrete viral lineages from acute subjects (mean 0.12%; median 0.12%; 
range 0.04–0.19%) was significantly lower than the overall diversity observed within chronic 
subjects (mean 2.27%; median 2.37%; range 0.56–3.83%; p<0.0001, unpaired T-test with 
Welch’s correction) (Figure 2.3). 
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 Figure 2.2 Maximum-likelihood tree (ML) of HCV sequences from acute and chronic 
infection subjects. 5' quarter 1 genomesequences (core, E1, E2) from acute (red) and chronic 
(blue) subjects are shown along with HCV genotype 1 to 7 reference sequences (gray). Bootstrap 
values represent 100 repetitions in this and subsequent figures. The horizontal scale bar 
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Table 2.2. Diversity and mutation analyses of HCV sequences in acute infection. 




































































10021 1998 1a 5q1, 5q2, 5h 4878 151 1 0.14 v1 151 0.14 0.000000 0.000002 0.000003 0.000079 0.000052 0.000007 0.000137 0.326129 31/24 0.735/0.562 Y/Y 
10051 1998 1b 5q1, 5q2, 5h 4863 303 1 0.19 v1 303 0.19 0.000003 0.000002 0.000001 0.000056 0.000035 0.000007 0.000098 0.557751 46/45 0.237/0.601 Y/Y 
10025 1994 1a 5q1, 5q2, 5h 4881 175 1 0.16 v1 175 0.16 0.000002 0.000003 0.000000 0.000089 0.000075 0.000018 0.000182 0.687757 40/43 0.758/0.270 Y/Y 
10024 1994 1a 5q1, 5q2, 5h 4881 222 6 1.35 v1 212 0.12 0.000001 0.000004 0.000000 0.000063 0.000028 0.000008 0.000098 0.414301 37/68 0.390/0.898 Y/Y 
10012 1998 1a 5q1, 5q2, 5h 4881 230 3 3.34 v1 96 0.12 0.000000 0.000000 0.000000 0.000061 0.000061 0.000019 0.000141 0.322564 13/26 0.867/0.890 Y/Y 
        
v2 96 0.14 0.000000 0.000006 0.000000 0.000075 0.000054 0.000015 0.000143 0.307586 34/20 0.916/0.870 Y/Y 
        
v3 38 0.12 0.000006 0.000000 0.000006 0.000115 0.000048 0.000012 0.000175 0.166389 5/3 0.794/0.563 Y/Y 
10029 1998 1a 5q1, 5q2, 5h 4875 322 9 3.08 v1 241 0.18 0.000000 0.000002 0.000000 0.000083 0.000057 0.000016 0.000156 0.413231 55/38 0.584/0.283 Y/Y 
        
v2 19 0.10 0.000000 0.000000 0.000000 0.000096 0.000055 0.000000 0.000151 0.401201 4
d
 0.59 Y 
        
v5 18 0.06 0.000000 0.000000 0.000000 0.000050 0.000037 0.000012 0.000099 0.166901 4
d
 0.59 Y 
        
v6 11 0.04 0.000015 0.000015 0.000000 0.000075 0.000015 0.000000 0.000090 0.067286 5
d
 0.612 Y 
        
v8 13 0.12 0.000000 0.000000 0.000000 0.000132 0.000066 0.000016 0.000214 0.534788 4
d
 0.64 Y 
10062 1996 1a 5q1, 5q2, 5h 4857 188 3 0.80 v1 163 0.16 0.000001 0.000000 0.000000 0.000046 0.000051 0.000019 0.000116 0.356217 19/19 0.801/0.598 Y/Y 
        
v2 20 0.06 0.000000 0.000000 0.000000 0.000024 0.000036 0.000012 0.000073 1.665695 5
d
 0.852 Y 
10017 1993 1a 5q1, 5q2, 5h 4887 249 4 1.39 v1 220 0.16 0.000003 0.000009 0.000001 0.000078 0.000062 0.000016 0.000156 0.428199 30/21 0.536/0.879 Y/Y 
        









6213 1992 1a 5h 4905 41 3 6.40 v1 31 0.14 0.000000 0.000033 0.000000 0.000118 0.000039 0.000026 0.000184 0.238436 31 0.93 Y 
        
v3 9 0.08 0.000000 0.000000 0.000000 0.000113 0.000045 0.000023 0.000181 0.329702 9 0.668 Y 
6222 1992 1a 5h 4902 17 4 0.59 v1 7 0.10 0.000000 0.000000 0.000000 0.000058 0.000117 0.000117 0.000291 0.774175 7 0.753 Y 
10020 1998 1a 5q1, 5h 4905 122 10 0.27 all 122 N/A
g
 N/A N/A N/A N/A N/A N/A N/A N/A 57 0.0494 N 
        
06.QB18
f
 27 0.12 0.000000 0.000000 0.000000 0.000060 0.000048 0.000012 0.000120 0.148288 18 0.65 Y 
10002 1994 1a 5h 4905 31 13 3.12 v5 5 0.08 0.000000 0.000000 0.000000 0.000122 0.000163 0.000000 0.000285 0.249986 5 0.232 Y 
10004 1998 2b 5q1 2802 36 3 4.39 v1 16 0.11 0.000000 0.000000 0.000000 0.000156 0.000022 0.000000 0.000178 0.039859 16 0.65 Y 
        
v2 11 0.11 0.000000 0.000000 0.000000 0.000065 0.000032 0.000000 0.000097 0.639207 11 0.662 Y 
        
v3 9 0.14 0.000000 0.000000 0.000000 0.000119 0.000119 0.000000 0.000238 1.593102 9 0.837 Y 
10016 1998 2b 5q1 2804 72 15 0.36 all 72 N/A N/A N/A N/A N/A N/A N/A N/A N/A 53 0.001 N 
        
10.QE4
f
 10 0.18 0.000000 0.000000 0.000000 0.000214 0.000071 0.000036 0.000321 0.253774 8 0.873 Y 
9055 1998 3a 5h 4911 157 1 0.18 v1 157 0.18 0.000000 0.000001 0.000000 0.000082 0.000061 0.000019 0.000162 0.407277 44 0.23 Y 
10003 1998 3a 5h 4911 133 37 0.41 all 134 N/A N/A N/A N/A N/A N/A N/A N/A N/A 121 0 N 
        
07NA5
f
 10 0.14 0.000000 0.000020 0.000000 0.000102 0.000143 0.000081 0.000326 0.468484 7 0.166 Y 
        
07B13
f
 11 0.10 0.000000 0.000000 0.000000 0.000074 0.000130 0.000000 0.000204 0.273291 10 0.94 Y 
106889 2008 1a 5h 4902 87 >30 1.02 all 87 N/A N/A N/A N/A N/A N/A N/A N/A N/A 87 0 N 
        
5.B.F9
f
 10 0.06 0.000000 0.000000 0.000000 0.000061 0.000000 0.000041 0.000102 0.220469 10 0.815 Y 
        
5.02C22
f




          
0.000001 0.000003 0.000001 0.000075 0.000053 0.000014 0.000143 0.392939 
   
Median 
    
151 4 0.80 
  
0.12 
           a 5h - 5' half genome contains core, E1, E2, p7, NS2, and NS3;  5q1- 5' quarter 1 genome contains core, E1, E2, p7 and partial NS2;  5q2 - 5' quarter 2 genome contains partial NS2 and NS3. 
b
 Rate calculations were derived from sequences from each discrete transmitted/founder lineage.  
c
 Sequences from 1st sampled time point with ! 4 sequences per lineage were analyzed. If 5' half genomes were not available, quarter genomes 1 and 2 were analyzed with each result shown. 
d
 Sequences from 2nd sampled time point were analyzed due to insufficient number of sequences or sequence diversity from 1st sampled time point. 
e
 Insufficient numbers of sequences from each time point to calculate fit to Poisson or star-like phylogeny. 
f 
Transmitted/founder lineage identified by this sequence in respective ML tree and Highlighter plot. 
g
 N/A, not applicable due to multiple transmitted/founder virus genome. 
h
 Averages were calculated from total mutations in all transmitted/founder lineages from all subjects combined. Because of low numbers of sequences and mutations in some lineages, certain values (e.g. dN/dS for subjects 10062 v2 and 10004 v3) vary substantially from 
the mean. 
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a 5h - 5' half genome 
b Rate calculations were derived from sequences from each discrete transmitted/founder lineage. 
c Sequences from 1st sampled time point with ≥ 4 sequences per lineage were analyzed. If 5' half genomes were 
d Sequences from 2nd sampled time point were analyzed due to insufficient number of sequences or sequence diversity from 1st sampled time 
point. 
e Insufficient numbers of sequences from each time point to calculate fit to Poisson or star-like phylogeny. 
f Transmitted/founder lineage identified by this sequence in respective ML tree and Highlighter plot. 
g N/A, not applicable due to multiple transmitted/founder virus genome. 
h Averages were calculated from total mutations in all transmitted/founder lineages from all subjects combined. Because of low numbers of 




Figure 2.3. Maximum diversity of discrete HCV sequence lineages from acute infection 
subjects versus maximum sequence diversity in chronic subjects. Primary data are derived 
from Tables 2.1 and 2.2. Mean (695% CI) values are represented by horizontal lines. Differences 
between the two groups were highly significant (p,0.0001; unpaired T-test with Welch’s 





























 Mathematical models of early HCV diversification. Because of the distinctive 
replication strategy of HCV, which is still not fully understood (196, 198), we could not predict a 
priori the patterns of early virus diversification that we might observe in acutely infected subjects. 
Thus, we developed two mathematical models to analyze HCV sequence diversity (Figure 2.4). 
The first model (82, 128, 151), employed previously to analyze early HIV-1 sequence 
diversification, assumes a narrow genetic bottleneck associated with virus transmission, initial 
rapid exponential virus growth, constant lineage-independent mutation rates at all sites, no 
recombination between sequences or back mutations, and no differential selection. When 
diversity is low, most base substitutions occur at distinct loci, pairwise differences between 
sequences (i.e., Hamming distances, HD) follow a Poisson distribution, and sequences exhibit a 
star-like phylogeny and coalesce to distinct unambiguous T/F genomes (128, 129, 258). Early 
HIV-1 diversification conforms well to this model and it was suggested that other viruses including 
HCV might also (82). However, HCV replication differs from HIV-1 in that HCV RNA does not 
integrate into chromosomal DNA and it does not produce all of its daughter progeny in a large 
burst of viruses within a couple days after infecting a cell (216). Instead, it forms as many as 40 
cytosolic replication complexes that continue to produce virions throughout the lifetime of the cell 
(230, 238). In early infection prior to the onset of HCV specific cellular immune responses, the 
lifetime of infected cells is likely to span our sampling period given that the lifetime of uninfected 
hepatocytes is estimated to be months to years (174, 272). To account for these differences with 
HIV-1, we developed an alternative simplified deterministic model of HCV diversification (Figure 
2.4). This model predicts occasional violations in star-like diversification and in the Poisson fit of 
mutations with increasing probability as time goes on, and it predicts greater numbers of shared 
stochastic mutations between HCV sequences compared with HIV-1 sequences. The latter 
model provided us with a mathematical and statistical basis for distinguishing closely related T/F 
HCV lineages from sequences that evolved from a single genome but shared early stochastic 
mutations. Importantly, it allowed us to vary key assumptions regarding the contributions of long-
lived hepatocytes containing multiple generations of replication complexes and assess the effects 
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on sample-based T/ F virus enumeration. From this analysis, we adopted a conservative 
operational cut-off of >2 shared mutations per quarter genome (~2500 bp) or >4 shared 
mutations per half genome (~5000 bp) to distinguish T/F genomes in most cases of HCV 
transmission from chronically infected individuals (see Chapter 2 Material and Methods). In more 
complicated transmission scenarios, where the index case was hypothesized to be either acutely 
infected or to have experienced a viral genetic bottleneck due to antiviral drug therapy, we 
applied both an empirical approach where a single shared polymorphism could represent a 
distinct T/F viral genome as well as the more conservative modeling approaches. Importantly, 
both empirical and model-based analyses predicted that consensus sequences of low diversity 
lineages before the onset of immune-driven positive selection coalesced to founder viral 




Figure 2.4. Models of HCV and HIV-1 diversification in acute infection. Panels A and C 
depict patterns of HIV-1 replication and diversification compared with HCV in panels B and D.  
The various generations of HIV-1 (panel C) and HCV (panel D) are indicated as filled dots to 
represent HIV-1 proviruses or HCV replication complexes. The symbol t indicates the time to 
sampling in units of provirus generations for HIV-1 (~2 days) and of replication complex 
generations for HCV (~1 day).  Whereas HIV-1 is produced only from the latest generation of 
provirus, HCV is produced from replication complexes of all generations. In this model, the 
number of HCV replication complexes of generation g at time t is given by . For HIV-1 each 
provirus of the same generation produces roughly equal numbers of descendant HIV viruses.  
The replication complexes of HCV produce widely different number of descendant viruses.  


























































































chronic infection (WIMI4025, panel A) and one illustrating the
reduced genetic diversity characteristic of a subject productively
infected by a single viral genome (10051, panel B). Sequences from
the chronic subject showed broad genotypic heterogeneity with a
maximum inter-sequence diversity of 3.83% (mean 1.2%; median
1.21%; range 0.12–3.83%) typical of chronic infection (Table S1).
Sequences from the acute subject revealed a very different pattern
of diversification (Figure 4B). These sequences, which were derived
from the last sampled time point 21 days after the beginning of
documented viremia (see Figure 1), were extremely homogeneous
with a mean diversity of 0.03%, median diversity of 0.02%, and a
range in diversity of 0–0.19%. Nucleotide substitutions corre-
sponded to a near star-like phylogeny, although unlike most early
HIV-1 sequence sets they deviated from a Poisson distribution
(p,561025), a finding consistent with predictions of the HCV
adapted model. This deviation resulted from two sequences (2C3
and 2C2) that contained a single shared polymorphismat position
2197 and two other sequences (2A2 and 2B34) that contained a
different shared polymorphism at position 4344. The shared
polymorphism at position 2197 was a first position GAG to TAG
transversion that resulted in the introduction of a stop codon.
Surprisingly, the same nonsense mutation was found in the
identical position in two additional sequences (2B8 and 2B9) from
this subject in a plasma sample taken 12 days earlier (Genbank
Figure 3. Models of HCV and HIV-1 diversification in acute infection. Panels A and C depict patterns of HIV-1 replication and diversification
compared with HCV in panels B and D. The various generations of HIV-1 (panel C) and HCV (panel D) are indicated as filled dots to represent HIV-1
proviruses or HCV replication complexes. The symbol t indicates the time to sampling in units of provirus generations for HIV-1 (,2 days) and of
replication complex generations for HCV (,1 day). Whereas HIV-1 is produced only from the latest generation of provirus, HCV is produced from





each provirus of the same generation produces roughly equal numbers of descendant HIV viruses. The replication complexes of HCV produce widely
different number of descendant viruses. Panels A and B show the impact of this difference on the expected fraction of pairs of viruses, sampled at







2n{1 2n{1ð Þ. One sees that HCV viruses typically share 50% more generations of ancestors than HIV, and with the
estimated mutation rates, this means that they share about 3 times the stochastic mutation events expected in HIV.
doi:10.1371/journal.ppat.1002880.g003
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sampled at various times, that share a given number of ancestors. For HCV, the number of pairs 
of viruses sampled at time t that share at least g generations is given by  
One sees that HCV viruses typically share 50% more generations of ancestors than HIV, and with 
the estimated mutation rates, this means that they share about 3 times the stochastic mutation 
events expected in HIV. 
chronic infection (WIMI4025, panel A) and one illustrating the
reduced genetic diversity characteristic of a subject productively
infected by a single viral genome (10051, panel B). Sequences from
the chronic subject showed broad genotypic heterogeneity with a
maximum inter-sequence diversity of 3.83% (mean 1.2%; median
1.21%; range 0.12–3.83%) typical of chronic infection (Table S1).
Sequences from the acute subject revealed a very different pattern
of diversification (Figure 4B). These sequences, which were derived
from the last sampled time point 21 days after the beginning of
documented viremia (see Figure 1), were extremely homogeneous
with a mean diversity of 0.03%, median diversity of 0.02%, and a
range in diversity of 0–0.19%. Nucleotide substitutions corre-
sponded to a near star-like phylogeny, although unlike most early
HIV-1 sequence sets they deviated from a Poisson distribution
(p,561025), a finding consistent with predictions of the HCV
adapted model. This deviation resulted from two sequences (2C3
and 2C2) that contained a single shared polymorphismat position
2197 and two other sequences (2A2 and 2B34) that contained a
different shared polymorphism at position 4344. The shared
polymorphism at position 2197 was a first position GAG to TAG
transversion that resulted in the introduction of a stop codon.
Surprisingly, the same nonsense mutation was found in the
identical position in two additional sequences (2B8 and 2B9) from
this subject in a plasma sample taken 12 days earlier (Genbank
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compared with HCV in panels B and D. The various generations of HIV-1 (panel C) and HCV (panel D) are indicated as filled dots to represent HIV-1
proviruses or HCV replication complexes. The symbol t indicates the time to sampling in units of provirus generations for HIV-1 (,2 days) and of
replication complex generations for HCV (,1 day). Whereas HIV-1 is produced only from the latest generation of provirus, HCV is produced from





each provirus of the same generation produces roughly equal numbers of descendant HIV viruses. The replication complexes of HCV produce widely
different number of descendant viruses. Panels A and B show the impact of this difference on the expected fraction of pairs of viruses, sampled at







2n{1 2n{1ð Þ. One sees that HCV viruses typically share 50% more generations of ancestors than HIV, and with the
estimated mutation rates, this means that they share about 3 times the stochastic mutation events expected in HIV.
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Identification and enumeration of T/F genomes. Figure 2.5 depicts ML phylogenetic trees and 
Highlighter plots of viral 5' half genome sequences from two subjects, one typical of chronic 
infection (WIMI4025, panel A) and one illustrating the reduced genetic diversity characteristic of a 
subject productively infected by a single viral genome (10051, panel B). Sequences from the 
chronic subject showed broad genotypic heterogeneity with a maximum inter-sequence diversity 
of 3.83% (mean 1.2%; median 1.21%; range 0.12–3.83%) typical of chronic infection (Table 2.1). 
Sequences from the acute subject revealed a very different pattern of diversification (Figure 
2.5B). These sequences, which were derived from the last sampled time point 21 days after the 
beginning of documented viremia (see Figure 2.1), were extremely homogeneous with a mean 
diversity of 0.03%, median diversity of 0.02%, and a range in diversity of 0–0.19%. Nucleotide 
substitutions corresponded to a near star-like phylogeny, although unlike most early HIV-1 
sequence sets they deviated from a Poisson distribution (p<5x10-5), a finding consistent with 
predictions of the HCV adapted model. This deviation resulted from two sequences (2C3 and 
2C2) that contained a single shared polymorphism at position 2197 and two other sequences 
(2A2 and 2B34) that contained a different shared polymorphism at position 4344. The shared 
polymorphism at position 2197 was a first position GAG to TAG transversion that resulted in the 
introduction of a stop codon. Surprisingly, the same nonsense mutation was found in the identical 
position in two additional sequences (2B8 and 2B9) from this subject in a plasma sample taken 
12 days earlier (Genbank accession nos. JQ803586, JQ803587, JQ803590 and JQ803591). We 
could be assured that these persistent but defective genomes were authentic and did not result 
from cross-contamination of amplicon sequences since each of the four sequences had 
additional distinguishing nucleotide polymorphisms (e.g., compare sequences 2C3 and 2C2 in 
Figure 2.5B) or were processed, PCR amplified and analyzed on different days (e.g., 2C3 and 
2C2 versus 2B8 and 2B9). Occasional shared polymorphisms are commonly found in acute HIV-
1 infection sequences and can be explained by polymerase errors early in infection being 
retained in the population (128, 151), but for neither HIV-1 nor HCV would nonsense mutations 
be expected to be retained unless they were complemented by competent genomes (51, 238, 
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261). Regardless, the 60 sequences depicted in Figure 2.5B coalesced to a single unambiguous 
consensus, which we inferred to represent a likely T/F virus in this subject. To explore if 
additional T/F sequence lineages might have been overlooked due to inadequate sampling, we 
sampled 243 additional 5' quarter genome sequences from this subject at three earlier time 
points spanning a 19 day period (Figures 2.1 and 2.6). Power calculations indicate that a sample 
size of 60 sequences provides 95% likelihood of detecting variants present at 5% in the 
population (128), whereas a sample size of 303 sequences provides 95% likelihood of detecting 
variants present at 1% prevalence. 43 of 46 (93%) of the sequences at the initial time point were 
identical, and diversity increased with time (Figure 2.6). Whether the 303 5' quarter genome 
sequences from the different time points were considered separately or together, they conformed 
to a near star-like phylogeny and coalesced to the same T/F genome. Thus, we can conclude 
with a high level of confidence that subject 10051 was productively infected by a single virus 
whose sequence is represented by the consensus in Figure 2.5B and 2.6. 
 Figure 2.7 extends the analysis of T/F HCV genomes to four acutely infected subjects 
where sequences from sequential time points revealed variable patterns of early viral diversity. In 
each subject, sequences from the initial sample were more homogeneous than those from later 
time points, as expected in a model of random accumulation of mutations. For subject 10021 
(panel A), 19 of 24 (79%) sequences from the initial timepoint were identical. For subject 10025 
(panel B), 32 of 43 (74%) of initial sequences were identical. The remaining sequences from this 
first time point in each subject differed from the respective consensus sequences by only 1 or 2 
nucleotides. At the second and third sampling time points 1–4 weeks later, an increasing 
proportion of sequences from each subject differed from the respective consensus sequences by 
as many as 3 or 4 nucleotides. Interestingly, in both samples rare shared mutations became 
evident at later time points, again consistent with predictions of the HCV adapted model. For 
subjects 10021 and 10025, we thus concluded that the respective consensus sequences 
corresponded to single T/F HCV genomes. Of the 17 acutely infected subjects, four had evidence 
of productive clinical infection by single viruses (Tables 2.1 and 2.2) Panels C and D depict 
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sequences from subjects 10012 and 10062, each of whom had evidence of productive infection 
by more than one genetically distinct virus based on the presence of multiple discrete low 
diversity lineages whose consensus sequences differed from each other by far more than the 2 
nucleotides per quarter genome cut-off. Importantly, unlike HIV-1 where viral recombination in 
acute and early infection is extremely common (11, 154), we found no evidence of inter-lineage 
recombination in HCV sequences from these subjects or from any other subjects in this study. 
We thus interpreted the consensus sequences of each low diversity lineage in subjects 10012 
and 10062 to correspond to a unique T/F HCV genome, three for each subject. This represents a 
minimum estimate, since deeper sampling could conceivably identify additional T/F sequence 
lineages, although with 188–230 sequences analyzed there was a 95% likelihood of detecting 
variants present at 2% in the population (Table 2.1). Figure 2.6 depicts sequences from subject 
10029 where discrete low diversity sequence lineages indicated clinical acquisition of a minimum 
of 9 T/F viruses. In 6 additional acutely infected subjects, clearly distinguishable T/F lineages 
ranged from 3 to 13 per subject (Figures S3, S4, S5, S6, S7, S8). Importantly, for all of the 
acutely infected subjects described above, the numbers of T/F sequence lineages identified by 
visual inspection using the cut-off of >2 per quarter genome and >4 per half genome were nearly 
identical to those inferred from the HCV adapted model of early virus diversification using 
standard (maximum cut-off) or stringent (average cut-off) assumptions (Table 2.1). 
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Figure 2.5. HCV diversity in chronic (WIMI4025) and acute (10051) subjects.  5′ half genome 
sequences (core, E1, E2, p7, NS2 and NS3) from WIMI4025 (A) and 10051 (B) are depicted by 









































































































































































































































Figure 2.6. HCV diversity in acute subject 10051. 5′ quarter 1 genome sequences are color 
coded in orange, green, blue and black in chronological order to reflect sampling time points in 
Figure 2.1 and are represented in a ML tree and Highlighter plot.  Sequences show evidence of 
productive clinical infection by a single virus. The horizontal scale bar indicates genetic distance. 












Figure 2.7. HCV diversity in acute infection. ML trees and Highlighter plots of 5′ quarter 2 
genome sequences from four acutely infected subjects.  Sequences are color coded to reflect 
sampling time points indicated in Figure 2.1. Subjects 10021 (A) and 10025 (B) revealed 
productive clinical infection by a single viruses whereas subjects 10012 (C) and 10062 (D) each 
showed infection by three viruses (v1-3). 











































Figure 2.8. HCV diversity in acute subject 10029. ML tree and Highlighter plot of 5′ quarter 1 
genome sequences, color coded to reflect sampling time points in Figure 1, reveal productive 




































Figure 2.9. HCV diversity in acute subject 10024. 5′ quarter 1 genome sequences are color 
coded in blue, green and black in chronological order to reflect sampling time points in Figure 2.1 
and are represented in a ML tree and Highlighter plot. Sequences show evidence of productive 
clinical infection by at least 6 T/F viruses. Bootstrap values are indicated and represent 100 








































































































































































































































































































































Figure 2.10. HCV diversity in acute subject 6213. 5′ half genome sequences are represented 
in a ML tree and Highlighter plot. Sequences show evidence of productive clinical infection by at 
least 3 T/F viruses. Bootstrap values are indicated and represent 100 repetitions. The horizontal 





































































































Figure 2.11. HCV diversity in acute subject 6222. 5′ half genome sequences are represented 
in a ML tree and Highlighter plot. Sequences show evidence of productive clinical infection by at 
least 4 T/F viruses. Bootstrap values are indicated and represent 100 repetitions. The horizontal 





























































Figure 2.12. HCV diversity in acute subject 10004. 5′ quarter 1 genome sequences are 
represented in a ML tree and Highlighter plot. Sequences show evidence of productive clinical 
infection by at least 3 T/F viruses. Bootstrap values are indicated and represent 100 repetitions. 































































































Figure 2.13. HCV diversity in acute subject 10002. 5′ half genome sequences are represented 
in a ML tree and Highlighter plot. Sequences show evidence of productive clinical infection by at 
least 13 T/F viruses. Bootstrap values are indicated and represent 100 repetitions. The horizontal 








































































































Figure 2.14. HCV diversity in acute subject 10017. 5′ quarter 1 genome sequences are color 
coded in red, orange, green, blue and black in chronological order to reflect sampling time points 
in Figure 2.1 and are represented in a ML tree and Highlighter plot. Sequences show evidence of 
productive clinical infection by at least 4 T/F viruses. Bootstrap values are indicated and 




































































































































































































































































































































































































































































Evidence of acute-to-acute HCV transmission. Virus diversity in three acutely infected 
subjects (10003, Figure 2.15; 10020, Figure 2.16A; 10016, Figure 2.16B) shared features that 
distinguished them from the other 14 acute subjects. In each case, maximum sequence diversity 
was relatively low (0.27%–0.41%), consistent with recent infection. However, unlike in other 
subjects, samples from 10003, 10020 and 10016 exhibited many closely related sets of 
sequences that shared unique polymorphisms, which appeared as multiple vertical ‘stripes’ in the 
Highlighter plots and shared nodes in the phylogenetic trees (Figures 2.15 and 2.16A, B). In 
subject 10003 (Figure 2.15), there were at least 37 distinct sequence sets, and in subjects 10020 
(Figure 2.16A) and 10016 (Figure 2.16B) there were 10 and 15, respectively. Although we 
recognized that occasional shared mutations are predicted by the model and were found in 
samples from subjects infected by single or few viruses with well-defined T/F sequence lineages 
(e.g., see Figures 2.5B, 2.7 and 2.8), the high frequency of unique shared mutations in subjects 
10003 (Figure 2.15), 10020 (Figure 2.16A) and 10016 (Figure 2.16B) was quite unusual and led 
us to hypothesize that most of the 10–37 distinct virus lineages observed in these individuals 
resulted from discrete transmitted viruses from individuals who themselves were recently infected 
by a single virus or by closely related viruses. An alternative hypothesis that we considered was 
that infection by single viruses had occurred in subjects 10003, 10020 and 10016 but was 
followed by atypical diversification patterns not seen in any of the other acutely infected subjects. 
Our strategy to distinguish between these scenarios was both empirical and model-based. First, 
we observed that the maximum Hamming distances, expressed as per cent diversity, between 
the consensus sequences of the discrete sequence sets (i.e., between potential T/F genomes) 
from subjects 10016, 10020 and 10003, were 0.21%, 0.28% and 0.35% (mean 0.28%; median 
0.28%), respectively. These values exceeded the maximum intra-lineage diversity (mean 0.12%; 
median 0.12%; range 0.04–0.19%; p = 0.0051, Mann-Whitney test) found in all lineages from all 
subjects in the initial ~6 weeks of infection. These findings suggested acquisition of multiple 
distinct variants from recently infected subjects, not evolution of viruses from single transmitted 
variants. Secondly, we found that the multiple sequence sets in subjects 10016, 10020 and 
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10003 were present from the initial sampling time points and did not accumulate over time, again 
suggesting acquisition not evolution of the variants. Thirdly, we noted that the linear distribution of 
shared nonsynonymous nucleotide substitutions across the viral genomes in subjects 10016, 
10020 and 10003 was not random but instead was concentrated in regions of E1 and E2 (Figure 
2.17) previously associated with immune escape (61, 164, 330). Inspection of the amino acid 
substitutions in the E2 region of the putative T/F genomes revealed combinations of different 
nonsynonymous mutations in identical or neighboring positions in the primary sequence that 
were unlikely to have occurred by chance (probability estimates <0.001). Since these subjects 
were sampled very early after infection, well before antibody seroconversion (Figure 2.1) or the 
onset of cellular immune responses (25, 236), the data suggest that the patterns of viral diversity 
observed in the putative T/F viral genomes from subjects 10016, 10020 and 10003 were the 
consequence of acquisition of multiple variants from transmitting individuals who themselves had 
become infected in the preceding ~6 months and whose viral sequences had been subjected to 
early epitope-focused immune selection. 
We next applied our HCV adapted model of early virus diversification to the sequences from the 
three subjects 10016, 10020 and 10003 (Figures 2.18; 2.19–20). Under standard model 
assumptions (maximum cut-off, see Chapter 2 Materials and Methods) for delineating T/F 
lineages, transmission by at least 6–19 genetically distinct viruses was necessary to explain the 
viral diversity observed in the three subjects. Even under the most conservative model 
assumptions (average cut-off), transmission of at least 2–9 distinct viruses was required. Based 
on these findings, we conclude that the pattern of viral sequence variation in subjects 10003, 




Figure 2.15. HCV diversity in subject 10003. ML tree and Highlighter plot of 5′ half genome 












































































































































































































































































































Figure 2.16. HCV diversity in acute subjects 10020 and 10016. 5′ quarter 1 genome 
sequences from subject 10020 (panel A) and 10016 (panel B) are depicted by ML tree and 
Highlighter plots. Many sets of closely related sequences distinguished by unique shared 






































































































































































































































































































































































































































Figure 2.17. Nonsynonymous and synonymous mutations in HCV sequences from acute 
subjects 10003, 10020 and 10016. Highlighter plots of 5′ half or quarter 1 genome sequences 
are color coded to denote nonynonymous (red) and synonymous (green) mutations for subjects 
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Figure 2.18. HCV diversity analysis in subject 10016 suggests acute-to-acute transmission. 
Highlighter plot and neighbor-joining tree of 5′ quarter 1 genome sequences. Visualization of 15 
potential T/F viral lineages distinguished by unique shared mutations is indicated by lower case 
(blue) letters. Model estimates of T/F virus lineages using maximum (red) and average (green) 
cut-offs reveal 10 and 4 potential T/F virus lineages, respectively, based on increasingly stringent 




























































































































































Figure 2.19. HCV diversity analysis in subject 10020 suggests acute-to-acute transmission. 
Highlighter plot and neighbor-joining tree of 5′ quarter 1 genome sequences. Visualization of 10 
potential T/F viral sequences distinguished by unique shared mutations is indicated by lower 
case (blue) letters. Model estimates of T/F virus lineages using maximum (red) and average 
(green) cut-offs reveals 5 and 3 potential T/F virus lineages, respectively, based on increasingly 



































































































































































































Figure 2.20. HCV diversity analysis in subject 10003 suggests acute-to-acute transmission. 
Highlighter plot and neighbor-joining tree of 5′ half genome sequences. Visualization of 37 
potential T/F viral sequences distinguished by unique shared mutations is indicated by lower 
case (blue) letters. Model estimates of T/F virus lineages using maximum (red) and average 
(green) cut-offs reveals 15 and 8 potential T/F virus lineages, respectively, based on increasingly 




































































































































































































































































Transmission of multiple NS3A drug resistant variants. The phylogenetic pattern of 
sequences from subject 106889 (Figure 2.21) was still more complicated than that of any of the 
other 16 acutely infected subjects. This subject exhibited a typical acute infection viral kinetic 
profile with four sequential plasma samples negative for HCV vRNA and antibody followed by 
rapid vRNA ramp-up to nearly 4x106 vRNA IU/ml (Figure 2.21 insert). These plasma samples 
from subject 106889 were obtained in June and July 2008 and were preceded by over 150 
plasma collections from this individual in 2003–2008, all of which were negative for HCV RNA or 
antibody, proving this individual had incident infection. Eighty-seven 5' half genome sequences 
were obtained from the initial plasma vRNA positive time point (Figure 2.21). Maximum diversity 
of these sequences was 1.03%, indicating multi-variant transmission. Similar to subjects 10003, 
10020 and 10016, numerous discrete, low diversity sequence clades, many of which were closely 
related to each other, were apparent in the maximum-likelihood tree and Highlighter plot. Unlike 
sequences from the other subjects, however, the distinct sequence sets in 106889 clustered with 
high bootstrap values into larger lineages (color-coded in Figure 2.21). Those clades that 
contained sufficiently large numbers of sequences for analysis (e.g., clades identified by 
sequences 5.B.F9 and 5.02C22) exhibited a star-like phylogeny and Poisson distribution of 
mutations (Table 2.2), indicating that they had evolved very recently from discrete T/F genomes. 
These findings suggested that subject 106889 had been infected by large numbers of viruses 
from a chronically infected individual whose HCV sequences had been subjected to a stringent 
genetic bottleneck. A quite unexpected finding suggested a likely explanation: 86 of the 87 
sequences from subject 106889 were found to contain two signature mutations in the NS3 
protease gene (V36M and R155K) that confer high level drug resistance to the NS3 protease 
inhibitors Boceprevir and Telaprevir (213). One of 87 sequences (sequence 02B11 in Figure 
2.21) contained one of these DAA resistance mutations (V36M). Since the combination of V36M 
and R155K mutations is uncommon in treatment-naïve individuals (141), this result suggested 
that a transmitting partner to 106889 was chronically infected with HCV, was treated with an 
investigational NS3 protease inhibitor, experienced a DAA- induced viral population bottleneck 
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followed by the emergence of NS3 protease resistant variants, and as these variants rebounded, 
transmitted multiple drug resistant variants directly to subject 106889 or indirectly through a 
second acutely infected individual. Under this scenario, where closely related sequences differing 
by as few as one nucleotide would be expected to be transmitted, we estimated by visual 
inspection of the phylogenetic tree that as many as 30 or more T/F virus could have been 
responsible for productive clinical infection (Table 2.3). By the standard model analysis, 28 
distinct T/F viral genomes were necessary to account for the observed diversity. By the more 





Figure 2.21. HCV plasma vRNA kinectics and diversity in subject 106889 reveals 
multivariant transmission of drug resistant mutants. vRNA kinetics (inset), ML phylogenetic 
tree, and Highlighter analysis of 5′ half genome sequences from the initial vRNA positive sample 
(circled). Sequences fall into distinct lineages (color-coded) with high statistical bootstrap support. 





































































































































































































































Table 2.3. Estimates of numbers of T/F viruses in acute HCV infection using empirical and 
model based methods. 
a Manual estimates were based on phylogenies and Highlighter plots of all time points combined. 
b Power calculation estimating an upper bound on the prevalence of unseen variants given the 
number of sequences analyzed. This estimate is based on the total number of sequences from all 
time points. 
Table S2. Estimates of numbers of T/F viruses in acute HCV infection using empirical and model based methods 











calculationb Points of interest 
9055 157 3 1 1 1 1.9% single founder genome 
10021 151 3 1 1 1 2.0% single founder genome 
10025 175 3 1 1 1 1.7% single founder genome 
10051 303 3 1 1 1 1.0% single founder genome 
10003 133 3 37 19 9 2.2% acute-to-acute transmission 
10016 72 2 15 11 5 4.1% acute-to-acute transmission 
10020 122 3 10 6 2 2.4% acute-to-acute transmission 
6213 41 1 3 3 3 7.0% 
 6222 17 1 4 4 4 16.2% 
 10002 31 2 12 13 11 9.2% 
 10004 36 1 3 3 3 8.0% 
 10012 230 4 3 3 3 1.3% 
 10017 249 5 5 3 3 1.2% 
 10024 222 3 6 6 6 1.3% 
 10029 322 4 9 9 9 0.9% 
 10062 188 4 3 3 3 1.6% 
 106889 87 1 >30 28 16 3.4% drug resistant T/F genomes  
a Manual estimates were based on phylogenies and Highlighter plots of all time points combined. 
b Power calculation estimating an upper bound on the prevalence of unseen variants given the number of sequences 
ana yzed. This esti te i  based on the total number of sequences from all time po ts. !
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Virus diversification from T/F genomes. The identification of T/F viral sequences in 17 subjects 
provided us with a unique opportunity for analyzing HCV sequence evolution in natural human 
infection beginning at or near the moment of virus transmission and extending through the 
establishment of early viral load setpoint, and in some subjects, antibody seroconversion. Among 
the 17 subjects, we identified a total of 146 T/F genomes. As expected, all 146 T/F sequences 
had intact open reading frames for core, E1, E2, P7, NS2 and NS3. Thirty T/F genomes had 5 or 
more identifiable progeny (range 5–303; median 19) from which we could analyze molecular 
features of sequence diversification in vivo using phylogenetic tools and algorithms. A summary 
of this analysis is presented in Table 2.2. Maximum intra-lineage diversity for the 17 subjects 
ranged from 0.04% to 0.19% (mean = 0.12%; median = 0.12%), which was significantly lower 
than the maximum, mean and median viral diversities observed in chronically infected subjects 
(3.83%, 2.27% and 2.37%, respectively; p<0.0001, unpaired T-test with Welch’s correction) 
(Tables 2.1 and 2.2; Figure 2.3). Evolved sequences compared to their respective T/F genomes 
revealed low frequencies of per nucleotide insertions (1x10-6), deletions (3x10-6) and stop codons 
(1x10-6). Transitions outnumbered transversions by 8.8 to 1, and when corrected for the number 
of available sites, by 18 to 1. The average dN/dS ratio was low at 0.39. The overall mutation 
frequency among all 17 acute subjects uncorrected for time from transmission or numbers of 
virus replication cycles was 1.4x10-4. When sequences were analyzed in the context of an agent-
based stochastic model of virus diversification that incorporates estimated time from transmission 
and HCV specific parameters of virus replication, the mutation rate of HCV in vivo was estimated 
to be 2.5x10-5 per nucleotide per genome replication (238). We confirmed this low value by an 
analysis of the nonsense codon frequency per nonsense mutation target site (238). Progeny of 
T/F viruses sampled at the earliest time points generally conformed to a star-like phylogeny and a 
Poisson distribution of random mutations (Table 2.2), but at later time points there were 
occasional deviations. Deviations from the model were of three types: (i) shared polymorphisms 
resulting from stochastic changes after the transmission event or from the transmission of 
multiple closely related viruses; (ii) immune selection or reversion in later samples at the time of 
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antibody seroconversion in a single subject 9055 (Figures 2.22, 2.23); (iii) rare examples of short 
perfect inverted repeats, 3–20 nucleotides in length, that resulted from template switching 
between double-stranded RNA molecules in locations prone to RNA stem-loop secondary 
structure (Figure 2.24). This latter finding, which was found in 7 sequences out of 2922 analyzed, 
was observed in samples from three different study subjects. Four of these strand transfers 
occurred at the same location in the core gene. 
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Figure 2.22. HCV diversity in acute subject 9055. 5′ half genome sequences are color coded in 
green, blue and black in chronological order to reflect sampling time points in Figure 1 and are 
represented in a ML tree and Highlighter plot. Sequences show evidence of productive clinical 
infection by one T/F virus with mutations accumulating at positions 3311 and 3346 at the last 
sampling time point coincident with antibody seroconversion. Bootstrap values represent 100 








































































































































































































































































































































Figure 2.23. Nonsynonymous and synonymous mutations in HCV sequences from acute 
subject 9055. A Highlighter plot (panel A) of 5′ half genome sequences is color coded to denote 
nonynonymous (red) and synonymous (green) mutations. The boxed area reveals a temporal 
expansion of sequences with concentrated amino acid subtitutions in NS3. In panel B, amino acid 
selection is evident in a previously identified CTL epitope highlighted in red. The top-most 
sequence represents the genotype 3a consensus. 
3a_con APITA YAQQTRGLLG TIVTSLTGRD KNVVTGEVQV LSTATQTFLG TTVGGVMWTV YHGAGSRTLA GAKHPALQMY TNVDQDLVGW PAPPGAKSLE PCACGSADLY LVTRDADVIP ARRRGDSTAS
APITA YAQQTRGLLG TIVTSLTGRD KNVVTGEVQV LSTATQTFLG TTVGGVMWTV YHGAGSRTLA GVKHPALQMY TNVDQDLVGW PAPPGAKSLE PCTCGTADLY LVTRDADVIP ARRRGDSTAS 
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Figure 2.24 Polymerase template switching. Template switching by the RNA polymerase 
between minus sense and plus sense strands of double-stranded HCV RNA resulted in short 
stretches of perfect inverted repeat sequences. Five examples are illustrated in panels A–E. 
Proposed mechanisms for template switching are illustrated. 
+ 5’ ...AACACCAACCACCGCCCGGGAACTTGACGTCCTGTGGGCGGCGGTCAGATCG... 3‘
- 3’ ...TTGTGGTTGGTGGCGGGCCCTTGAACTGCAGGACACCCGCCGCCAGTCTAGC... 5‘
+ 5’ ...AACACCAACCGCCGCCCACAGGACGTCAAGTTCCCGGGCGGTGGTCAGATCG... 3’










































+ 5’ ...AACACCAACCGTCGCCCACAGGACGTCAAGTTCCCGGGCGGCGGCCAGATCG... 3’
- 3’ ...TTGTGGTTGGCAGCGGGTGTCCTGCAGTTCAAGGGCCCGCCGCCGGTCTAGC... 5’
+ 5’ ...AACACCAACCGCCGCCCGGGAACTTGACGTCCTGTGGGCGACGGCCAGATCG... 3’










































+ 5’ ...GGCAGGACCTGGGCTCAGCCCGGGTACCCTT... 3‘
- 3’ ...CCGTCCTGGACCCGAGTCGGGCCCATGGGAA... 5‘
+ 5’ ...GGCAGGACCCGGGCTGAGCCCAGGTACCCTT... 3’
                 *     *     *
#
+ 5’ ……GGCAGGA


















+ 5’ ...GCTCGTCAGCGCCCCCAAGAGGGGCGCTGCCAGGG... 3‘
- 3’ ...CGAGCAGTCGCGGGGGTTCTCCCCGCGACGGTCCC... 5‘
+ 5’ ...GCTCGTCAGCGCCCCTCTTGGGGGCGCTGCCAGGG... 3’








































+ 5’ ...TGCGGGTGGG--CAGGATGGCTCCTGTCCCCACGCGG... 3‘
- 3’ ...ACGCCCACCC--GTCCTACCGAGGACAGGGGTGCGCC... 5‘
+ 5’ ...TGCGCGTGGGGACAGGAGCCATCCTGCCCCCACGCGG... 3’





























































 The present study provides new quantitative and qualitative insights into HCV 
transmission and early diversification in humans. Previous reports documented a virus population 
bottle- neck associated with HCV transmission, but none of those studies including ones based 
on 454 deep sequencing captured the broad range in multiplicity of infection or the full spectrum 
of genetic diversity that exists among transmitted viruses. In our study of 17 acutely infected 
subjects, we could unambiguously identify and determine the exact nucleotide sequences of one 
or more T/F virus genomes in each subject. This was true for all subjects whose HCV genomes 
were sequenced within the initial ~6–8 weeks of infection; beyond that there were examples of 
immune selection that confounded the identification of T/F virus genomes (Figures 2.22 and 
2.23). We estimated the multiplicity of infection (numbers of T/F viruses leading to productive 
clinical infection) to range from 1 to as many as 37 or more with a median of 4. These are 
minimum estimates given our sampling limitations, although we note that our median sampling 
depth of 151 sequences (Table 2.2) afforded us a 95% likelihood of detecting variants present at 
2% prevalence (128). In subjects productively infected by lower numbers of viruses (<10), where 
the progeny of each transmitted virus is repeatedly sampled, our estimates (Tables 2.1 and 2.2) 
are likely to be an accurate and precise measure of the number viruses that result in productive 
infection. In subjects infected by higher numbers of viruses, especially in the setting of acute-to-
acute transmission where transmitted viruses are expected to differ by as few as one nucleotide, 
the accuracy of our estimates are necessarily less. This is because we could not sample deeply 
enough due to practical constraints of single genome sequencing of quarter and half genomes, 
and because we could not distinguish between transmitted viruses that differ by one or few 
nucleotides from single variant transmission followed by early stochastic mutations. However, 
based on the striking differences in diversity patterns that we observed between subjects with 
chronic-to-acute versus apparent acute-to-acute transmission, we suspect that the actual 
numbers of T/F viruses in subjects 10016, 10020, 10003 and 106889 approximate or exceed our 
estimates of 15, 10, 37 and 30 T/F genomes, respectively (Tables 2.1 and 2.3). 
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 The broad range in numbers of T/F viruses responsible for acute HCV infection in our 
cohort must reflect the different transmission routes and risk practices of source plasma donors. 
Ostensibly, such individuals should be at low risk of acquiring HCV infection since they are 
qualified as regular source plasma donors only after extensive pre-enrollment screening that 
consists of medical histories, physical examinations and behavioral questionnaires designed 
specifically to eliminate from the donor pool individuals at risk for HCV, HBV or HIV infection 
(http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/default.
htm). However, self-reporting of risk behaviors among paid plasma donors is admittedly imperfect 
(322). Thus, it is likely that the subjects in the present study represent the broad clinical spectrum 
of community- acquired HCV infection in the United States, which includes injection drug users, 
men who have sex with men, heterosexuals, and possibly, household contacts of HCV infected 
individuals. 
 Our findings regarding the multiplicity of human infection by HCV are quite different from 
those obtained by 454 pyrosequencing in seven acutely infected subjects reported by two 
different investigative groups where the range in T/F viruses was one to four with a median one 
(32, 325). Our findings are also substantially different from estimates from other reports that 
employed reverse transcription, bulk PCR amplification, population sequencing or molecular 
cloning followed by sequencing (48, 61, 104, 142, 164, 302, 309). The latter studies showed that 
acutely infected subjects exhibited a spectrum in HCV sequence diversity that could at best be 
interpreted qualitatively as reflecting ‘few-variant’ versus ‘multi-variant’ transmission. We also 
note a recent study that used conventional bulk PCR amplification, cloning and sequencing to 
analyze acute and early HCV sequences consisting of a 225 bp hypervariable region of env from 
10 acute infection subjects following IDU, sexual or nosocomial exposures (285). This report 
described perplexing findings: 7 of 10 acutely infected subjects seemed to harbor more than one 
HCV genotype and sequential sequences obtained from these subjects a median of 17.5 days 
apart throughout the acute infection period suggested fluctuations in the prevalence of different 
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HCV genotypes, subtypes and clades. These findings are at odds with our results (Figures 2.2, 
2.5-2.18, 2.20-2.22) and those of most other studies (114). 
 The SGA-direct amplicon sequencing strategy used in the present study represents a 
substantial advance in sensitivity and molecular resolution for distinguishing closely and distantly 
related T/F HCV genomes and their evolving progeny. Studies of HCV specific CTL recognition 
and escape (47, 114, 142, 311), neutralizing antibody recognition and escape (61, 164), and DAA 
drug resistance development (213) have previously been performed without a precise 
identification of T/F viral genomes and future studies may benefit from such an approach. We 
could readily distinguish evolving viral lineages that differed from the T/F genome by just 1 
nucleotide in 5,000 (0.02%) at sites under selective pressure (Figures 2.22–2.23). This 
discriminating power further revealed evidence of acute-to-acute virus transmission in three 
subjects (Figures 2.15–2.18) and DAA drug-induced viral genetic bottlenecking in a donor to a 
fourth acutely infected subject (Figure 2.21). This exquisite sensitivity in distinguishing T/F virus 
genomes and their progeny stands in contrast to the 454- based approaches, which were unable 
to distinguish between T/F viruses that differed by less than 2.5% (325) and bulk PCR-clone- 
sequencing methods that used a cutoff of 3% diversity to distinguish homogeneous from 
heterogeneous virus transmission (104). Both of the latter methods are further confounded by the 
potential for Taq polymerase-mediated strand transfers leading to recombination artifacts in 
finished sequences (32, 128, 284). 
 The ability to identify actual T/F viral sequences and to track virus diversification from 
these sequences with single nucleotide resolution provided a unique opportunity to assess HCV 
sequence evolution in vivo. Virus diversification from discrete T/F viruses was generally star-like 
and conformed well to our HCV adapted model of early virus diversification. The finding of only a 
single instance of potential CTL escape or reversion among 17 acutely infected subjects at the 
last sampling time point is consistent with previous reports indicating substantial delays in the 
onset of adaptive immunity to HCV (25, 236). The overall nucleotide substitution frequency that 
we observed among all subjects and including all sampling time points was 1.4x10-4. This 
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substitution frequency is different from the mutation rate since it does not account for time, 
numbers of replication cycles, or different modes of HCV replication (linear versus geometric) (63, 
196, 261), nor does it account for nucleotide substitutions introduced by the MuLV polymerase 
(Superscript III) during cDNA synthesis. The latter is estimated to occur at a frequency as low as 
2x10-6 (178) and thus likely contributes negligibly to the mutation frequencies observed in the 
present study. Consistent with this interpretation were our results of single genome sequencing 
performed on the earliest vRNA positive plasma sample from subject 10051 where we found that 
43 of 46 5' quarter 1 genome sequences were identical (Figure 2.6). Among all 46 sequences, 
there were only four nucleotide substitutions in 100,050 nucleotides. This corresponds to a 
combined substitution frequency for the HCV polymerase and the Superscript III MuLV 
polymerase of 4x10-5, Again, this result does not account for the numbers of HCV replication 
cycles occurring between the moment of virus transmission and the time point of sampling, which 
in this case was very early during the viral ramp-up period when the plasma virus load was 
approximately 10,000 vRNA molecules/ml (Figure 2.1). In an accompanying report (238), we 
describe a new stochastic model of HCV replication and diversification that provides for a more 
precise estimation of the in vivo HCV RdRp error rate, which was found to be ~2.5x10-5 per base 
per generation. This is lower than previous reports for HCV (51, 261) and comparable to the RT 
error rate of HIV-1 (180, 261). 
 We found a low dN/dS ratio consistent with early negative or purifying selection and a 
strong 18 to 1 mutational bias for transitions over transversions in acute infection. The latter 
finding is consistent with a recent report by Gotte and colleagues (226) who studied sequence 
evolution in chronically infected subjects and in vitro where a strong preference for G:U/U:G 
mismatches was observed for recombinant HCV RdRp. A mutational bias favoring transitions 
may be a factor besides RdRp error rate that influences the rate of development of DAA 
resistance mutations (226). Importantly, we found no evidence of viral recombination in any 
subject, which would have been plainly evident in those subjects infected by multiple genetically 
diverse viral genomes (Figures 2.7C, D; 2.8; 2.9–2.14; 2.16). The absence of recombination 
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distinguishes HCV from HIV-1, where early recombination is widespread (11, 154, 275), but is 
consistent with molecular epidemiological data that suggest that HCV recombination is rare (17, 
123, 201, 300). In addition, the failure to find plus-plus strand recombination in any of the 
sequences in the present report shows that strand switching by the MuLV reverse transcriptase 
(RT) in vitro must be extremely rare. This is important because it demonstrates that MuLV RT-
mediated recombination does not confound single genome sequence analyses of HCV or other 
RNA viruses including HIV-1 and SIV (128, 129, 258). On the other hand, we did observe seven 
examples of template switching between plus and minus strands of double- stranded HCV RNA 
templates (Figure 2.24). We could not determine if this resulted from strand switching by MuLV 
RT in vitro or by HCV RdRp in vivo. We note that Branch and colleagues (133) recently reported 
high levels of double-stranded HCV RNA in hepatic tissue, thus providing a plausible source of 
dsRNA for the observed template switching events. 
 A surprising finding of the current study was evidence of acute- to-acute HCV 
transmission in a relatively high proportion (3 of 17) of subjects. The acute infection period of 
HCV, like that of HIV-1, is characterized by very high plasma virus loads, absence of neutralizing 
antibodies, and rapid expansion of biologically fit virus populations that are homogeneous relative 
to the respective T/F virus genomes (84, 177, 209). For HIV-1, the acute and early infection 
period has been shown to be associated with hyper- transmissibility with epidemiological studies 
and epidemic modeling indicating substantial enhancement in spread of the virus as long as six 
months post-transmission (28, 105, 222, 328). In the simian immunodeficiency virus (SIV) – 
Indian rhesus macaque transmission model, virus from acute infection plasma is up to 750-fold 
more transmissible on a per virion basis than is virus from chronic infection plasma (173). To our 
knowledge, a clinical predilection for acute-to-acute HCV transmission has not previously been 
reported. In addition to the three subjects whom we identified with putative acute-to-acute HCV 
transmission, an argument can be made for an additional potential case in subject 10017 in 
whom distinct subsets of closely related T/F sequences were found within a context of high 
overall sequence diversity (e.g., see lineages v1 and v3; Figure 2.14). In this example, a plausible 
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scenario is that a virus ‘donor’ to subject 10017 was acutely infected by multiple genetically-
diverse viruses and that multiple progeny representing several of these lineages were 
transmitted. The implication of these findings is that if the acute period of HCV infection is 
characterized by hyper-infectiousness as is the case for HIV-1, it could be a previously 
unrecognized but important contributing factor to the spread of HCV, potentially contributing to a 
recently described emerging HCV ‘epidemic’ in HIV-1 positive men who have sex with men (70, 
319). A limitation in our evidence supporting ‘acute-to-acute’ infection is that our study design did 
not allow us to identify paired donors and recipients of virus in order to analyze virus transmission 
directly. Future viral sequencing studies involving social networks of HCV transmission partners 
(252), or analyses of cryopreserved plasma specimens from previously conducted acute-to-acute 
human-to-chimpanzee HCV transmission studies (33), can provide corroborative evidence. We 
note that there is precedent for phylogenetic linkage of HCV sequences in a human-to-human 
transmission case where clinical epidemiologic linkage between donor and recipient was 
established (164). 
 Still another surprising observation in this study was transmission of what we estimated 
to be as many as 30 NS3 protease- resistant viruses to subject 106889 (Figure 2.21). These 
mutations (V36M and R155K) confer high-level resistance to both Boceprevir and Telaprevir, 
which were used in clinical trials near the time when 106889 samples were collected. Recently, 
we performed single genome sequencing of plasma viral RNA from subjects before and after 
treatment with a next generation investigational HCV protease inhibitor and observed viral genetic 
bottlenecking closely resembling that found in subject 106889 (unpublished data). To our 
knowledge, the data from subject 106889 is the first example of high multiplicity DAA drug 
resistant virus transmission, and the findings here illustrate how transmission of DAA resistant 
mutants can be deciphered with single genome specificity and sensitivity. 
 The identification of T/F genomes of HCV, HIV-1 (128), SIV (129) and potentially other 
RNA viruses by single genome sequencing is an enabling experimental strategy that captures 
molecular entities that are wholly sufficient and responsible for productive clinical infection and 
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disease causation. In an accompanying report (238), we use sequences derived by this approach 
to analyze and mathematically model the early dynamics of HCV replication and diversification in 
acutely infected humans and derive new estimates of the in vivo mutation rate of HCV. A second 
application of the single genome sequencing method is to reveal through enumeration of T/F 
genomes, the challenge that vaccine candidates face in attempting to prevent or constrain HCV 
transmission. In a third application of the method, we previously demonstrated for HIV-1 that 
single genome sequencing allows for the molecular identification, cloning and biological 
characterization of full-length T/F genomes and a comprehensive proteome-wide analysis of 
autologous, strain- specific patterns of cytotoxic T-cell and neutralizing antibody responses (12, 
88, 202, 258, 332). By demonstrating that early HCV diversification generally conforms to a 
model of essentially random virus evolution where sequences coalesce to distinct, unambiguous 
T/F genomes, the present study has taken the first critical steps to demonstrate the feasibility of 
similar genome-wide analyses for HCV. An intriguing possibility is that full-length T/F HCV 
genomes, which by definition possess nucleotide and amino acid sequences sufficient for efficient 
in vivo replication in humans, can be identified, molecularly cloned and expressed for biological 
analyses in cell culture and animal models. 
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Materials and Methods 
 Ethics statement. This study was conducted according to the principles expressed in the 
Declaration of Helsinki. It was approved by the Institutional Review Boards of the University of 
Pennsylvania, the University of Alabama at Birmingham and Duke University. Subjects provided 
written informed consent for the collection of blood samples and subsequent analyses. 
 Study subjects. Plasma samples were obtained from 17 subjects with acute HCV 
infection. These subjects were regular source plasma donors (ZeptoMetrix, Inc.; SeraCare, Inc.) 
who were HCV and HIV-1 antibody negative but who became HCV infected sometime in the 
course of their twice-weekly plasma donations as evidenced by the development of HCV viremia 
on sequential viral RNA testing (Figure 2.1). The subjects were asymptomatic throughout the 
collection period and did not receive anti-HCV treatment. By the time of the last sample collection, 
5 of the subjects had seroconverted to HCV antibody positivity. Plasma samples from 14 patients 
from University of Alabama at Birmingham with chronic, treatment-naïve HCV infection were 
obtained as controls. 
 HCV RNA and antibody assays. Plasma samples were tested for HCV RNA and 
antibodies by a battery of commercial tests. These included Roche COBAS AmpliPrep/COBAS 
Taqman HCV vRNA assay; ABBOTT Anti-HCV 3.0 Assay and ORTHO Enhanced SAVe Anti-
HCV 3.0 Assay. HCV vRNA analyses were performed according to manufacturer’s specifications 
(http://www.accessdata.fda.gov/ cdrh_docs/pdf6/P060030c.pdf) in a CLIA certified laboratory with 
all assay controls meeting predetermined parameters for assay sensitivity and specificity and with 
a dynamic linear range of 43 to 6.9x107 vRNA IU/ml. 
 Viral RNA extraction and cDNA synthesis. For each plasma sample, approximately 
100,000 viral RNA copies were extracted using the QiagenBioRobot EZ1 Workstation with EZ1 
Virus Mini Kit v2.0 (Qiagen, Valencia, CA). RNA was eluted and immediately subjected to cDNA 
synthesis. Reverse transcription of RNA to single stranded cDNA was performed using MuLV 
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(SuperScript III) reverse transcriptase using methods recommended by the manufacturer 
(Invitrogen Life Technologies, Carlsbad, CA). Briefly, each cDNA reaction included 16 RT buffer, 
0.5 mM of each deoxynucleoside triphosphate, 5 mM dithiothreitol, 2 units/ul RNaseOUT (RNase 
inhibitor), 10 units/ ul of SuperScript III reverse transcriptase, and 0.25 uM antisense primer. The 
antisense primers were designed specifically for different genotype. 1.NS4A-R1 5'-
GCACTCTTCCATCT-CATCGAACTC-3' (nt 5451–5474 H77 (accession number NC_004102)) for 
genotype 1, 2NS2-R1 5'-CCCCAGACGAT-GACTTTCTTCTCCAT-3' (nt 5445–5467 H77) for 
genotype 2 and 3aNS3-R2V2 5'-TTACTTCCAGATCAGCTGACA-3' for genotype 3. The reverse 
transcription reaction was carried out at 50°C for 60 minutes followed by an increase in 
temperature to 55°C for an additional 60 minutes. The reaction was then heat- inactivated at 
70°C for 15 minutes and then treated with 0.1 U/ul RNaseH at 37°C for 20 minutes. The newly 
synthesized cDNA was used immediately or kept frozen at -80°C. 
 Single genome amplification. cDNA was serially diluted and distributed among wells of 
replicate 96-well plates (Applied Biosystems, Foster City, CA) so as to identify a dilution where 
PCR positive wells constituted less than 30% of the total number of reactions. At this dilution, 
most wells contain amplicons derived from a single cDNA molecule. This was confirmed in every 
positive well by direct sequencing of the amplicon and inspection of the sequence for mixed 
bases (double peaks), which would be evidence of priming from more than one original template 
or the introduction of PCR error in early cycles. Any sequence with evidence of mixed bases was 
excluded from further analysis. PCR amplification was carried out in the presence of 16 High 
Fidelity Platinum PCR buffer, 2 mM MgSO4, 0.2 mM of each deoxynucleoside triphosphate, 0.2 
uM of each primer, and 0.025 units/ul Platinum Taq High Fidelity polymerase in a 20 ul reaction 
(Invitrogen, Carlsbad, CA). The nested or hemi-nested primers for generating 5' half or 5' quarter 
genome from different genotypes included: (1) 5' half genome of genotype 1:  1st round sense 
primer 1.core.F1 5'-ATGAGCACGAATCCTAAACCTCAAAGA-3' (nt 342–368 H77) and 1st round 
antisense primer 1.NS4A.R1 5'-GCACTCTTCCATCTCATCGAACTC-3' (nt 5451–5474 H77), 2nd 
round sense primer 1.core.F2 5'-TCAAAGAAAAACCAAACGTAACACCAACCG-3' (nt 362–391 
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H77 and 2nd round antisense primer 1.NS3A4A.R2 5'-AGGTGCTCGTGACGACCTCCAGG-3' (nt 
5297–5319 H77); (2) 5' quarter genome of genotype 2: 1st round sense primer 2.core.F1 5'-
ATGAGCACAAATCCTAAACCTCAAAGA-3' (nt 342–368 H77) and 1st round antisense primer 
2.NS2.R1 5'-CCCCACACAATGACCTTCTTCTCCATTG-3' (nt 5445–5467 H77), 2nd round sense 
primer 2.core.F2 5'-AATCCTAAACCTCAAAGAAAAACCAAA-3' (nt 351–377 H77) and 2nd round 
antisense primer 2.NS2.R2 5'-GGGGAGAGGTGGTCATAGATGTAA-3'; (3) 5' half genome of 
genotype 3: 1st round sense primer 3a.core.F1 5'-ATGAGCACACTTCCTAAACCTCAAAGA-3' 
and 1st round antisense primer 3aNS3-R1V2 5'-TTACTTCCAGATC-AGCTGACA-3', 2nd round 
sense primer 3a.core.F2 5'-TCAAAGAAAAACCAAAAGAAACACCATCCG-3' and 2nd round 
antisense primer PCR 3a.NS3-R2V2 5'-TTACTTCCAGATCAGCTGACA-3'. PCR was performed 
in MicroAmp 96- well reaction plates (Applied Biosystems, Foster City, CA) with the following 
PCR parameters: 1 cycle of 94°C for 2 min; 35 cycles of a denaturing step of 94°C for 15 s, an 
annealing step of 58°C for 30 s, an extension step of 68°C for 5 min, followed by a final extension 
of 68°C for 10 min. The product of the 1st round PCR was subsequently used as a template in 
the 2nd round PCR under same conditions but with a total of 45 cycles. Amplicons were 
inspected on precasted 1% agarose E-gels 96 (Invitrogen Life Technologies, Carlsbad, CA). All 
PCR procedures were carried out under PCR clean room conditions using procedural safeguards 
against sample contamination, including pre-aliquoting of all reagents, use of dedicated 
equipment, and physical separation of sample processing from pre- and post-PCR amplification 
steps. 
 DNA sequencing. PCR amplicons were directly sequenced by cycle-sequencing using 
BigDye terminator chemistry and protocols recommended by the manufacturer (Applied 
Biosystems; Foster City, CA). Sequencing reaction products were analyzed with an ABI 3730xl 
genetic analyzer (Applied Biosystems; Foster City, CA). Both DNA strands were sequenced using 
partially overlapping fragments. Individual sequence fragments for each amplicon were 
assembled and edited using the Sequencher program 5.0 (Gene Codes; Ann Arbor, MI). 
Inspection of individual chromatograms allowed for the identification of amplicons derived from 
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single versus multiple templates. The absence of mixed bases at each nucleotide position 
throughout the entire 5' half or quarter genome sequences was taken as evidence of amplification 
from a single viral RNA/cDNA template. This quality control measure enabled us to exclude from 
the analysis amplicons that resulted from PCR-generated in vitro recombination events or Taq 
polymerase errors and to obtain multiple individual sequences that proportionately represented 
those circulating HCV virions. 
 Sequence alignments. All the sequences alignments were initially made with ClustalW 
and then hand-checked using MacClade 4.08 to improve the alignments according to the codon 
translation. All 2922 5' half or quarter-genome sequences from acute and chronic patients were 
deposited in GenBank and edited alignments can be accessed at 
http://www.hiv.lanl.gov/content/sequence/hiv/user_alignments/Li2012.html. 
 Sequence diversity analysis. Two thousand three 5' half genomes and 919 5' quarter 
genomes were amplified by SGA-direct amplicon sequencing from the 31 subjects. Half genome 
sequences were generated so as to obtain longer sequences for linkage analyses, whereas 
quarter genome sequences were generated to enhance sensitivity of amplification from early 
samples with lower viral loads. Among the 3168 amplicons generated, the sequences of 2922 
were unambiguous at every position. The other 246 amplicons contained one or more ‘‘double 
peaks’’ representing mixed bases and these were discarded and not included in the analysis. The 
median number of sequences analyzed per time point was 54 (mean = 54; range = 5–122) for 
acutely infected subjects and 25 (mean = 27; range = 13–44) for chronically infected subjects. A 
total of 2922 sequences from all 17 acutely-infected and 14 chronically-infected subjects were 
analyzed using phylogenetic tree analysis together with a sequence visualization tool, Highlighter 
(www.HIV.lanl.gov), that allows tracing of common ancestry between sequences based on 
individual nucleotide polymorphisms. Phylogenetic trees were generated by maximum likelihood 
methods using PhyML (98) or RAxML-VI-HPC (287). For subjects productively infected by more 
than one T/F virus, lineages contained more than 5 closely related sequences were included in 
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the lineage diversity analyses. Lineage-specific sequences were analyzed by the Poisson Fitter 
program (www.HIV.lanl.gov). 
 Mutation rate calculation. A total of 30 T/F lineages from 17 acutely-infected subjects 
were analyzed. Each sequence within the lineage was compared with the T/F virus sequence of 
that lineage. The insertion, deletion, transition and transversion frequencies were counted 
manually or by computer program. The rates were calculated by taking the ratio of each 
frequency number and the total number of nucleotides of all the sequences within that lineage. 
 Synonymous and non-synonymous substitution rate analysis. The SNAP program 
(www.HIV.lanl.gov) was applied to the codon-aligned sequences of each T/F lineage. Within each 
lineage, the number of synonymous and nonsynonymous substitutions were derived by 
comparing to the T/F viral sequences. The accumulation rates of synonymous substitutions per 
potential synonymous site and nonsynonymous substitution per potential nonsynonymous site 
were compared to screen for positive selection. 
 Mathematical models and algorithms for estimating numbers of T/F variants. Two 
mathematical models were used to analyze early HCV sequence diversity. The first was originally 
designed for HIV-1 and has been previously described in detail (82, 128, 151). The second is a 
simplified deterministic model that accounts for the essential differences in replication dynamics 
between HCV and HIV-1, taking into account HCV’s replication cycle, that HCV replication occurs 
via a cytosolic replication complex, and that there can be many replication complexes 
continuously producing viruses from a long- lived infected cell. In this model, each HCV 
replication complex was assumed to give rise to a new replication complex at regular intervals by 
undergoing two RdRp copying events. These complexes, which may reach 40 per cell (230), 
were presumed to persist and produce viruses for the entire duration of the acute infection 
sampling period. Because of the sequential creation of the complexes, those at the same 
generation depth have widely varying number of descendants, unlike the situation in HIV (Figure 
2.4). An average pair of HCV viruses then has a later most common ancestor than does HIV. As 
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a result, the model predicts that sequences with a small number of shared mutations can arise in 
a subject at detectable frequencies prior to the onset of immune selection. This translates to an 
expectation of about 3 times larger numbers of stochastically shared mutations in HCV than in 
HIV, with the potential to violate the star-like hypothesis more often. Furthermore, the persistence 
of HCV replication complexes of all generations means that, in contrast to the situation in HIV, the 
Poisson distribution is not necessarily a good model for inter- sequence distances prior to 
selection, and sequences with distances that deviate from Poisson distribution canbe derived 
from a single T/F viral genome. Our simple model of HCV diversification accounts for these 
issues and is amenable to an analytical approach. At the same time, the numerical results from 
the simplified model are consistent with those from a more detailed agent based stochastic model 
of early HCV infection that we present in an accompanying paper (238). 
 The implementation of the clustering algorithm works on a phylogenetic tree describing 
the evolutionary relations between these sequences and aims to identify monophyletic clusters 
that could reasonably have arisen by evolution in the infected individual. The modeling in Ribeiro 
et al. (238) shows that these clusters should satisfy two separate criteria: (a) the total number of 
mutations that could have accumulated is limited by the mutation rate of the virus and the 
generation time, and (b) the number of mutations shared by distinct sequences from a single T/F 
virus is related by coalescent theory to the growth and stabilization of viral load in these acute 
infections. Starting at the tips of the phylogenetic tree, our algorithm identifies the largest clusters 
that are consistent with these two criteria. Following from (a), every replication complex present in 
the body produces a new generation of replication complexes about once a day. Following from 
this, at time t days into infection, the most divergent replication complex is t generations from the 
founder, but most replication complexes are of generation t/2. We therefore split the clusters 
whose average divergence is larger than expected from this scenario. Following from (b), if one 
samples approximately 30–100 sequences in the initial weeks of infection prior to the onset of 
immune selection, 1–10 pairs of sequences are expected to coalesce 4–7 generations after the 
T/F virus. Assuming a mutation rate of 2.5x10-5 per base per generation (238), this corresponds 
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to a probability of more than 5% of seeing 3–4 shared mutations in 5000 bases. Thus, to be 
conservative in our model estimates of minimum numbers of T/F genomes, wedefined clusters of 
sequences as having >4 shared mutations in a half genome, or >2 in a quarter genome, as 
unambiguously to have arisen from a different founder variant. 
 In the case of acute-to-acute infections, however, the average divergence is a very weak 
measure for delineating the clusters. In particular, transmission of one or a few highly divergent 
sequences affects the average little, and they are often not identified as separate variants when 
they are likely to represent a distinct founder. Thus, mean diversity is a robust measure but 
occasionally allows one or a few highly divergent sequences to be counted as a part of the 
cluster. To provide an estimate of the number of T/F variants that takes this into account, we also 
calculated the number of clusters by implementing a threshold on the most distant tip from the 
inferred ancestor for each cluster, splitting clusters based on the maximum distance that is 
improbable. Though this provides a better overall estimate for the number of clusters, such 
extreme-value statistics are more affected by the approximations made in going from the fully 
stochastic to the deterministic model. We verified that the main conclusions of this paper, 
including the identification of three subjects as cases of acute-to-acute transmission, follow from 
either of the two methods of identifying T/F lineages. Both of these methods provide a minimum 
estimate for the number of T/F viruses for two reasons. First, the number of shared mutations we 
have allowed within a cluster provides a highly conservative criterion and lineages could still 
contain closely related but distinct transmitted viral sequences, a situation made likely by our 
identification of probable cases of acute-to-acute virus transmission. Second, finite depth of 
sequencing means we might miss T/F clusters that are represented by a small fraction of 
sequences. To estimate the impact of this second scenario, we performed direct power 
calculations as previously described (128) to assess the likelihood of missing infrequent T/F 
sequence lineages based on sampling depth. 
 Finally, acute samples are often very homogeneous and can have conflicting 
phylogenetic signals, and these calculations rely on the phylogenetic tree being a description of 
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the true evolutionary relations. In cases of infection with two highly divergent strains, the 
descendants of the two strains form distant outgroups from each other, and homoplasy on the 
long branch linking the two may root the individual clusters suboptimally. To avoid this problem, 
our algorithm looks for long branches (longer than 30 mutations), deletes them, and applies the 
rest of the algorithm to each of the then disconnected clusters. After identifying these clusters, the 
roots of each of these is chosen as tentative transmitted founder viruses. The paths in the 
phylogenetic tree between these roots represent evolution that happened prior to infection, 
whereas the paths linking the roots to the tips indicate within host evolution. Occasionally, we find 
overlap between the two sets of paths indicating convergent evolution between the donor and the 
recipient infected individuals. Since convergent evolution is unlikely, we further subdivide the 
previously found clusters to avoid this. After finding the optimal clustering at each time point, the 
results are mapped on to a tree of all the sequences obtained at various time points from the 
same individual. The overall number of clusters is then found by merging clusters from different 
time points that interleave, and leaving the other clusters as distinct. In the scenario of early 
infection when there are very few mutations, the tree can be ambiguous because of single 
conflicting mutations causing polytomies; while this could theoretically make the number of 
transmitted variants ambiguous, this was not the case in our analysis of this sequence set. Codes 
written in C that implement these two clustering strategies (using either maximum or average 
distances to define clusters) are available at http://www.santafe.edu/~tanmoy/programs/HCV/. 
 Statistical analyses and power calculations. Standard descriptive statistics including 
Mann-Whitney and unpaired T-tests with Welch’s correction were employed and identified 
throughout the text. Power calculations to estimate the likelihood of detecting rare sequence 
variants based on sampling depth were performed as previously described (128). Estimates of 
the probability that observed clusters of nonsynonymous mutations in the Env E2 coding region of 
putative T/F viral genomes from subjects 10003, 10016 and 10020 could have occurred by 
chance were performed with a binomial expansion as previously reported (257). We considered 



















cell epitopes and potential linear neutralizing antibody epitopes. From the binomial expansion, the 




where r is the number of potential 10-mers, m is the total number of mutations relative to the 
consensus, and p is the probability that a mutation falls by chance in any particular 10-mer. We 
calculated the probability only for k' = k, since the results for all k'>k are very much smaller and 
can be ignored. Only nonsynonymous mutations were included in the analysis. Within the 10-
mers of interest, but not elsewhere along the alignment, different amino acid substitutions and 
combinations of substitutions were identified and analyzed. 
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Hepatitis C virus (HCV) is present in the host with multiple variants generated by its error prone 
RNA-dependent RNA polymerase. Little is known about the initial viral diversification and the viral 
life cycle processes that influence diversity. We studied the diversification of HCV during acute 
infection in 17 plasma donors, with frequent sampling early in infection. To analyze these data, 
we developed a new stochastic model of the HCV life cycle. We found that the accumulation of 
mutations is surprisingly slow: at 30 days, the viral population on average is still 46% identical to 
its transmitted viral genome. Fitting the model to the sequence data, we estimate the median in 
vivo viral mutation rate is 2.5x10-5 mutations per nucleotide per genome replication (range 1.6–
6.2 x10-5), about 5-fold lower than previous estimates. To confirm these results we analyzed the 
frequency of stop codons (N = 10) among all possible non-sense mutation targets (M = 898,335), 
and found a mutation rate of 2.8–3.2 x10-5, consistent with the estimate from the dynamical 
model. The slow accumulation of mutations is consistent with slow turnover of infected cells and 
replication complexes within infected cells. This slow turnover is also inferred from the viral load 
kinetics. Our estimated mutation rate, which is similar to that of other RNA viruses (e.g., HIV and 
influenza), is also compatible with the accumulation of substitutions seen in HCV at the 
population level. Our model identifies the relevant processes (long-lived cells and slow turnover of 




Hepatitis C virus (HCV) is a RNA virus that infects over 170 million people across the world. It 
leads to a chronic infection in the majority of people who are infected (>70%). Most people only 
discover that they are infected long after initial infection. Thus, it is difficult to study the very early 
events in infection. Here we study 17 individuals during the earliest possible stages of infection, 
from before the virus is detectable in the plasma to around 35 days post- infection. We focus on 
understanding the viral kinetics and the diversification of HCV during this acute phase of infection. 
During chronic infection HCV is present in the host as a swarm of multiple variants generated by 
its error prone copying. We studied the early diversification of HCV during acute infection using a 
new mathematical model of HCV replication. We found that after a phase of fast increase in viral 
load, accompanied by viral diversification, there is a stabilization of viral load and diversity levels. 
Using our model, we were able to estimate for the first time the HCV mutation rate during acute 
infection. We estimated the median in vivo viral mutation rate is 2.5x10-5 mutations per nucleotide 
per genome replication (range 1.6–6.2x10-5), about 5-fold lower than previous estimates. We also 
used a different approach, based on results of classical genetics, to calculate HCV’s mutation 




Hepatitis C virus (HCV) is a member of the hepacivirus genus within the flaviviridae family of 
virus, and it has a single positive stranded RNA molecule (~9500 nucleotides) as its genome 
(161, 193, 196). After entering a cell this RNA is translated into a single large polyprotein, which 
is cleaved to produce the viral structural and non-structural (NS) proteins (161, 193, 196). The 
NS5B protein is a viralspecific polymerase, which is involved in replicating the HCV RNA genome 
(161, 193, 196, 230). During genome replication the virion’s positive strand RNA is copied into a 
complementary negative strand, which then must be copied back to produce a new positive 
strand. In the simplest replication model, this negative strand or a complex of the original positive 
strand and the newly created negative strand form an intermediate that acts as the template for 
producing new positive strands. This template plus various nonstructural proteins form a structure 
called a replication complex (232). If all new positive strands, and hence virions, are created from 
the same replication complex, we say that replication occurs by a ‘‘stamping machine’’ 
mechanism (42, 261, 263, 268). However, HCV infected cells often have more than one 
replication complex; indeed in vitro and in situ studies suggest there are about 40 such 
complexes in one infected cell (40, 230). 
The HCV polymerase is an RNA-dependent RNA polymerase (RdRp) and hence does not 
possess error correcting mechanisms. Thus HCV replication, like that of other RNA viruses, is 
highly error prone (161, 193, 196). Measuring the actual mutation rate, which derives both from 
the (+)RNA to (-)RNA and the (-)RNA to (+)RNA steps of replication, has been difficult (63, 226, 
259). A recent study determined the intrinsic error rate of the HCV polymerase in vitro using 
enzyme kinetic measurements (226). They found high error rates, of ~10-3 per site, for transitions 
and about 100-fold lower rates for transversions. Still, the in vivo mutation rate is likely different. 
Mutation is difficult to estimate in vivo due to selection, multiple rounds of replication and 
incomplete sampling (63, 259). One proposed way to determine the in vivo mutation rate is to 
estimate it based on the frequency of lethal mutants in the viral population at any given time (51). 
In fact, classical genetics shows that the frequency of a lethal mutation in a haploid population in 
82	  
mutation-selection balance is µ, the mutation rate. A recent study used this method to estimate 
an upper limit for the in vivo mutation rate of HCV as (1.15 ± 0.29)x10-4 per nucleotide per 
replication round (51), which is within the range of other RNA viruses (261). 
This high mutation rate is consistent with the high degree of HCV diversity found across the 
population of infected individuals (276, 344). Indeed, HCV is highly variable, with multiple 
subtypes, and a global diversity that is higher than that of HIV-1 (344). Clearly, this population 
level diversity, which reflects the HCV evolution rate, is in part prescribed by the mutation rate of 
the virus in vivo (260). Moreover, in chronically infected individuals the HCV viral population is 
also diverse (181). This diversity allows fast evolution and escape from immune (72) or antiviral 
drug pressure (248), and may contribute to HCV pathogenesis (72, 271). 
An important question is how HCV diversity is generated. While it clearly depends on the 
mutation rate, we shall show using a model of HCV replication that it also depends on other 
parameters of the HCV life cycle (42, 263, 268), such as the long-lived nature of infected cells, as 
compared to HIV infected cells (199, 215), the existence of multiple replication complexes within 
an infected cell (40, 230), and the turnover rate of these replication complexes. In order to 
validate this model and obtain quantitative estimates of the in vivo HCV mutation rate, we shall 
exploit our observations in an accompanying report (155) and those of others (32, 325) that 
during the initial stages of primary infection the viral population is comprised of discrete low 
diversity lineages of viral sequences emanating from the transmitted/founder viral genomes (155). 
Further, early on, diversity increases with time since infection. We shall show that the rate of 
diversification is not constant but rather slows as infection is established. Our model provides a 
quantitative explanation for this phenomenon. Analyses of HIV evolution in acute infection have 
been used to estimate the time since infection (128, 151). Here, we know with reasonable 





In Primary Infection HCV RNA Levels Expand Quickly and then Plateau at a High Level. 
The early dynamics of viral increase in HCV infection is different from that seen in other chronic 
infections, such as HIV (239) and HBV (45). The HCV viral load in the subjects in this study 
increases roughly exponentially until it reaches a plateau (Figure 3.1A). This has also been 
observed in a prior study of acute HCV infection (84) and observed in chimpanzees 
experimentally infected with HCV (52). Quantitative characteristics of this early increase are given 
in Table 3.1. The median time between the last negative sample and the first HCV positive 
sample in our dataset was 5 days, which is consistent with a viral dynamics analysis of larger 
numbers of plasma donors (84). Because of this short interval, we assumed that the virus started 
expanding at the last negative sample. If the virus started expanding after this, our estimated 
expansion rate would be an underestimate. The median HCV RNA exponential growth rate was 
2.2/day, corresponding to a doubling time of 0.31 days (or 7.4 hours). The median peak viral load 
observed was 3x106 HCV RNA IU/ml and it took a median of 21 days to reach this level. The 
virus then stayed at approximately this high viral load level for a median of at least 26 days. In 
two subjects, we did not have enough follow-up to conclusively affirm whether a plateau exists or 
not. These estimates are in agreement with a previous study of 77 plasma donors with longer 
follow-ups, which reported an estimate of ~6 days of viral expansion before the first positive 
measurement (compared to a median of 5 days in our dataset) and a mean plateau duration of 
~56 days (84). 
The observation of the viral load plateau suggests that the number of infected cells reaches a 
steady state level a couple of weeks post infection. It is possible that this is a dynamic steady 
state, with removal of infected cells in equilibrium with generation of new infected cells. However, 
HCV is likely non-cytolytic (282), consistent with the normal levels of alanine aminotransferase 
(ALT<40 IU/L is upper limit of normal (125, 250) in these individuals early in infection (Figure 
3.1B). In addition, prior work has suggested that the cytolytic immune response takes weeks to 
months to emerge (52, 237, 272) (consistent with an increase in ALT to 10X to 20X the normal 
84	  
level late in acute infection (106)). Thus, it is likely that the rate of infected cell death during this 
early period is comparable to that of uninfected cells. The lifespan of uninfected hepatocytes has 
been estimated as being on the scale of months to years (174, 251), and thus infected cell death 
is probably negligible at these early times. In this case, the plateau in viral load suggests an 
equilibrium where all cells that can be infected are infected and producing virus. Assuming that 
there are 1011 hepatocytes in the liver (208), we estimate that a median of 6% (with range 1.7%–
22%) of these are infected across our subjects (Table 3.1), consistent with experimental 
measurements in chronic infection (39), including recent estimates by two-photon microscopy of 
frozen sections of liver tissue (160). Thus, primary HCV infection is characterized by fast growth 





Figure 3.1. Profile of (A) viral load and (B) ALT in the subjects studied. The black symbols 
are the observed viral loads, the lines are the simulated trajectories with the model described in 
methods, and the dashed lines correspond to 95% CI based on 100 simulations. The parameters 
used for the simulations are given in Table 3.1. (The first week of increase in virus is very variable 
due to the stochastic nature of the process, and it is not represented in the graphs.). The profiles 
of ALT in (B) are about normal (the upper limit of normal – ULN – is ~40 IU/ml (125, 250)) and 





















Table 3.1. Kinetic and simulation parameters for each subject studied. r – exponential 
growth rate; t2 – doubling time; VLmax – maximum viral load; Plateau – time that the virus remains 
at the plateau; Iss – percentage of cells infected at viral plateau, assuming that there are 1011 
hepatocytes (19); Q1/Q2/5h – quarter 1, quarter 2 and 5’ half HCV genome, respectively. Other 
symbols described in text. The mutation rate is µ×10-5 per nucleotide per replication cycle. 
followed by direct amplicon sequencing [23,26], otherwise known
as single genome sequencing [43], at multiple time points in the
subjects shown in Figure 1. SGA is achieved through serial dilution
of the cDNA obtained by reverse transcription of HCV RNA from
plasma (see Methods and [23] for details). We amplified 59 half-
genome sequences, on average 4879 nucleotides, covering core,
E1, E2, p7, NS2 and most of the NS3 proteins of HCV. For early
samples, with low viral loads, we amplified the same region, but in
two separate assays of one quarter genome each to enhance
sensitivity of amplification. In this way, we obtained 84 sets of
sequences for the 9 subjects at multiple (between 3 and 5) time
points. On average, we had 44 sequences per time point. All of the
sequences were deposited in Genbank; see Li et al. [23] for further
details and accession numbers.
Figure 1. Profile of (A) viral load and (B) ALT in the subjects studied. The black symbols are the observed viral loads, the lines are the
simulated trajectories with the model described in methods, and the dashed lines correspond to 95% CI based on 100 simulations. The parameters
used for the simulations are given in Table 1. (The first week of increase in virus is very variable due to the stochastic nature of the process, and it is
not represented in the graphs.). The profiles of ALT in (B) are about normal (the upper limit of normal – ULN – is ,40 IU/ml [33,34]) and much less
than typical later in primary infection, where they can reach 106 to 206 the normal value [37].
doi:10.1371/journal.ppat.1002881.g001
Table 1. Kinetic and simulation parameters for each subject studied.
Subject r t2 VLmax Plateau Iss h k m m m
(/day) (days) (log10/ml) (days) (%) (Q1) (Q2) (5 h)
9055 2.4 0.29 5.93 31 1.8 0.019 0.75 N/A N/A 4.5
10012 2.6 0.27 7.01 26 22 0.022 0.73 2.6 3.5 2.2
10017 2.0 0.35 5.98 26 2.1 0.014 0.89 5.3 3.8 3.9
10021 1.6 0.44 6.82 26 14 0.013 0.77 2.3 2.6 2.7
10024 1.2 0.59 6.47 N/A 6.4 0.008 0.86 2.6 1.9 2.5
10025 3.7 0.19 5.89 28 1.7 0.052 0.42 4.8 6.2 5.9
10029 1.8 0.39 6.77 23 13 0.014 0.82 2.2 2.4 2.3
10051 4.6 0.15 6.66 N/A 9.9 0.033 0.84 1.8 3.0 2.1
10062 2.2 0.31 6.42 38 5.7 0.018 0.75 3.8 1.6 2.3
Median 2.2 0.31 6.47 26 6.4 0.018 0.77 2.6 2.8 2.5
Mean 2.4 0.33 6.44 28 8.5 0.021 0.75 3.2 3.1 3.1
Std Err 0.4 0.04 0.14 2 2.3 0.004 0.04 0.43 0.48 0.45
r – exponential growth rate; t2 – doubling time; VLmax – maximum viral load; Plateau – time that the virus remains at the plateau; Iss – percentage of cells infected at viral
plateau, assuming that there are 1011 hepatocytes [40]; Q1/Q2/5 h – quarter 1, quarter 2 and 59 half HCV genome, respectively. Other symbols described in text. The
mutation rate is m61025 per nucleotide per replication cycle.
doi:10.1371/journal.ppat.1002881.t001
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Dynamics of Early HCV Diversification. To evaluate how HCV diversity changes during primary 
infection, we performed single genome amplification (SGA) followed by direct amplicon 
sequencing (128, 155), otherwise known as single genome sequencing (210), at multiple time 
points in the subjects shown in Figure 3.1. SGA is achieved through serial dilution of the cDNA 
obtained by reverse transcription of HCV RNA from plasma (see Methods and (155) for details). 
We amplified 5' half- genome sequences, on average 4879 nucleotides, covering core, E1, E2, 
p7, NS2 and most of the NS3 proteins of HCV. For early samples, with low viral loads, we 
amplified the same region, but in two separate assays of one quarter genome each to enhance 
sensitivity of amplification. In this way, we obtained 84 sets of sequences for the 9 subjects at 
multiple (between 3 and 5) time points. On average, we had 44 sequences per time point. All of 
the sequences were deposited in Genbank; see Chapter 2 for further details and accession 
numbers. 
We then aligned separately the set of sequences for each time point and for each sequence 
region and used a sequence visualization tool (Highlighter – www.HIV.lanl.gov), to analyze the 
sequence diversity based on individual nucleotides. This tool allowed us to identify low diversity 
monophyletic lineages corresponding to the putative transmitted/founder (T/F) viruses – the 
consensus at the earliest time point from SGA data (155). We next confirmed that these lineages 
were maintained across the times sampled, to guarantee that we were analyzing the 
diversification of the same lineage over time. In cases where there were two or more putative T/F 
viruses, we analyze only the dominant lineage, as SGA sequence data was too limited to study 
the minor lineages. 
From these 84 sequence alignments, we were able to study the evolution of the virus and the 
emergence of new mutations from very early in infection (mean: 7 days, range 2 to 15 days since 
the last negative sample across the 9 patients) until late in the plateau phase of viral load (mean: 
33 days, range 21 to 42 days). We found that HCV sequence diversity increases quickly early on, 
but then stabilizes in 7 patients, starting at about day 14; in subject 10051 there was not enough 
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follow up to assess this issue, and in subject 10029 a clear stabilization of diversity was not 
observed. The plateau of diversity occurred when an average of 46% of the sequences were still 
identical to the inferred T/F viral genomes. In three subjects (10029, 10062, 9055) there was an 
increase in diversity at late times, ~35 days. Note that for 10062, this is coincident with an 
increase in ALT levels suggesting turnover of infected hepatocytes (Figure 3.1B). 
We also found that in the vast majority of cases, HCV diversity at each time point was consistent 
with a star-like phylogeny, i.e. the viruses’ sequences coalesce at a single genome founder (82, 
151). The only exception was the 5'-half of 9055 at the last sampling time point, day 38, when 
there was evidence for the onset of immune selection (155). The mutations detected in the 
sequence sets also conformed to a Poisson distribution in the inter-sequence pairwise Hamming 
distances (151). The exceptions were the 5'-half of 10029 at day 13, the second 5' quarter of 
10029 at day 34, the second 5' quarter of 10051 at day 7, and the first quarter and 5'- half of 
10051 at day 21. Due to the specifics of the HCV replication life-cycle, one predicts occasional 
violations in star-like diversification and in the fit to the Poisson distribution, because there is a 
non-negligible probability of shared stochastic mutations between HCV sequences. That is, 
shared mutations may occur even in the absence of selective forces. See Chapter 2 for a more 
detailed discussion of these issues. 
Model of HCV Replication during Primary Infection. We next developed a model of HCV 
replication to study the time course of accumulation of mutations and to estimate the in vivo 
mutation rate of HCV needed to describe the observations above. This stochastic model of HCV 
replication allowed us to study the time course of viral load changes and the accumulation of 
mutations in the study subjects (see Chapter 3 Materials and Methods). In the model, we assume 
cells are infected by a single virion, i.e., that superinfection does not occur (265, 314). We further 
assume that in every infected cell, on average, only a fraction k of newly synthesized viral (+) 
strand RNA (vRNA) is exported in new virions, and the rest, 1-k, forms new replication complexes 
(RC). We assume that vRNA degradation can be neglected, i.e., that the newly synthesized 
vRNA is either rapidly complexed with proteins and converted into stable RC, or rapidly 
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encapsidated and exported. (Note that this is very different from analyses of HCV treatment, 
when production of vRNA and/or virion assembly/release may be blocked, and vRNA degradation 
becomes an important parameter in the clearance of infection (96)). These processes are 
assumed to continue until the cell generates a maximum number of replication complexes (RCM). 
Note that if we set k = 1, so that all synthesized vRNAs are exported, we recover the ‘‘stamping 
machine’’ mode of replication (42, 263, 268), where all virions result from the same replication 
complex, i.e., the same negative strand of RNA. The existence of multiple replication complexes 
within one cell corresponds to ‘‘geometric growth’’. In our model, after a virus is exported, a 
fraction 1-θ of the released virions is assumed to be cleared from circulation (232), and the 
remaining fraction, θ, is assumed to infect new cells. We also assume infected cells are long 
lived, and thus, we initially neglect death of infected cells during the first few weeks of infection. 
This assumption is consistent with the viral load profiles seen in the infected subjects, where viral 
load increases rapidly to a maximum level and plateaus at this level for weeks. 
We used our model to reproduce the viral load data (Figure 3.1A). For each subject, the only free 
parameter available to determine the trajectory of virus over time is the fraction of vRNA 
exported, k, since all other parameters are fixed a priori or are calculated as a function of k (see 
Chapter 3 Methods). We found that the model could describe the viral load data well with just this 
single adjustable parameter. The values estimated for k indicate that most of the synthesized 
vRNA is exported as virions (median k = 0.77, range 0.42–0.89). Moreover, the estimated values 
of k are quite similar among the different individuals, with the exception of 10025, who has a 
lower estimated k ( = 0.42). However, this subject has only one viral load measurement during 
the up-slope of the virus, which strongly influences the value estimated for k. Indeed, for this 
individual, choosing higher values for k lead to only slightly lower quality fits (not shown). 
The Mutation Rate of HCV In Vivo. Next, we used our model to analyze the diversification 
profiles of HCV in these patients. As the viral RNA is copied, errors in the incorporation of 
nucleotides are possible, i.e., mutations occur. If we let m denote the probability that a base in the 
newly produced virion differs from that in the infecting virion, then for the stamping machine 
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model the mutation rate, µ, is simply twice the rate at which bases are miscopied by the HCV 
RdRp, to account for the cycle of (+)RNA strand → (-)RNA strand → (+)RNA strand copying. With 
multiple replication complexes in a cell, opportunities exist for additional copying errors to be 
made since a newly synthesized (+)RNA strand needs to be copied again to make a replication 
complex. Every time a RNA strand incorporating a mutation is made, there is a probability that 
this mutation is lethal, and the virus or replication complex made from such RNA is nonfunctional. 
Prior experimental studies indicate that the fraction of random mutations that are lethal is about 
40% in RNA viruses (259). 
We incorporated mutation in our model to analyze the viral diversification data and estimate the 
mutation rate needed to match the observed accumulation of mutations. We assume that at time 
zero the putative T/F virus starts replicating and mutating. We then compute the decrease over 
time in the fraction of sequences identical to the T/F virus (i.e., ‘‘the fraction of unmutated 
viruses’’). We compare this model prediction to the identical measurement in our subjects and 
varied the mutation rate to obtain the best agreement between model and sequence data 
obtained from plasma HCV RNA, which corresponds to (+)RNA strands. 
The best description of the data was obtained for a median mutation rate (for the half-genomes) 
of µ = 2.5x10-5 per nucleotide per replication (Figure 3.2A–C). Moreover, this estimate was 
consistent across subjects and across regions of the genome (range: 1.6x10-5 – 6.2x10-5 per 
nucleotide per replication, Table 3.1). 
Our model exhibits a fast decrease in sequence identity early in infection, as the viral load 
increases exponentially and more and more cells are infected, followed by a stable viral diversity 
level as the virus reaches and stays at its plateau. This stasis in viral diversification is compatible 
with the assumption that the plateau in viral load corresponds to a stable pool of infected cells. 
This indeed seems to be the case for 5 of the patients (Figure 3.2A–C); for 1 case there is not 
enough data. If the plateau in viral load corresponded to a dynamic steady state in which infected 
cells were dying and being rapidly replaced, our model would predict a continuous increase in 
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diversification resulting from the continuous replacement of replication complexes. In a few cases, 
we did see an increase in diversity at times later than 30 days, and in three patients (10029, 
10062, and 9055) the observed long term behavior (later than about day 35) deviates from that 
predicted by our simulations. This difference between model and data could be due to sampling 
error, for example the 95% CI for theory and data at day 42 overlap for patient 10062. 
Alternatively, some processes not accounted for in the model may be operational at these later 
time points, leading to increased diversity. For example, for subject 9055 anti-HCV antibodies are 
detectable at this late time point and there is strong evidence of CTL selection (escape or 
reversion) (155); and for 10062 there is a late increase in ALT (Figure 3.1B), which suggests the 
initiation of a CTL response consistent with renewed cycles of infection. 
Our model also makes predictions about the distribution of mutations across the population. 
Interestingly, our model not only matches the fraction of unmutated viruses, but also the fraction 
of viruses with 1, 2, 3, ... mutations, even though this detailed data was not used to parameterize 
the model (Figure 3.3A–C). We obtained excellent agreement with the data, except when we 
observed a late increase in diversity in the three patients discussed above (10029, 10062, 9055). 
We tested this agreement for the 5' half genomes by a Monte Carlo test (108), since the number 
of expected mutations is low (<5) in several cases. The null hypothesis is that the data follows the 
theoretical expected values, and with the exception of those three patients, there was good 
agreement between observed and predicted mutation counts (p>0.05). Moreover, if we consider 
the distribution of mutations at the previous time for which we have SGA data, this agreement 
was also seen in 10029 and 10062 (p>0.05, and we cannot reject the null hypothesis). 
We next tested whether our results were dependent on the particular values assigned to the 
parameters that we fixed in the simulation (see Chapter 3 Methods). We found that both the viral 
load time course and the viral diversification were not sensitive to particular values of these 
parameters (Figure 3.4). For example, we assumed a maximum of RCM = 40 replication 
complexes per infected cell, as seen in vitro (230) and in situ (40). Clearly this number could be 
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different in vivo. However, our results were essentially the same, when we varied RCM from 10 to 
80 (Figure 3.4). 
To further confirm the robustness of our results, we next used the method suggested by Cuevas 
et al. (51) for estimating the mutation rate of HCV by analyzing the frequency of lethal mutations. 
Classical genetics shows that the frequency of lethal mutations is equal to the mutation rate, 
since all such mutations should be produced directly by mutation in the last replication round. As 
in Cuevas et al. (51), we used non-sense (stop codon) mutations as a proxy for lethal mutations. 
The concept is to count all stop codons in the data set and to divide this by the number of 
mutation targets (non-sense mutation targets – NSMT), i.e. codons that by a single mutation 
could generate a stop codon (see Chapter 3 Supporting Information for details). For these 
analyses, we were able to use all 17 patients in our cohort, thus expanding our data set. 
In total we had 898,335 NSMTs and 13 stop codons in the over 1x107 bases sequenced (155) 
(Tables 3.2 and 3.3). Surprisingly, 4 of the stop codons were identical and at the same position in 
10051 at two different time points (see Table 3.2). This strongly indicates that this stop codon 
appeared only once in this patient, and that stop codons may not be lethal in HCV but instead 
complemented by intact genomes within the same cell. Thus, we counted this stop codon only 
once, for a total of 10 mutations leading to stop codons. A calculation identical to that proposed in 
(51) then shows that µ = 3.2x10-5 per nucleotide per replication, which is fully consistent with our 
estimate above. We also propose an improved way to calculate this rate from the same data (see 
Chapter 3 Supporting Information), and with this method obtain µ = 2.8x10-5 (binomial 95% CI: 
1.4–5.2x10-5). 
Altogether, these data and analyses indicate that HCV sequences diversify early in infection, 
during the exponential increase of viral load, which is then followed by a plateau in diversity for up 
to a few weeks. The mutation rate needed to explain these observations (µ ≈ 2.5–3.2x10-5 per 
nucleotide per replication, Figure 3.3D) is 5 and 100 times smaller than previously reported for 
HCV (51) and its purified RdRp (226), respectively. 
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We next investigated in detail why HCV diversification appears to stop after a few weeks of 
infection, and what processes could break this plateau in diversity, since in chronic HCV infection 
the virus is much more diverse (155). In particular, we analyzed the effect of turnover of 
replication complexes and the emergence of the cytolytic immune response. 
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Figure 3.2. Fraction of sequences identical to the T/F virus over time. The symbols represent 
the SGA data and corresponding binomial 95% CI; the solid line is the average from 100 
simulations and the dashed line the 95% CI for the proportion (286). (A) data for the first quarter 
(Q1) of the 5' HCV genome (note that for subject 9055, there is no data for Q1 or Q2); (B) data for 
the second quarter (Q2) of the 5' HCV genome; (C) data for the 5' half of the HCV genome. 
(range: 1.661025–6.261025 per nucleotide per replication,
Table 1).
Our model exhibits a fast decrease in sequence identity early in
infection, as the viral load increases exponentially and ore and
more cells are infected, followed by a stable viral diversity level as
the virus reaches and stays at its plateau. This stasis in viral
diversification is compatible with the assumption that the plateau
in viral load corresponds to a stable pool of infected cells. This
indeed seems to be the case for 5 of the patients (Figure 2A–C); for
1 case there is not enough data. If the plateau in viral load
corresponded to a dynamic steady state in which infected cells
were dying and being rapidly replaced, our model would predict a
continuous increase in diversification resulting from the continu-
ous replacement of replication complexes. In a few cases, we did
see an increase in diversity at times later than 30 days, and in three
patients (10029, 10062, and 9055) the observed long term
behavior (later than about day 35) deviates from that predicted
by our simulations. This difference between model and data could
be due to sampling error, for example the 95% CI for theory and
data at day 42 overlap for patient 10062. Alternatively, some
Figure 2. Fraction of sequences identical to the T/F virus over time. The symbols represent the SGA data and corresponding binomial 95%
CI; the solid line is the average from 100 simulations and the dashed line the 95% CI for the proportion [64]. (A) data for the first quarter (Q1) of the 59
HCV genome (note that for subject 9055, there is no data for Q1 or Q2); (B) data for the second quarter (Q2) of the 59 HCV genome; (C) data for the 59
half of the HCV genome.
doi:10.1371/journal.ppat.1002881.g002
Estimates of the In Vivo HCV Mutation Rate
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Figure 3.3. Spectrum of mutations in the data. The last sampling time (closed symbol) and the 
corresponding prediction by the model derived as the average of 100 simulations (open symbol) 
and respective 95% binomial CI based on the estimated mutation rates indicated in Table 3.1 and 
Figure 3.2 for each subject. (A) data for the first quarter (Q1) of the 5' HCV genome (note that for 
subject 9055, there is no data for Q1 or Q2); (B) data for the second quarter (Q2) of the 5' HCV 
turnover. Rather than a sampling issue, it is possible that the
observed increase in diversity is due to an immune response
emerging at late time points, which leads to an increase of the
infected cell death rate (d). Indeed, this is indicated in studies of
experimental infection of chimpanzees, where the immune
response is delayed several weeks [31,36]. In this context, an
alternative explanation for the increase in diversity in 10062 is the
appearance of such an immune response as suggested by the
increase in ALT in this subject (Figure 1B). To study the effect of a
late immune respon e that kills infected cells, we allowed for this
process starting at 30 days post infection (Figure 4B). As expected,
the emergence of an immune response lowers the viral load,
possibly leading to a new lower viral load steady state, as is
observed in some experimentally infected chimpanzees [31]. With
the loss of infected cells, new cycles of infection occur along with
creation of new replication complexes, and the model predicts a
renewed increase in the accumulation of diversity, which mimics
the data in some subjects (eg., 10062, 9055). However, we do not
Figure 3. Spectrum of mutations in the data. The last sampling time (closed symbol) and the corresponding prediction by the model derived as
the average of 100 simulations (open symbol) and respective 95% binomial CI based on the estimated mutation rates indicated in Table 1 and
F ure 2 for each subjec . (A) data for the first quarter (Q1) of the 59 HCV genome (note that for subj ct 9055, there is no data for Q1 or Q2); (B) data
for the second quarter (Q2) of the 59 HCV genome; (C) data for the 59 half of the HCV genome. (D) Summary box plot of estimated mutation rates for
the different genomic segments.
doi:10.1371/journal.ppat.1002881.g003
Estimates of the In Vivo HCV Mutation Rate
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genome; (C) data for the 5' half of the HCV genome. (D) Summary box plot of estimated mutation 

















Figure 3.4. Changes in viral load and mutation profile predicted by the model for different 
values of the (A) maximum number of replication complexes (RCM) in an infected cell, (B) time 





















Table 3.2. Stop codons found in the acute infection data set. (1617 half genomes, 556 1st 
quarter and 363 2nd quarter genomes). Thirteen stop codons were observed but 4, bolded in the 
table, were at the same site and apparently from a single replication complex so they were 





5"*3%/*&67& '%82%/-%&67& 9+.+/& :;+<& !+& =2*"*3+/& !>,%&
5(??@(& (??@()(()ABC& DEE& FGF& HGF& FIJH& !;"/0K%;03+/&
5(??@(& (??@()(()ABL& DEE& FGF& HGF& FIJH& !;"/0K%;03+/&
5(??@(& (??@()(M)A9A& DEE& FGF& HGF& FIJH& !;"/0K%;03+/&
5(??@(& (??@()(M)A9E& DEE& FGF& HGF& FIJH& !;"/0K%;03+/&
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E#FF8#! #FF8#:FG:1S8:P#8! ##F! JKK! JLK! KMNL! ;5',/<2<-,!






9FG& 9GG& 9GF& HFF& JJL! LKL! JRL! KLL! LLL!
#1F%7! 7G1HF! $7GB$! G%1#H! #8G$H! #H%#$! 8##%7! 8#77B! 811H#!
JRK! JKJ! KKL! JLJ! LLK! JJK! KLK! JKR! JLR!






Table 3.3. Number of NSMT in our data set. We indicate in bold those codons that can mutate 
to a stop codon by a transition, the others require a transversion. Note that UGG should be 
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Turnover of Replication Complexes. In the baseline simulations of the model, we neglected the 
turnover of replication complexes (RC). However, RC may degrade. In this case, to sustain viral 
replication, the RC would need to be continuously produced to balance their degradation. Thus, 
we next analyzed the impact on our model predictions of including RC degradation. 
For fast RC turnover (e.g., half-life 1.5 d), most (median of 59%) of the simulated infections die 
out, and those that lead to sustained infection show a slow growth of the virus that is not 
compatible with the data (Figure 3.5A, left panel). It is possible to recover fast viral growth rates, if 
one postulates that a larger fraction of newly synthesized RNA is used to form new replication 
complexes (i.e., if k is smaller). When the turnover of replication complexes is not negligible 
(t1/2<5 days), on the time scale of our simulations, the accumulation of mutations is faster at later 
times as replacement of replication complexes occurs (Figure 3.5A, right panel). In this case, to 
describe the data a smaller mutation rate would be needed, at least in some patients. Importantly, 
turnover of replication complexes also implies a continued increase in diversity throughout the 
observation period, since more (-) strand RNA needs to be made and hence there is more 
opportunity for mutations to occur. However, such a continued increase in diversity is not seen for 
subjects 10012, 10017, 10021 and 10025. On the other hand, this process could help explain the 
marked increase in diversity seen at late time points in subjects 10029, 10062 and 9055. Note 
however that even these subjects seem to have a stabilization of diversity prior to this marked 
increase, which is not compatible with fast turnover of replication complexes. If the turnover of 
replication complexes is much slower (eg., ~15-day half-life) then the profiles do not differ from 
our baseline case where there is no turnover over the 50 day period studied. 
Here we studied RC turnover inside the cell, but it is also possible that cells die due to the 
immune response against HCV, thus forcing re-generation of RC. Thus, we next considered the 
effects of cell turnover on the results of our model. 
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Figure 3.5. Changes in viral load and mutation profile predicted by the model. (A) different 
values for the half-life of replication complexes (ln 2/ρ), and (B) the emergence of a cytolytic 
immune response at 30 days post-infection. Note that if there were less than 5 runs leading to 
establishment of infection, no line is plotted, because the noise is too large. Thus in (A) for short 
half-life of replication complexes (i.e., t1/2 = 0.74 d in cyan) the line may not appear, because the 
infection was not established, or the line may disappear, because an initial infection was aborted. 
have enough data to precisely estimate the timing and magnitude
of this immune response.
Discussion
We analyzed the viral dynamics and viral diversification of
HCV very early in acute infection. The early diversity of HCV is
very low, and the inter-sequence Hamming distances follow a
Poisson distribution, as would be expected when the mutations
occur approximately at the same rate at all positions and the
sequences are not selected for diversity [27,44]. Given this
observation, the number of mutations at early times should
depend on the time since infection, the mutation rate and the
biology of viral replication. This idea has been used before in the
context of primary HIV infection to estimate the time of infection,
assuming a given mutati n rate [26,27]. In the present study, the
time of infection is known to within a short time window, with the
first HCV positive sample within 5 days of the last negative
sample. With this information, we could use our data to estimate
the in vivo HCV mutation rate. By developing a model of HCV
Figure 4. Changes in viral load and mutation profile predicted by the model. (A) different values for the half-life of replication complexes
(ln 2/r), and (B) the emergence of a cytolytic immune response at 30 days post-infection. Note that if there were less than 5 runs leading to
establishment of infection, no line is plotted, because the noise is too large. Thus in (A) for short half-life of replication complexes (i.e., t1/2 = 0.74 d in
cyan) the line may not appear, because the infection was not established, or the line may disappear, because an initial infection was aborted.
doi:10.1371/journal.ppat.1002881.g004
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Effect of the Immune Response. An effect of immune processes is removal of infected cells. 
Because there may be some limit to the number of infected cells in the liver (160), the death of 
infected cells may allow new cells to be infected, which in turn generates new RC and the 
opportunity for mutation accumulation. For all subjects for whom there is enough data, we find a 
stabilization of diversity, which in a few cases is then followed by a "sudden" marked increase at 
a later time point (10029, 10062, 9055). It could be that this latter pattern is an artifact of 
sampling. For example for 10062, the observed fraction of unmutated sequences at the three 
time points sampled have confidence intervals that overlap, and those fractions are not 
significantly different, p = 0.07 (Figure 3.2C, overlap of vertical bars). In our model this 
stabilization in diversity accumulation occurs because a steady-state is attained for the numbers 
of replication complexes and infected cells, without continued turnover. Rather than a sampling 
issue, it is possible that the observed increase in diversity is due to an immune response 
emerging at late time points, which leads to an increase of the infected cell death rate (δ). Indeed, 
this is indicated in studies of experimental infection of chimpanzees, where the immune response 
is delayed several weeks (52, 272). In this context, an alternative explanation for the increase in 
diversity in 10062 is the appearance of such an immune response as suggested by the increase 
in ALT in this subject (Figure 3.1B). To study the effect of a late immune response that kills 
infected cells, we allowed for this process starting at 30 days post infection (Figure 3.5B). As 
expected, the emergence of an immune response lowers the viral load, possibly leading to a new 
lower viral load steady state, as is observed in some experimentally infected chimpanzees (52). 
With the loss of infected cells, new cycles of infection occur along with creation of new replication 
complexes, and the model predicts a renewed increase in the accumulation of diversity, which 
mimics the data in some subjects (eg., 10062, 9055). However, we do not have enough data to 




 We analyzed the viral dynamics and viral diversification of HCV very early in acute 
infection. The early diversity of HCV is very low, and the inter-sequence Hamming distances 
follow a Poisson distribution, as would be expected when the mutations occur approximately at 
the same rate at all positions and the sequences are not selected for diversity (82, 151). Given 
this observation, the number of mutations at early times should depend on the time since 
infection, the mutation rate and the biology of viral replication. This idea has been used before in 
the context of primary HIV infection to estimate the time of infection, assuming a given mutation 
rate (128, 151). In the present study, the time of infection is known to within a short time window, 
with the first HCV positive sample within 5 days of the last negative sample. With this information, 
we could use our data to estimate the in vivo HCV mutation rate. By developing a model of HCV 
replication that takes into account the details of the viral lifecycle, we found the estimated 
mutation rate varied among subjects between 1.6x10-5–6.2x10-5 mutations per nucleotide per 
replication cycle, with a median of 2.5x10-5 (Table 3.1, 5' half genome). This estimate was very 
robust to different assumptions about model parameter values (see Chapter 3 Supporting 
Information). Moreover, we systematically made conservative assumptions for the less well 
known parameter values leading to higher estimates for the mutation rate. To further confirm our 
results, we estimated the mutation rate by a completely different approach based on the 
frequency of stop codons (non-sense mutations), corrected by the number of non-sense mutation 
targets, as proposed by Cuevas et al. (51). With this calculation we obtained a mutation rate of 
2.8x10-5 or 3.2x10-5 mutations per nucleotide per replication cycle depending on the calculation 
method (see Chapter 3 Supporting Information), which is consistent with the estimate from our 
more complex dynamical model and substantially less than the rate (~10-4) estimated by Cuevas 
et al. (51). A likely explanation for the difference between the findings of our nonsense mutation 
analysis and that of Cuevas et al. is that in our study Taq polymerase errors are eliminated from 
the finished sequences by the SGA-direct amplicon sequencing method and thus do not enter in 
the error rate calculations; this was not the case for the previous analyses (51, 261). We further 
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note that estimates of the HCV mutation rate based on nonsense mutations are likely to be 
overestimates since we found that stop codons were not always lethal (see Chapter 3 Supporting 
Information). One explanation for this observation is that there are multiple HCV RNAs in an 
infected cell and another RNA may complement nonsense mutations. Indeed, we also found a 
case of a chronically infected patient who has a strain with a large deletion replicating in plasma 
at multiple time points (155). Moreover, for dengue virus (in the same Flaviviridae family of HCV) 
there is a report of a viral strain with a stop codon that spread and attained a high frequency in 
the population, implying replication in both humans and mosquitoes (1). 
 In addition, our analysis does not account for mutational errors resulting from the cDNA 
synthesis step of the sequencing process, which again may lead to an overestimation of the 
mutation rate. However, we used Superscript III Reverse Transcriptase (Cat. No. 18080-093, 
2000 units, Invitrogen Life Technologies, Carlsbad, CA) that has been reported to have an error 
rate of ~2x10-6 mutations/nucleotide/replication (155, 178), which is at least 10-fold lower than our 
HCV mutation rate estimates, and hence should not significantly influence our estimates. 
 Our estimates of the mutation rate for the HCV RdRp of ~2.5x10-5 are notable because 
previous reports have suggested that the in vivo mutation rate of HCV is of the order of 10-4 
mutations per nucleotide per replication (51); and that the in vitro rate of the isolated RdRp could 
be as high as 10-3 (226). One possible explanation for the latter discrepancy is that the mutation 
rates observed with purified RdRp enzymes are generally larger than those seen in vivo, because 
in vitro analyses cannot recapitulate the intracellular milieu of the replication or polymerase 
complex. For example, in the case of HIV reverse transcriptase, the errors measured with purified 
enzyme were found to be up to 20-fold higher than those measured in infected cells (180). 
Another possibility is that we may have missed some low prevalence strains. However, a detailed 
power calculation shows that with the number of sequences obtained per patient, we would only 
miss strains that are present at very low levels, below 2% (155), which is much better than was 
possible before (104, 325) (see Chapter 2 for a detailed discussion). Moreover, for the dynamical 
model we follow time courses and analyzed the fraction of virus identical to the T/F virus; and for 
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the stop codon analyses, we corrected for the mutational targets. Both of these lower the impact 
of missing strains. 
 Given the low level of diversity observed in early infection and the relatively low mutation 
rate, the enormous diversity of HCV (72, 276, 344) and its high substitution rate (i.e., 
substitutions/site/ year) have to be understood in light of HCV’s replication mechanism (260). 
Relatively long-lived infected cells, with multiple replication complexes allow for the accumulation 
of diversity in the virions produced. At the same time, the turnover of both replication complexes 
and infected cells, which must surely ensue as the immune response develops, allows for 
renewed generation of diversity throughout the course of infection (compare 10062 in Figure 3.1B 
and Figure 3.2C). Indeed, it could be that these details of the life cycle are responsible for the 
large diversity of HCV. We note that HIV and influenza, which are thought to have similar 
mutation rates to the one estimated here (180, 261), also have high substitution rates (118). In 
this context, we see that accumulation of diversity is not only dependent on mutation rate, but 
also to a great extent on the particular processes of the viral life cycle (260, 263, 268). Clearly, 
the pressure of the immune response, once established, will be important in determining relative 
fitness of many of the mutations and in determining the spectrum of mutations observed. That we 
see only scarce evidence of positive selection in our dataset indicates that there is a window of 
several weeks before the effects of the immune response can be detected. 
 Another important parameter that we estimated was the fraction of infected cells during 
the early plateau in viral load, which ranged between 1.7% and 22% of hepatocytes. This fraction 
is in reasonable agreement with other studies of HCV (39, 160). In our model, this fraction 
depends on the value assumed for the maximum number of replication complexes (RCM). The 
larger the number of replication complexes in an infected cell, the more viruses this cell can 
produce per unit of time, and thus the fewer the number of infected cells needed to maintain a 
given steady state viral load. However, increasing RCM has little effect on our estimate of the 
mutation rate (see Chapter 3 Supporting Information). 
107	  
 In this study, we constructed a simple model of HCV replication that tried to capture the 
most salient features of the viral life cycle. Moreover, we were careful to choose parameters 
consistent with the literature a priori, so that only 2 parameters had to be adjusted to fit the data 
on viral growth and diversity increase. We tested variation in the model assumptions and found 
that the results were quite robust. Still, it is clear that many complexities could be added to the 
model. For example, instead of having a fixed RCM, we could allow it to vary from cell to cell and 
possibly even from time to time; or we could allow for a distribution of generation times for RNA 
synthesis. These and other processes are easy to include in the model, however we opted to 
keep to the essential aspects of the replication process, so that we did not have to make further 
assumptions, which would complicate the interpretation of the results. In essence, this is akin to 
choosing a simple experimental system that is amenable to easy manipulation and interpretation 
of results, even if it does not represent fully all the details of in vivo system. 
 Altogether, the unique dataset presented here, including HCV viral kinetics and genomic 
diversification very early in infection, revealed that the initial exponential expansion of HCV RNA 
is followed by a plateau in viral load that lasts up to a few weeks (84). The initial viral expansion is 
accompanied by a fast early increase in sequence diversity, whereas during the viral plateau viral 
diversity remains approximately constant. During the plateau viral production continues but is 
simply balanced by the rate of viral clearance. In order to understand why viral diversity did not 
continue to increase during this period, we develop a novel stochastic model of HCV infection. 
The basic idea behind the model is that during the early exponential expansion of the virus, new 
cells are being infected and generating multiple replication complexes in each infected cell. This 
involves multiple copying events of (+)RNA to (-)RNA to (+)RNA, etc, with errors potentially being 
generated at each stage. We postulate that once the viral plateau is reached a stable population 
of long-lived infected cells has been generated which then produce the plateau virus without any 
need for new RC generation. If no new replication templates are made then there is little 
opportunity for mutations to accumulate, though each virus can still mutate in relation to its parent 
RC due to the (-)RNA to (+)RNA copying event. We found that our model, based on this idea, 
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agreed with both the viral load kinetic data and the sequence diversity data if we assumed that 
the in vivo mutation rate of HCV is ~2.5x10-5 per nucleotide per replication cycle. This is about 5-
fold lower than previously reported, but still high enough that coupled with the long-lasting nature 
of HCV infection and the very high turnover of virus in chronic infection leads to substantial HCV 
diversity in an individual and in the population. 
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Materials and Methods 
 Patient Population. Plasma samples were obtained from seventeen regular source 
plasma donors, who became HCV infected during periods of twice-weekly plasma donations. The 
donors were untreated and asymptomatic throughout the collection period. All subjects gave 
written, informed consent and the study protocols were approved by institutional review boards at 
the University of Pennsylvania, the University of Alabama at Birmingham and Duke University. 
HCV RNA and antibodies were analyzed as described elsewhere (155). 
 Single Genome Sequencing. Single genome amplification (SGA) followed by direct 
amplicon sequencing was performed on sequential plasma vRNA samples (i.e., (+) RNA 
strands), as described in detail elsewhere (155). 
 For our dynamical analyses, we selected subjects who had at least two time points 
sampled with single genome amplification assays (155). Thus, three subjects were not included – 
6213, 6222, 10004. Six subjects (10002, 10003, 10016, 10020, 10029, 106889) had more than 7 
putative T/F viruses, which makes a diversification analysis impractical, both due to the 
complexity of the viral species in the subjects and the small number of sequences representing 
each lineage (155). The exception was 10029, who had a dominant lineage with more than 38 
sequences for each time point, and we included this subject in our analyses. Thus, there were 9 
subjects who were sampled at multiple time points and who had a clearly dominant putative T/F 
virus lineage (155). Here we only analyzed these dominant lineages, for which we have the most 
data (SGA sequences). 
 Sequence Analysis. Sequence alignments were initially made with ClustalW and then 
checked individually using JalView 2.6.1 (www.jalview.org). We used ConsensusMaker 
(www.HIV.lanl.gov) to calculate the consensus of the first set of sequences sampled by SGA, 
which is the putative T/F virus (155). The set of sequences from each SGA sample with the 
corresponding consensus was analyzed by PoissonFitter (www.HIV.lanl.gov) to calculate for each 
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sequence the number of mutations away (i.e., Hamming distance) from the T/F, and to test 
whether sequence diversification conforms to a star-phylogeny and if the set of inter-sequence 
Hamming distances follow a Poisson distribution (82). 
 Altogether we analyzed time courses of thousands of sequences with over 11.9 million 
base pairs and 1887 mutations (155). 
 Model. To analyze the process of replication of HCV and how it affects the generation of 
diversity in primary infection, we developed an agent-based model of HCV infection and 
replication. We assumed cells are infected by a single virion, and that in every infected cell, on 
average a fraction k of newly synthesized viral RNA (vRNA) is exported in new virions, and the 
rest, 1-k, form new replication complexes in the cell. These processes continue until the cell 
contains a maximum number of replication complexes (RCM). We assume this maximum value is 
set by the availability of host factors. After a virus is exported, a fraction 1- θ of released virions 
are cleared from circulation, and the rest, θ, infect new cells. 
 As the vRNA is copied, errors in the incorporation of nucleotides are possible. Every time 
a mutation occurs, there is a probability that this mutation is lethal, implying a virus or replication 
complex made using such mutant vRNA is non-viable. Sanjuan (259) estimates that the fraction 
of random mutations that are lethal is about 40% for RNA viruses. 
 We assumed HCV is noncytolytic (282). Thus, infected cells can produce virus for long 
periods of time – until the infected cell dies, either from natural death or immune attack. Early in 
acute infection there is little evidence of cytotoxic T cell activity and CD8+ T cells do not appear to 
enter the liver until many weeks after infection (272). In addition, normal hepatocytes live for 
months (251) to a year or more (174), thus, we either totally neglect death of infected cells or 
allow death after the first few weeks of infection. The assumption of no early death is consistent 
with the normal levels of alanine aminotransferase (ALT) measured in these individuals (Figure 
1B) and the viral load profiles, where viral load increases rapidly to a maximum level and then 
stays at that level for some time. (This is in stark contrast for example with HIV, a cytolytic virus, 
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where a clear peak in viral load is seen during primary infection followed by a decrease in viral 
load (239).) 
 Replication of the RNA and formation of a new virion or replication complexes is not 
instantaneous, as it takes a certain amount of time for synthesis of the different molecular 
components and their assembly. Although this time is most likely variable from replication cycle to 
replication cycle and from cell to cell, we assume that it is similar for all replication events in our 
model, fixing it at an average time to complete all the replication steps. This time we call the 
‘‘generation time’’. Most likely it will take longer to produce the first copied RNA upon cell infection 
than later ones, as various molecular events need to occur before virus production begins (eg., 
uncoating, polyprotein synthesis and cleavage, assembly of the replication complex, etc) (232). 
 In the simulation, based on the assumptions described above, we follow the number, age 
(in the sense of generations) and mutational burden of each virion and each replication complex 
inside infected cells. The simulation was implemented in the R language (www.r-project.org). 
Because these are stochastic simulations, there is variability from one run to the next, even when 
all parameters remain the same. Thus, for each patient and each set of parameters (in Figures 1–
4) we present results from 100 runs. Including more runs (we tested some cases with 200 runs) 
does not significantly alter the results presented 
 Model Parameters. The parameters of the stochastic model are as follows: 
Generation time. During stable cell infection and virus production, we assume that it takes ~6 h 
for a cycle of replication to produce new virions or replication complexes based on the following 
argument. A study of HCV replication kinetics (230) found that there are about 200 (+)RNA 
strands in a cell at steady state. With 40 replication complexes per cell, if we assume at steady 
state (+)RNA is being produced at rate α and degraded by a first-order process at rate dR, then at 
steady state 200 = α/dR. In treatment experiments in the replicon system the half-life of (+)RNA 
was found to be between 11 and 18 h (53, 99, 212), i.e. ,15 h, so that dR = 0.693/15 = 0.0462 h-1 
and α = 9.24 h-1. Then with 40 replication complexes per cell, each one would be producing 
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(+)RNA at a rate of 9.24 h-1/40 = 0.231 h-1 and it would take 1/ 0.231 h-1 = 4.33 h to produce one 
new (+)RNA. Allowing for some extra time for assembly of a virion or a new replication complex, 
we thus assume ~6 h for a cycle of replication. 
RCM – maximum number of replication complexes in an infected cell. Experimental results 
show that about 40 replication complexes can exist in one infected cell (40, 230). Our baseline 
results use this number, but we also vary this parameter. 
ρ – turnover of replication complexes. It has been observed after introducing treatment in a 
replicon system, that the half-life of (-)RNA was ~12 h (99), but this decay only started after a 12 
h delay. In our simulation, this would correspond to a degradation probability for the replication 
complex of ~0.3 per generation. To see this, note that with a half-life of 12 h, a (-)RNA, or we 
assume equivalently a RC, decays at an average rate dRC = 0.693/12 h = 0.0577 h-1. To convert a 
continuous rate to a probability that an event occurs during a time interval Δt , note that by the 
exponential distribution the probability that a RC that is decaying with an average rate dRC 
degrades at or before a time Δt has elapsed is given by 1- exp(-dRC Δt) (41). Choosing Δt = 6 h, 
i.e. a generation and dRC = 0.057 h-1, the probability of degrading in one generation is ρ ~0.3. 
However, we expect this to be an upper limit for ρ, the probability of degradation in the absence 
of treatment, because replication complexes are protected within vesicular membranous 
structures (VMS) adjacent to the ER membrane (220). Indeed, the 12 h delay until the start of 
degradation of (-)RNA, which is thought to be mainly localized within the VMS, supports this idea. 
Initially, as a conservative approach to estimate the maximum mutation rate, we will assume that 
replication complexes are not degraded on the time-scales involved in primary infection, i.e., ρ 
=0. We later allow RC degradation (ρ >0) and ask what impact it has in the dynamics of virus and 
viral diversity. 
k – probability that a newly formed vRNA is exported as a virion. For each subject, we 
choose k to match the observed viral load profile. We varied k between 0 and 1 in increments of 
0.01 and found the value that best describes the data by minimizing the sum of squared 
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residuals, i.e. the difference between model and viral load data. For each case, we ran 100 
simulations and then chose the value of k that led to the best match of the average of the viral 
load in the simulations with the observed viral load. 
δ – turnover of infected cells. Hepatocytes are in general long lived cells, but infected cells may 
die faster due to viral effects. However, HCV is thought to be non-cytolytic (282), thus, we 
assume that the infected cell death rate is similar to that of uninfected hepatocytes, and can be 
neglected (δ=0) in the time frame of our study. We also investigate the effect of the emergence of 
the cytolytic response (δ>0) sometime after infection (272). Initial estimates, mostly based on 
interferon therapy of chronically infected patients, found that the loss rate of infected cells was 
quite variable with median half-lives of about 7 days (60, 150, 199), corresponding to a probability 
of death per generation δ = 0.025 (by the same argument using the exponential distribution as 
above to estimate ρ). 
θ – probability of a free virus infecting a target cell (if these are available). In this model, as 
well as in the standard model of viral infection (i.e., the differential equation model that has been 
widely used to analyze both primary infection and antiviral treatment (149, 199)), free virus can 
either be cleared or infect a new cell. In the standard model these processes occur at rates c and 
βT, respectively, where T is the available target cell density. If we write the differential equations 
corresponding to the infected cells, I, and free virus, V, we have 
 
where p is the daily viral production rate per infected cell. If we make the common assumption of 
quasi-steady state, then I ≈ (c/p) V (149, 199). This essentially means that the viral dynamics are 
much faster than the infected cell dynamics. From the first equation above, we can now write 
 
Generation time. During stable cell infection and virus
production, we assume that it takes ,6 h for a cycle of replication
to produce new virions or replication complexes based on the
following argument. A study of HCV replication kinetics [4] found
that there are about 200 (+)RNA strands in a cell at steady state.
With 40 replication complexes per cell, if we assume at steady state
(+)RNA is being produced at rate a and degraded by a first-order
process at rate dR, then at steady state 200= a/dR. In treatment
experiments in the replicon system the half-life of (+)RNA was
found to be between 11 and 18 h [55–57], i.e. ,15 h, so that
dR=0.693/15= 0.0462 h
21 and a=9.24 h21. Then with 40
replication complexes per cell, each one would be producing
(+)RNA at a rate of 9.24 h21/40= 0.231 h21 and it would take 1/
0.231 h21 = 4.33 h to produce one new (+)RNA. Allowing for
some extra time for assembly of a virion or a new replication
complex, we thus assume ,6 h for a cycle of replication.
RCM – maximum number of replication complexes in an
infected cell. Experimental results show that about 40 replica-
tion complexes can exist in one infected cell [4,10]. Our baseline
results use this number, but we also vary this parameter.
r – turnover of replication complexes. It has been
observed after introducing treatment in a replicon system, that
the half-life of (2)RNA was ,12 h [56], but this decay only
started after a 12 h delay. In our simulation, this would correspond
to a degradation probability for the replication complex of ,0.3
per generation. To see this, note that with a half-life of 12 h, a
(2)RNA, or we assume equivalently a RC, decays at an average
rate dRC=0.693/12 h=0.0577 h
21. To convert a continuous rate
to a probability that an event occurs during a time interval Dt ,
note that by the exponential distribution the probability that a RC
that is decaying with an average rate dRC degrades at or before a
time Dt has elapsed is given by 1- exp(-dRC Dt) [58]. Choosing
Dt = 6 h, i.e. a generation and dRC=0.057 h
21, the probability of
degrading in one generation is r,0.3. However, we expect this to
be an upper limit for r, the probability of degradation in the
absence of treatment, because replication complexes are protected
within vesicular membranous structures (VMS) adjacent to the ER
membrane [59]. Indeed, the 12 h delay until the start of
degradation of (2)RNA, which is thought to be mainly localized
within the VMS, supports this idea. Initially, as a conservative
approach to estimate the maximum mutation rate, we will assume
that replication complexes are not degraded on the time-scales
involved in primary infection, i.e., r=0. We later allow RC
degradation (r.0) and ask what impact it has in the dynamics of
virus and viral diversity.
k – probability that a newly formed vRNA is exported as a
virion. For each subject, we choose k to match the observed viral
load profile. We varied k between 0 and 1 in increments of 0.01 and
found the value that best describes the data by minimizing the sum
of squared residuals, i.e. the difference betweenmodel and viral load
data. For each case, we ran 100 simulations and then chose the
value of k that led to the best match of the average of the viral load in
the simulations with the observed viral load.
d – turnover of infected cells. Hepatocytes are in general
long lived cells, but infected cells may die faster due to viral effects.
However, HCV is thought to be non-cytolytic [32], thus, we
assume that the infected cell death rate is similar to that of
uninfected hepatocytes, and can be neglected (d=0) in the time
frame of our study. We also investigate the effect of the emergence
of the cytolytic response (d.0) sometime after infection [36].
Initial estimates, mostly based on interferon therapy of chronically
infected patients, found that the loss rate of infected cells was quite
variable with median half-lives of about 7 days [21,60,61],
corresponding to a probability of death per generation d=0.025
(by the same a gument using th exponential distribution s above
to estimate r).
h – probability of a free virus infecting a target cell (if
these are available). In this model, as well as in the standard
model of viral infection (i.e., the differential equation model that
has been widely used to analyze both primary infection and
antiviral treatment [21,62]), free virus can either be cleared or
infect a new cell. In the standard model these processes occur at
rates c and bT, respectively, where T is the available target cell
density. If we write the differential equations corresponding to the







where p is the daily viral production rate per infected cell. If we
make the common assumption of quasi-steady state, then I<(c/p)
V [21,62]. This essentially means that the viral dynamics are much
faster than the infected cell dynamics. From the first equation







with the initial exponential rate of increase of the virus, r, given by
r= pbT/c. Moreover, in this model the probability of infection is
given by h=bT/(c+bT), because infection (bT) is one of two
possible events, the other being virion clearance (c). We can write
this probability of infection in terms of r and p as h= r/(r+p). Here,
r can be measured directly from the rate of exponential increase in
viral load observed in the data of each individual. Indeed, the
initial rise in viral load is well described by a constant exponential
rate of increase, as has been suggested before [30]. In our model, p,
the daily virus production rate varies over time, because the
number of replication complexes in each infected cell is increasing.
However, to be consistent with the observed constant rate of
increase, r, we assumed that p= ng6RCM6k; where ng is the
number of generations per day (converting the production of
viruses per generation of the simulation into the production rate
per day), RCM is the maximum number of replication complexes,
and k is the fraction of newly synthesized RNA that is exported as
virions. Because we are fitting k, this expression for p corresponds
to a constant effective production rate throughout primary
infection that matches the viral load. Substituting this expression




Iss –number of infected cells at steady state. The data of
most individuals exhibits a viral plateau a couple of weeks after
infection (see also [30]). That is, the virus does not continue to
grow exponentially. With our assumption of negligible infected cell
death (d=0), the logical implication of the observation of this
steady state is that the number of infected cells reaches a
maximum and is then kept constant at this level, Iss. When the
virus reaches the plateau, Vss, we can calculate from the standard








where the daily production of virus per infected cell at the steady
state is p= ng6RCM. Note that at the steady state, each cell has the
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Generation time. During stable cell infection and virus
production, we assume that it takes ,6 h for a cycle of replication
to produce new virions or replication complexes based on the
following argument. A study of HCV replication kinetics [4] found
that there are about 200 (+)RNA strands in a cell at steady state.
With 40 replication complexes per cell, if we assume at steady state
(+)RNA is being produced at rate a and degraded by a first-order
process at rate dR, then at steady state 200= a/dR. In treatment
experiments in the replicon system the half-life of (+)RNA was
found to be between 11 and 18 h [55–57], i.e. ,15 h, so that
dR=0.693/15= 0.0462 h
21 and a=9.24 h21. Then with 40
replication complexes per cell, each one would be producing
(+)RNA at a rate of 9.24 h21/40= 0.231 h21 and it would take 1/
0.231 h21 = 4.33 h to produce one new (+)RNA. Allowing for
some extra time for assembly of a virion or a new replication
complex, we thus assume ,6 h for a cycle of replication.
RCM – maximum number of replication com lexes in n
infected cell. Experimental results show that about 40 replica-
tion complexes can exist in one infected cell [4,10]. Our baseline
results use this number, but we also vary this parameter.
r – turnover of replication complexes. It has been
observed after introducing treatment in a replicon system, that
the half-life of (2)RNA was ,12 h [56], but this decay only
started after a 12 h delay. In our simulation, this would correspond
to a degradation probability for the replication complex of ,0.3
per generation. To see this, note that with a half-life of 12 h, a
(2)RNA, or we assume equivalently a RC, decays at an average
rate dRC=0.693/12 h=0.0577 h
21. To convert a continuous rate
to a probability that an event occurs during a time interval Dt ,
note that by the exponential distribution the probability that a RC
that is decaying with an average rate dRC degrades at or before a
time Dt has elapsed is given by 1- exp(-dRC Dt) [58]. Choosing
Dt = 6 h, i.e. a generation and dRC=0.057 h
21, the probability of
degrading in one generation is r,0.3. However, we expect this to
be an upper limit for r, the probability of degradation in the
absence of treatment, because replication complexes are protected
within vesicular membranous structures (VMS) adjacent to the ER
membrane [59]. Indeed, the 12 h delay until the start of
degradation of (2)RNA, which is thought to be mainly localized
within the VMS, supports this idea. Initially, as a conservative
approach to estimate the maximum mutation rate, we will assume
that replication complexes are not degraded on the time-scales
involved in primary infection, i.e., r=0. We later allow RC
degradation (r.0) and ask what impact it has in the dynamics of
virus and viral diversity.
k – probability that a newly formed vRNA is exported as a
virion. For each subject, we choose k to match the observed viral
load profile. We varied k between 0 and 1 in increments of 0.01 and
found the value that best describes the data by minimizing the sum
of squared residuals, i.e. the difference betweenmodel and viral load
data. For each case, we ran 100 simulations and then chose the
value of k that led to the best match of the average of the viral load in
the simulations with the observed viral load.
d – turnover of infected cells. Hepatocytes are in general
long lived cells, but infected cells may die faster due to viral effects.
However, HCV is thought to be non-cytolytic [32], thus, we
assume that the infected cell death rate is similar to that of
uninfected hepatocytes, and can be neglected (d=0) in the time
frame of our study. We also investigate the effect of the emergence
of the cytolytic response (d.0) sometime after infection [36].
Initial estimates, mostly based on interferon therapy of chronically
infected patients, found that the loss rate of infected cells was quite
variable with median half-lives of about 7 days [21,60,61],
corresponding to a probability of death per generation d=0.025
(by the same argument using the exponential distribution as above
to estimate r).
h – probability of a free virus infecting a target cell (if
these are available). In this model, as well as in the standard
model of viral infection (i.e., the differential equation model that
has been widely used to analyze both primary infection and
antiviral treatment [21,62]), free virus can either be cleared or
infect a new cell. In the standard model these processes occur at
rates c and bT, respectively, where T is the available target cell
density. If we write the differential equations corresponding to the







where p is the daily viral production rate per infected cell. If we
make the common assumption of quasi-steady state, then I<(c/p)
V [21,62]. This essentially means that the viral dynamics are much
faster than the i fected cell dynamics. From the first equation







with the initial exponential rate of increase of the virus, r, given by
r= pbT/c. Moreover, in this model the probability of infection is
given by h=bT/(c+bT), because infection (bT) is one of two
possible events, the other being virion clearance (c). We can write
this probability of infection in terms of r and p as h= r/(r+p). Here,
r can be measured directly from the rate of exponential increase in
viral load observed in the data of each individual. Indeed, the
initial rise in viral load is well described by a constant exponential
rate of increase, as has been suggested before [30]. In our model, p,
the daily virus production rate varies over time, because the
number of replication complexes in each infected cell is increasing.
However, to be consistent with the observed constant rate of
increase, r, we assumed that p= ng6RCM6k; where ng is the
number of generations per day (converting the production of
viruses per generation of the simulation into the production rate
per day), RCM is the maximum number of replication complexes,
and k is the fraction of newly synthesized RNA that is exported as
virions. Becaus we are fitting k, this expression for p corresponds
to a constant effective production rate throughout primary
infection that matches the viral load. Substituting this expression




Iss –number of infected cells at steady state. The data of
most individuals exhibits a viral plateau a couple of weeks after
infection (see also [30]). That is, the virus does not continue to
grow exponentially. With our assumption of negligible infected cell
death (d=0), the logical implication of the observation of this
steady state is that the number of infected cells reaches a
maximum and is then kept constant at this level, Iss. When the
virus reaches the plateau, Vss, we an calculate from the standard








where the daily production of virus per infected cell at the steady
state is p= ng6RCM. Note that at the steady state, each cell has the
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with the initial exponential rate of increase of the virus, r, given by r = pβT/c. Moreover, in this 
model the probability of infection is given by θ = βT/(c+βT), because infection (βT) is one of two 
possible events, the other being virion clearance (c). We can write this probability of infection in 
terms of r and p as θ = r/(r+p). Here, r can be measured directly from the rate of exponential 
increase in viral load observed in the data of each individual. Indeed, the initial rise in viral load is 
well described by a constant exponential rate of increase, as has been suggested before (84). In 
our model, p, the daily virus production rate varies over time, because the number of replication 
complexes in each infected cell is increasing. However, to be consistent with the observed 
constant rate of increase, r, we assumed that p = ngxRCMxk; where ng is the number of 
generations per day (converting the production of viruses per generation of the simulation into the 
production rate per day), RCM is the maximum number of replication complexes, and k is the 
fraction of newly synthesized RNA that is exported as virions. Because we are fitting k, this 
expression for p corresponds to a constant effective production rate throughout primary infection 
that matches the viral load. Substituting this expression for p into θ, we have 
 
Iss –number of infected cells at steady state. The data of most individuals exhibits a viral 
plateau a couple of weeks after infection (see also (84)). That is, the virus does not continue to 
grow exponentially. With our assumption of negligible infected cell death (δ=0), the logical 
implication of the observation of this steady state is that the number of infected cells reaches a 
maximum and is then kept constant at this level, Iss. When the virus reaches the plateau, Vss, we 
can calculate from the standard model and the quasi steady-state assumption (149, 199) that 
 
where the daily production of virus per infected cell at the steady state is p = ngxRCM. Note that at 
the steady state, each cell has the maximum number of replication complexes, because if it did 
not then the production per cell would increase further contradicting the assumption of a steady 
Generation time. During stable cell infection and virus
production, we assume that it takes ,6 h for a cycle of replication
to produce new virions or replication complexes based on the
following argument. A study of HCV replication kinetics [4] found
that there are about 200 (+)RNA strands in a cell at steady state.
With 40 replication complexes per cell, if we assume at steady state
(+)RNA is being produced at rate a and degraded by a first-order
process at rate dR, then at steady state 200= a/dR. In treatment
experiments in the replicon system the half-life of (+)RNA was
found to be between 11 and 18 h [55–57], i.e. ,15 h, so that
dR=0.693/15= 0.0462 h
21 and a=9.24 h21. Then with 40
replication complexes per cell, each one would be producing
(+)RNA at a rate of 9.24 h21/40= 0.231 h21 and it would take 1/
0.231 h21 = 4.33 h to produce one new (+)RNA. Allowing for
some extra time for assembly of a virion or a new replication
complex, we thus assume ,6 h for a cycle of replication.
RCM – maximum number of replication complexes in an
infected cell. Experimental results show that about 40 replica-
tion complexes can exist in one infected cell [4,10]. Our baseline
results use this number, but we also vary this parameter.
r – turnover of replication complexes. It has been
observed after introducing treatment in a replicon system, that
the half-life of (2)RNA was ,12 h [56], but this decay only
started after a 12 h delay. In our simulation, this would correspond
to a degradation probability for the replication complex of ,0.3
per generation. To see this, note that with a half-life of 12 h, a
(2)RNA, or we assume equivalently a RC, decays at an average
rate dRC=0.693/12 h=0.0577 h
21. To convert a continuous rate
to a probability that an event occurs during a time interval Dt ,
note that by the exponential distribution the probability that a RC
that is decaying with an average rate dRC degrades at or before a
time Dt has elapsed is given by 1- exp(-dRC Dt) [58]. Choosing
Dt = 6 h, i.e. a generation and dRC=0.057 h
21, the probability of
degrading in one generation is r,0.3. However, we expect this to
be an upper limit for r, the probability of degradation in the
absence of treatment, because replication complexes are protected
within vesicular membranous structures (VMS) adjacent to the ER
membrane [59]. Indeed, the 12 h delay until the start of
degradation of (2)RNA, which is thought to be mainly localized
within the VMS, supports this idea. Initially, as a conservative
approach to estimate the maximum mutation rate, we will assume
that replication complexes are not degraded on the time-scales
involved in primary infection, i.e., r=0. We later allow RC
degradation (r.0) and ask what impact it has in the dynamics of
virus and viral diversity.
k – probability that a newly formed vRNA is exported as a
virion. For each subject, we choose k to match the observed viral
load profile. We varied k between 0 and 1 in increments of 0.01 and
found the value that best describes the data by minimizing the sum
of squared residuals, i.e. the difference betweenmodel and viral load
data. For each case, we ran 100 simulations and then chose the
value of k that led to the best match of the average of the viral load in
the simulations with the observed viral load.
d – turnover of infected cells. Hepatocytes are in general
long lived cells, but infected cells may die faster due to viral effects.
However, HCV is thought to be non-cytolytic [32], thus, we
assume that the infected cell death rate is similar to that of
uninfected hepatocytes, and can be neglected (d=0) in the time
frame of our study. We also investigate the effect of the emergence
of the cytolytic response (d.0) sometime after infection [36].
Initial estimates, mostly based on interferon therapy of chronically
infected patients, found that the loss rate of infected cells was quite
variable with median half-lives of about 7 days [21,60,61],
corresponding to a probability of death per generation d=0.025
(by the same argument using the exponential distribution as above
to estimate r).
h – probability of a free virus infecting a target cell (if
these are available). In this model, as well as in the standard
model of viral infection (i.e., the differential equation model that
has been widely used to analyze both primary infection and
antiviral treatment [21,62]), free virus can either be cleared or
infect a new cell. In the standard model these processes occur at
rates c and bT, respectively, where T is the available target cell
density. If we write the differential equations corresponding to the







where p is the daily viral production rate per infected cell. If we
make the common assumption of quasi-steady state, then I<(c/p)
V [21,62]. This essentially means that the viral dynamics are much
faster than the infected cell dynamics. From the first equation







with the initial exponential rate of increase of the virus, r, given by
r= pbT/c. Moreover, in this model the probability of infection is
given by h=bT/(c+bT), because infection ( T) is one of two
possible events, the other being virion clearance (c). We can write
this probability of infection in terms of r and p as h= r/(r+p). Here,
r can be measured directly from the rate of exponential increase in
viral load observed in the data of each individual. Indeed, the
initial rise in viral load is well described by a constant exponential
rate of increase, as has been suggested before [30]. In our model, p,
the daily virus production rate varies over time, because the
number of replication complexes in each infected cell is increasing.
However, to be consistent with the observed constant rate of
increase, r, we assumed that p= ng6RCM6k; where ng is the
number of generations per day (converting the production of
viruses per generation of the simulation into the production rate
er day), RCM is the maximum number of replication complexes,
and k is the fraction of newly synthesized RNA that is exported as
virions. Because we are fitting k, this expressio f r p corresponds
to a constant effective production rate throughout primary
infection that matches the viral load. Substituting this expression




Iss –number of infected cells at steady state. The data of
most individuals exhibits a viral plateau a couple of weeks after
infection (see also [30]). That is, the virus does not continue to
grow exponentially. With our assumption of negligible infected cell
death (d=0), the logical implication of the observation of this
steady state is that the number of infected cells reaches a
maximum and is then kept constant at this level, Iss. When the
virus reaches the plateau, Vss, we can calculate from the standard








where the daily production of virus per infected c ll at the steady
state is p= ng6RCM. Note that at the steady state, each cell has the
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Generation time. During stable cell infection nd vi us
production, we assume that it akes ,6 h for a cycle of replication
to produce new virions or replication complex s based on the
following argum nt. A study of HCV replication kinetics [4] f und
that there are about 200 (+)RNA str nds in a cell at steady state.
With 40 repli ation compl xes per cell, if we assume at steady state
(+)RNA is being produced at rate a and degraded by a first-order
process at rate dR, then at steady state 200= a/dR. In treatment
experiments in the replicon system the half-life of (+)RNA was
found to be between 11 and 18 h [55–57], i.e. ,15 h, so that
dR=0.693/15= 0.0462 h
21 and a=9.24 h21. Then with 40
replica ion complexes per cel , ach one would be producing
(+)RNA at a rate of 9.24 h21/40= 0.231 h21 and it would take 1/
0.231 h21 = 4.33 h to produce one new (+)RNA. Allowing for
some extra time for assembly of a virion or a new replication
c mplex, we thus assume ,6 h for a cycle of replication.
RCM – maximum number of replication complex s in a
infected c ll. Experimental results show that ab t 40 eplica-
tion complexes can exist in one infected cell [4,10]. Our baseline
results us th s number, but we also v ry this par met r.
r – turnover of replicatio complexes. It has been
observed after introducing treatment in a replicon system, th t
the half-life of (2)RNA was ,12 h [56], but this decay only
start d after a 12 h delay. In our sim lation, this would correspond
to a degrad tion probability for the replication complex of ,0.3
per generation. To see th s, ote that with a half-life of 12 h, a
(2)RNA, or we assume equivalently a RC, decays at an verage
rat dRC=0.693/12 h=0.0577 h
21. To conv rt a continuous rate
to a probability that an event occurs during a time interval Dt ,
note that by he exponential dist ibution the probability that a RC
that is decaying with an verage rate dRC degrades at or before a
ti Dt has elapsed is given by 1- exp(-dRC Dt) [58]. Choosing
Dt = 6 h, i.e. a generation and dRC=0.057 h
21, the probability of
degrading in one generation is r,0.3. However we expect this o
be an upper limit for r, the probability of degradation in the
absence of treatment, becau e plication complexes are protected
within vesicular membra ous structures (VMS) adjacent to the E
membrane [59]. Indeed, the 12 h delay until the start of
degrad tion of (2)RNA, which is thought to be mainly localized
within the VMS, supports this idea. Initially, as a conservative
approach to estimate the maximum mutation rate, we will assume
that replication complexes ar ot degraded on the time-scales
involved in primary infection, i.e., r=0. We later allow RC
degrad tion (r.0) and ask what impact it has in th dynamics f
virus and vir l diversity.
k – probability that a newly formed vRNA is exported as a
virion. For each subject, we choose k to match the observed viral
load profile. We varied k be ween 0 and 1 in increments of 0.01 and
fou d th value that best d scribes the data by minimizing the sum
of squared residuals, i.e. the differenc betweenmodel and viral load
d ta. For each case, we ran 100 simulations and then chose the
value of k that led t the best match of the av rage of the viral load in
the simulations with the ob erved v ral load.
d – turnover of infect d cells. Hepatocytes are in general
lo g lived cells, but infected cells may die faster due to viral effe ts.
Howev r, HCV is thoug t o be non-cytolyti [32], thus, we
assume that the infected cell death r te is simil r to that of
uninf cted hepat cytes, and can be neglected (d=0) in the time
frame of our study. We also investigate the effect of the emergence
of the cytolytic response (d.0) sometime after infection [36].
Initial estimates, mostly based on interferon therapy of chronically
infected patients, found that the loss rate of infected cells was quite
variable with median half-lives of about 7 days [21,60,61],
corresponding to a probability of death per generation d=0.025
(by he same rgument using the exponenti l dis ribution as above
to estim te r).
h – proba ility of a free virus infec ing a t rg t cell (if
th se are available). In this model, s well as in the standard
model of viral infection (i.e., the differential equation model that
has been widely used to analyze both primary infection and
antiviral treatment [21,62]), free virus can either be cleared or
infect a new cell. In the standard model these processes occur at
rates c and bT, respectively, where T is the available target cell
density. If we write the differential equations corresponding to the







where p is the daily viral production rate per infected cell. If we
make the common assumption of quasi-steady state, then I<(c/p)
V [21,62]. This essentially means that the viral dynamics are much
faster an the infected cell dynami s. From the first equation







with the initial exponential rate of incr se of the virus, r, given by
r= pbT/c. Moreover, in this model th prob bility of infection is
given by h=bT/(c+bT), because infection (bT) is ne of two
possible events, the other being virion clearance (c). We can wri e
this probability of infecti n in terms of r and p as h= r/(r+p). Here,
r can be measured directly from t e rate f exponential increase in
viral load observed in the data of each individual. Indeed, the
initial rise in viral load is well described by a constant exponential
rate of increase, as has been suggested before [30]. In our model, p,
the dail virus production rate varies ove time, because th
number of r plicati complexes in each infected cell is increasing.
However, to be consisten with e obse ved c nstant rate of
incre se, r, we assumed that p= ng6RCM6k; where ng is the
number of gener tion p r d y (converting the production of
viruses per generation of the simulation into the production rate
per day), RCM is the maximum number of replication complexes,
and k is the fraction of newly synthesized RNA that is exported as
viri ns. Because we are fitting k, this expression for p corresponds
to a c stant effective production rate through ut pr mary
infection that matches the viral load. Substituting this expression




Iss –n ber of infected cells at steady tate. The data of
most individuals xhibits a viral plateau a couple of weeks afte
infection (see also [30]). That is, the virus does not continue to
grow exponentially. With our assumption of negligible infected cell
death (d=0), the logical implication of the observation of this
st ady state is tha the number of infected cells reaches a
maximum and is then kept constant at this level, Iss. When the
virus reaches the plateau, Vss, we can calculate from the standard








where the daily production of virus per infected cell at the steady
state is p= ng6RCM. Note that at the steady state, each cell has the
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state. Thus, at the steady-state all newly synthesized RNA is exported as new virions, and k does 
not appear in the formula for Iss. This number represents the number of infected cells at the 
plateau. For those few cases where we did not observe the viral plateau, because of loss to 
follow-up, we use for Vss the maximum viral load observed. To calculate Iss, we use c=23 day-1, 
estimated from the rate of decay of HCV RNA in patients treated with an NS5A inhibitor (77). 
Δ – fraction of lethal mutations. We assume that 40% of all mutations are lethal and that the 
rest are neutral. The fraction of lethal mutations has been estimated in different viruses using site- 
directed mutagenesis (259). For two eukaryotic RNA viruses this fraction was 40% as used here, 
whereas for an RNA bacteriophage it was 30% (259). The lethal phenotype can have different 
causes (from improper folding of the RNA molecule to lack of protease function). Here we will 
assume that lethal mutations lead to vRNAs that do not contribute to viral load or to make new 
replication complexes. An alternative view would be that some lethal mutations still allow 
production of viral particles, but that these are not infectious. In this case, they would be included 
in viral load measurements, but they would not infect new cells. In our model, this possibility is 
accounted for by the parameter θ, the fraction of virus that infects new cells. 
τ – time (in generations) that a cell takes to start producing RNA upon first infection. 
During stable cell infection and virus production, we have assumed that it takes, ~6 h for a cycle 
of replication to produce new virions or replication complexes. However, upon initial virus 
infection, a cell does not produce virus immediately. It goes through an eclipse phase before the 
first RNAs are produced. Replication in cellular cultures is readily detectable at 24 h, albeit at low 
levels (230). Thus, for the baseline scenario, we assume that upon infection cells can start 
producing vRNAs after a time corresponding to two generations, i.e. 12 h. However, we also 
investigate the effect of larger values for τ. 
µ – mutation rate per base per replication (2 copying events). The mutation rate for HCV has 
been estimated maximally at µ = 1.2x10-4 per base per replication (51). In our simulations, we 
choose µ to match the observed profile in the decrease over time of the fraction of sequences 
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without mutations in relation to the putative T/F virus. That is, at each time point for which we 
have a SGA sample, we calculate for the data and in the simulations the fraction of virus that has 
not mutated and hence has a genome (segment) still identical to the T/F virus. For each individual 
and genome segment (quarter or 5' half), we vary µ in increments of 0.01/Nb, where Nb is the 
number of nucleotides of the SGA sequence, and find the mutation rate that provides the best fit 
to the data (i.e., minimizes the sum of the squared residuals). Again, we ran 100 simulations for 




 The Mutation Rate Estimates are Robust to Different Choice of Parameters. In the 
results presented in the main text and our estimation of the mutation rate, we made certain 
assumptions about model parameters. Here we show that many of these assumptions are not 
critical or are conservative, in the sense that they lead to higher estimated mutation rates than 
other parameter possibilities. In each case, we vary only the parameter discussed, and keep all 
others at the values indicated in the main text and in Table 1. 
 We show, in Figure 3.4A, the effect of considering other values for the maximum number 
of replication complexes, RCM, within a cell. In the main text we used RCM=40, but for values 
above 10 (we show 10, 20, 40 and 80) there is almost no difference, and the result is certainly 
within the expected variation, in the predicted viral load profile (left panel) and pattern of 
accumulation of mutations (right panel). Moreover, analysis of the model shows that there is a 
trade-off between RCM and the number of infected cells at the plateau (Iss), explaining why 
different values of RCM do not change much the predictions of the model. In the case of a 
mechanism of replication akin to a “stamping machine”, i.e. RCM=1, we find that the maximum 
predicted accumulation of mutations is lower than that observed in the data. At the same time, the 
virus rises faster than seen in the data. This can be understood, because with RCM =1 all newly 
synthesized RNA is exported as virions (so k is larger). At the same time, all virions coming from 
an infected cell have, on average, the same number of mutations, because all virions result from 
two passages of the polymerase (+)RNA to (-)RNA to (+)RNA. This number of mutations is much 
less than when multiple replication complexes exist inside that cell. 
 Next, we varied the initial time it takes for the first RNA to be synthesized upon cell 
infection (Figure S1B). Again, for a range of realistic values between 12 h and 48 h, there is very 
little difference in the results predicted by the model. It is only when τ is unrealistically high (here 
5 days) that a significant delay is observed. Even in this case, though, we observe only a shift in 
the profiles of viral load and of accumulation of mutations. If indeed, the delay in first production 
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of RNA were that large, then one would predict that each individual was infected a few days 
earlier than the infection date on the graph. With such shift of time zero, the model would still fit 
the data accurately. 
 We also varied the fraction of mutations that are considered to be lethal, and that lead to 
non- productive RNA synthesis, Δ, (Figure S1C). For our baseline results we used Δ =0.4. 
However, if we take this fraction to be 0, 0.2, or 0.8, this does not affect the viral load profile 
during primary infection (left panel). This may be expected as the RNAs with lethal mutations are 
a very small fraction of the total number of RNAs produced, since they correspond to 40% of the 
~10-5 mutated RNAs. On the other hand, the effect of different Δ on the expected accumulation of 
mutations is large (right panel). If the fraction of lethal mutations is less than the original 0.4, then 
the model predicts more mutations than observed in the data, and to fit the latter we would need 
even smaller mutation rates than those estimated in the baseline scenario (Table 3.1). If the 
fraction of lethal mutations is larger than our original assumption of Δ=0.4, say Δ=0.8 (Figure 
S1C), then the model predicts a slower accumulation of mutations and to fit the data we would 
need a larger value for the mutation rate. Still, even in this extreme case, the median estimated 
mutation is only 5.5×10-5 per nucleotide per replication cycle, about twice our estimate for Δ=0.4. 
However, the value of Δ=0.4 used here is already high, corresponding to the maximum reported 
in the literature to date (259). 
 Estimating the Mutation Rate from Stop Codon Frequencies. Classical genetics 
shows that for a population in mutation-selection balance the frequency, f, of single point 
mutations with selection disadvantage s is given by f= µ/s, where µ is the mutation rate. For lethal 
mutations, s=1, and the frequency of these mutations is simply f=µ, since they must have been 
generated at the last replication cycle. Cuevas et al. (51) proposed using this approach to 
estimate the mutation rate of HCV, using non-sense mutations, i.e. stop codons (UAA, UAG, 
UGA) as a proxy for lethal mutations. 
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 There are 18 codons that upon mutation may generate a stop codon. These are: UUA, 
UUG, UCA, UCG, UAU, UAC, UGU, UGC, UGG, CAA, CAG, CGA, AAA, AAG, AGA, GAA, GAG, 
GGA. Following the notation in (51), in each codon we underline the nucleotide that is the 
mutation target, for a total of 19 non-sense mutation targets – NSMT (note that UGG has two 
targets). A priori, each of these targets can mutate to any of the other 3 nucleotides, but in most 
cases only the mutation to one of those 3 will generate a stop codon (for example, UGU → UGA). 
In a few cases the underlined nucleotide can mutate to 2 of the 3 possibilities and generate a stop 
codon, and we use boldface to indicate such cases (for example, UAU → UAA or UAG). We can 
now count in the data the number of NSMT (M), the number of stop codons (N), and the parental 
NSMT of each stop codon, such that we have N1 stop codons generated by mutation of non-
boldface, underlined nucleotides and N2 stop codons originated by mutation of boldface, 
underlined nucleotides. 
 Cuevas et al. (51) then used the following reasoning. Let us assume that there are M1 
codons (underlined), for which a single nucleotide substitution leads to a stop codon; M2 codons 
(underlined, boldface), for which two possible mutations lead to stop codons, with M= M1 + M2; 
and that the mutation rate per nucleotide per replication cycle is m. Then in one replication cycle, 
we can write  and , where the 1/3 comes from the fact that 
only one of the three possible nucleotide changes leads to a stop codon, and similarly for the 2/3 
when two of the three possible changes lead to a stop codon. Note also that we added N1 to M1 
and N2 to M2, because the codons that did mutate were also targets before this replication cycle, 
and since they mutated they were not counted in M1 or M2. However, because N1 and N2 are 
about 105-fold smaller than M1 and M2, respectively, to simplify we can also neglect the N1 added 
to M1 and the N2 added to M2. Upon rearrangement of the two expressions, this simplification 
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 By counting each stop codon appropriately and the total number of NSMT, one can use 
this formula to directly estimate the mutation rate, as we do in the text. 
 It is important to note that each of the two expressions alone would allow us to estimate µ 
(i.e., µ=µ1≡3N1/M1 or µ=µ2≡(3/2)(N2/M2)). By using both together, we are in a way averaging 
those two individual mutations estimates. We now propose a slightly different way to estimate µ 
(i.e., in effect a different linear combination of those two expressions), by summing the 
expressions defining N1 and N2 to obtain 
 
 This expression for µ has a simple interpretation. We divide the actual number of stop 
codons observed (N1+N2) by the total number of possible mutations leading to stop codons 
(M1+2M2). The factor 3 corrects for the fact that for each stop codon mutation observed, it is 
equally likely that the original nucleotide mutated to a non-stop codon nucleotide, which we did 
not count (62). The two expressions that we derived for µ give very similar estimates as shown in 
the main text, and we can show that in the limit of infinite data they are the same. Further, as we 
show below, the second expression is statistically a more efficient estimator, because it has a 
smaller sampling variance. 
 Since both µ1 and µ2 are independent estimates of µ, we can use the weighted average        
γµ1+(1-γ)µ2 for any weight γ (0<γ<1) as an estimator of µ. The sampling variances of the two 
starting estimators are, however, different in general, and hence, the sampling variance of these 
averages depends on α. In particular, since µ is small, we can ignore the possibility of multiple 
mutations within a single codon, and the distributions of N1 and N2 are binomial with rates µ/3 and 
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M2(2µ/3)(1- 2µ/3), respectively. However, from the definitions of µ1 and µ2, N1= M1µ1/3 and N2 = 
2M2µ2/3, thus the variance (Var) of Var(N1) = Var(M1µ1/3)= (M1/3)2Var(µ1) and similarly 
Var(N2)=(2M2/3)2Var(µ2). The resulting sampling variances of µ1 and µ2 are then given by     
3µ1(1-µ1/3)/M1≈3µ1/M1 and 3µ2(1-2µ2/3)/2M2≈3µ2/2M2, respectively. The sampling variance of the 
weighted average is then 3[γ2/M1+(1-γ)2/2M2] µ (where we have used µ in place µ1 and µ2), which 
is minimized when γ= M1/(M1+2M2). The use of this optimal weight for the weighted average of 
the two estimates µ1 and µ2 leads to our second expression above for estimating µ. This result 
can be trivially generalized to an arbitrary number of independent binomial processes with rates 
proportional to a single parameter, µ, to be estimated: when the rates are small, the minimal 
variance estimator is given by the total number of observed events divided by the expected 
number per unit µ.  
 We note that both expressions for µ are still an approximation, because they assume that 
all types of substitutions are equally likely, which is not correct. For example, transitions are 
preferred over transversions, and indeed we found that this bias is 18 to 1 (α=18) in our data set, 
when corrected for available sites (155). One way to implement this correction in the last formula 
for µ is to count the possible mutations according to whether they represent transitions (T) or 
transversions (V), so that M1=M1T+M1V and M2=M2T+M2V. The codons that can mutate by 
transition to a stop codon are: CGA, CAA, CAG, and UGG; all others require a transversion. Then 
one uses the bias ratio (α) to weigh the mutations, such that we have a new effective number of 
allowed mutations M1*=(αM1T+M1V)/α and 2M2*=((1+ α)M2T+2M2V)/α. In the same way, the factor 
3, which assumes that any nucleotide substitution is equally likely, has to be replaced by (α+2)/α, 
since a nucleotide can mutate by a transition or two transversions. Thus, we have 
 
and if α=1, i.e. transitions occur at the same rate as transversions, one recovers the previous 

























µ=(N1+N2)/(M1T+M2T). In the same spirit, other corrections, such as codon usage or matrices for 
favored mutations, could also be accounted for. 
 In Table 3.2, we present the details of the stop codons found in our data set. In Table 3.3, 
we show the NSMT in the data set. With this data, we can calculate the mutation rates presented 
in the text. Thus, if instead of assuming that transitions and transversions occur at the same rate, 
we assume the limit case of allowing only transitions, then we obtain µ= 3.4×10-5 (95% CI 
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 Previously, we hypothesized that transmitted hepatitis C virus (HCV) genomes that lead 
to productive clinical infection in humans could be identified unambiguously based on newly 
developed vRNA sequencing and modeling strategies. By analyzing plasma vRNA sequences 
from subjects with acute HCV infection in the context of different mathematical models of early 
virus evolution, we obtained evidence strongly supporting but not formally proving this hypothesis. 
Here, we tested the hypothesis by analyzing HCV plasma vRNA sequences from paired 
transmission subjects including epidemiologically-linked human-to-human and experimental 
human-to-chimpanzee transmission pairs where actual transmitted viral genomes could be 
tracked from donor to recipient. Using single genome sequencing of quarter, half, and near-full 
length HCV genomes from acutely infected humans and chimpanzees, we show that early virus 
diversification is essentially random with low diversity sequence lineages coalescing to discrete 
founder viral genomes. We show that the inferred transmitted/founder (T/F) sequences (These 
are the viral genomes that are transmitted and found the productive infection) are identical to 
sequences found to preexist in the donors in paired transmission donors and recipients. These 
findings demonstrate formally that low diversity sequence lineages of HCV evolve essentially 
randomly and coalesce to unambiguous T/F viral genomes. This conclusion implies that T/F 
sequences contain the essential genetic information that is necessary and sufficient for 
transmission and productive infection of human and chimpanzee hepatocytes and that 
subsequent virus evolutionary patterns emanating from T/F genomes reflect the composite 
effects of host innate and adaptive immune responses. Molecular identification of T/F genomes 





 Hepatitis C virus (HCV) is a single stranded, positive sense RNA virus in the Flaviviridiae 
and an important blood-borne pathogen (161, 235). Approximately 2% to 3% of the world 
population is chronically infected with HCV, and it is a major cause of hepatitis, cirrhosis, and 
hepatocellular carcinoma (8). While HCV demonstrates remarkable intra-host diversity due to the 
error-prone nature of HCV replication (66), transmission results in population bottlenecking (32, 
155, 325). Understanding the precise genetic composition of transmitted viral genomes could be 
instrumental in elucidating the earliest molecular events underlying virus transmission and the 
early innate and adaptive immune responses that are able to contain and eradicate infection in a 
minority of subjects. 
 Using experimental approaches pioneered and validated in HIV-1 and SIV transmission 
studies (82, 128, 129, 151, 257), we previously obtained evidence for HCV that the nucleotide 
sequences of the viruses at or near the moment of transmission could be inferred (155, 290). 
These genomes, which were inferred based on SGS, mathematical modeling of virus replication 
and diversification, and phylogenetic analysis, were termed transmitted/founder or T/F genomes 
to acknowledge the inferential nature of the approach (155, 290). The limitation of these earlier 
studies was that T/F genomes were inferred based on a number of assumptions regarding the life 
span of infected hepatocytes and their associated replication complexes, the error rate of HCV 
polymerase, an absence of early host-related selection pressures, and other variables (155, 238). 
Because of substantial differences in the replication strategies for HIV-1 and HCV, we developed 
different mathematical models to interrogate and hopefully explain viral sequence data from 
acutely infected individuals. While a simple deterministic model of random virus evolution could 
explain early sequence data from most subjects, a smaller proportion (~25%) of subjects 
contained early HCV sequences that violated model parameters of random diversification and a 
Poisson distribution of mutations (155). We speculated that these cases might represent 
acquisition of multiple viruses that had undergone genetic bottlenecking in the donor (see Figure 
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4.1), a finding that has previously been described in SGS studies of HIV-1 diversification (154). 
However, an alternative explanation we also considered was that these sequences diversified in 
a manner better explained by a more complicated model of virus replication and diversification 
(155). In an attempt to distinguish between these possibilities and to obtain definitive evidence 
that viral sequences obtain early in acute infection coalesce to unambiguous T/F genomes 
(including viruses that are actually transmitted from one individual to another), we examined in 
this study HCV sequences for epidemiologically linked human-to-human and human-to-





Figure 4.1. Conceptual depiction of acute-to-acute transmission. Viral genomes are depicted 
as colored rectangles and grey circles represent infected cells or enveloped virions. Single 
nucleotide mutations are denoted by colored tics on the viral genomes. Several virions are 
transmitted from the original donor into the recipient. Of these, only those with an R0 greater than 
1 are productive and begin to expand while accumulating mutations. Passage of this acute phase 
inoculum to a second subject results in transmission of multiple closely related genomes with R0 



















Transmission in humans. The human paired subjects were obtained from a cohort of men who 
have sex with men (MSM) in the New York area (49, 252) and the clinical or experimental data 
and circumstances surrounding the HCV infection events are presented in Table 4.1. Figure 4.2 
shows phylogentic trees and Highlighter plots from subject BGI to CCI. This case of transmission 
is remarkable for the high homogeneity both in the donor and the recipient. Phylogenetic 
inference in the recipient clearly shows that the T/F genetic sequence (represented as the 
topmost sequence in Figure 4.2B) is present in the donor (Figure 4.2C) and is identical to the 
sequence most commonly found in the donor. Diversification in both the donor and the recipient 
resulted in star-like phylogenies with a highly significant Poisson goodness-of-fit p-value for the 
donor (0.6639) and a weaker, but still significant, p-value of 0.2812 for the recipient (Table 4.1). 
Close phylogenetic analysis revealed four clusters (defined here as phylogenetic structures 
where sequences in the combined donor-recipient tree shares a node and at least one of these 
sequences was from the recipient) that exist in the recipient. Of these clusters, two out of four 
were found to be T/F variants (defined as phylogenetic constructs where at least one donor and 
recipient sequence are identical or where the recipient sequence interleaves with donor 
sequences) (Figure 4.2). 
In order to further study whether shared stochastic mutations occurring post-infection accumulate 
so as to represent as substantial fraction of early viral sequences (and thus obscure the inference 
of T/F genomes) or if these closely related genomes were acquired from the donor subject, we 
examined an acutely infected human by near full-length HCV genome analysis (Figure 4.3). This 
subject was initially infected with at least four T/F viruses, of which only one persisted over the 
course of the five month time period sampled. ~9kb genome amplicons were generated by SGS 
for this analysis in order to enhance the odds of seeing shared structures develop at any location 
in the viral genome and over the course of the early acute phase. Sampling in the earliest and 
second time point did not show evidence of complex intra-lineage phylogenetic structures. In the 
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case of the final time point, the phylogenetic structure was heterogeneous with the Hamming 
distance of the final time point differed from their ancestral T/F sequence, labeled as variant 1 in 
Figure 4.3, by a median of 10 nucleotides (range 8 to 18). This extrapolates to an accumulation 
of 0.24 to 0.48% diversity in a year and is comparable to rates of in vivo diversification previously 
reported for HCV (277) and suggesting that evolutionary stasis was not occurring in this subject. 
Indeed, at least 4 single nucleotide changes, each nonsynonymous, reached fixation in the 
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Table 4.1. Clinical context and phylogenetic analysis for paired transmission events. a Not 
applicable, b For humans, the days since the last negative quantitative nucleic acid assay is 
listed, whereas for chimpanzees, the days since transfusion of viral infectious material is listed. 
No HCV negative point was available for BGI, CCI, and 110069, so the dates sampled are 
reported. c Viral load is reported as IU/mL for subjects BGI and CCI and as estimated HCV RNA 
copies/mL for subjects 10081, X355, 10083, and X331. d Clusters are defined as phylogenetic 
structures where sequences in the combined donor-recipient tree share a node and at least one 
of these is a recipient sequence. These are indicated with vertical lines and text. e T/F variants 
are defined as phylogenetic clusters where at least one donor and recipient sequence are 
identical, or where the recipient sequence interleaves with donor sequences f Poisson distribution 
goodness-of-fit test p-values are reported here with the alpha value considered to be 0.05. 
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Figure 4.2. Single T/F transmission in humans. Human donor sequences are represented in 
orange and recipient sequences in blue. Clusters are defined as phylogenetic structures where 
sequences in the combined donor-recipient tree share a node and at least one of these is a 
recipient sequence. Transmitted T/F variants are defined as phylogenetic clusters were at least 
one donor and recipient sequence are identical, or where the recipient sequence interleaves with 
donor sequences. Both are indicated with vertical lines and labels. Ticks on the Highlighter plot 
represent nucleotide changes from the consensus sequence with the following identities: Red - T, 
Cyan - C, Orange - G, Green - A, Grey - Gap. 
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Figure 4.3. Diversification of T/F viruses after ~150 Days in human subject 110069. Time 
point one is represented in blue, point two in red and time point three in green. Ticks on the 
Highlighter plot represent nucleotide changes from the consensus sequence with the following 
identities: Red - T, Cyan - C, Orange - G, Green - A, Grey - Gap. 














































Experimental acute-to-acute transmission from humans to chimpanzees. A recent study by 
Busch and colleagues (33) afforded an excellent opportunity to observe early viral diversification 
in chimpanzees experimentally infected with acute phase plasmas from human subjects. In these 
experiments two chimpanzees were infected: chimpanzee X355 was infected with a very low 
multiplicity of infection inoculum containing a total of 60 HCV RNA copies whereas X331 was 
infected with a large inoculum containing 3.4x107 RNA copies. 
In the case of recipient X355 (Figure 4.4), a simple pattern of diversification was observed and 
T/F inference was uncomplicated. Genetic diversification in the recipient adhered to a model of 
star-like phylogeny and accumulation of mutations described by the Poisson distribution with a 
goodness-of-fit test p-value of 0.6245 (Table 4.1). The predicted T/F sequence is identical to 
sequences from one of the minor lineages found in the donor. 
Figure 4.5 shows the sampling and phylogeny structures of 146 donor and 292 recipient 
sequences obtained from human donor 10083 and chimpanzee recipient X331. Notably viral 
phylogenies from both the donor and recipient were highly complex and contained large numbers 
of closely related sequences. In figure 4.6A the donor and recipient sequences lineages were 
analyzed together and 25 phylogenetic clusters were identified where more than one sequence in 
the combined donor-recipient tree shares a node (a shared node is equivalent to a shared 
mutation that distinguishes the cluster from other sequences) and at least one of these 
sequences was from the recipient. Transmitted variants were defined here as phylogenetic 
clusters were at least one donor and one recipient sequence was identical. Panel 4.6B shows a 
second phylogeny where only these identical sequences found both in the donor and recipient 
are included. These shows that 13 (or 52%) of the lineages found in the recipient were likely 
transmitted from the donor rather than arising de novo in the recipient. 75.3% (110 out of 146) of 
the sequences from the donor and 61.3% (179 out of 292) of the sequences from the recipient 
are identical to those found in their partner.
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Figure 4.4. Experimental Infection of Chimpanzee X355 with a Limiting Inoculum From Acutely Infected Human 10081. Donor time point 
one is represented in red and time point two in black. Recipient time point one is in blue and time point two in green. Viral loads are shown in solid 
black lines with the ALT liver function test values in dashed lines. Ticks on the Highlighter plot represent nucleotide changes from the consensus 
sequence with the following identities: Red - T, Cyan - C, Orange - G, Green - A, Grey - Gap. 
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Figure 4.5. Experimental Infection of Chimpanzee X331 with a Large Inoculum From 
Acutely Infected Human 10083 Reveals a Complex Pylogenetic Pattern in the Recipient. (A) 
Donor time point one is represented in light green and time point two in dark green. (B) Recipient 
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loads are in solid black lines with the ALT liver function test values in dashed lines. Ticks on the 
Highlighter plot represent nucleotide changes from the consensus sequence with the following 





































































Figure 4.6. Combined Tree Phylogenetic Analysis of 10083 to X331 Transmission. (A) Donor time point one is represented in light green and 
time point two in dark green while recipient time points one through three are indicated with increasingly dark shaded blue symbols. Clusters are 
defined as phylogenetic structures where sequences in the combined donor-recipient tree share a node and at least one of these is a recipient 
sequence. These are indicated with vertical lines and text. (B) Transmitted T/F variants are defined as phylogenetic clusters where at least one 
donor and recipient sequence are identical, or where the recipient sequence interleaves with donor sequences. Both are indicated with vertical 
lines and labels. Ticks on the Highlighter plot represent nucleotide changes from the consensus sequence with the following identities: Red - T, 




This study provides empirical data supporting the model of random diversification we previously 
proposed for HCV (155) by validating that this mathematical and phylogenetic framework 
correctly infers the transmitted variants in both human-to-human and human-to-chimpanzee 
transmission. This was the case for transmission of an essentially monoclonal population in 
human-to-human transmission (Figure 4.2) and was also the case in the human-to-chimpanzee 
experiments involving passage of more heterogeneous genomes and both small and large 
inoculum sizes. (Figures 4.4 to 4.6). 
These findings also characterize a key scenario where the mathematical and phylogenetic 
predictions made by our model of random viral diversification is violated during analysis of 
sequences from recently infected individuals. Previously, we had proposed two possible 
explanations for these violations: that this was a product of an intrinsic propensity of HCV to 
accumulate stochastic mutations during viral ramp-up or that it occurs when the virus in the donor 
is rapidly expanding and a substantial inoculum is passed to a recipient (e.g. acute-to-acute 
infection) (155). This second scenario is of note since if this is analogous to findings in HIV-1 (28, 
105, 222, 328), and it suggests that HCV might have a clinical propensity for hyper-
transmissibility during acute phase infection. Phylogenetic analysis in both human-to-human 
(Figure 4.2) and human-to-chimp transmission (Figure 4.5) shows that at approximately half of 
the phylogenetic structures found in the recipients could most parsimoniously be explained as 
viral sequences transmitted from an acutely infected donor. Furthermore, these complex 
phylogenetic structures were not found to arise spontaneously in a human subject (Figure 4.3) 
that was followed until patterns suggestive of immune selection and the emergence of 
heterogeneity similar to that found in chronic subjects was apparent. 
Analysis of sequencing data from the human-to-chimpanzee experiments represented a more 
direct way of testing the relative contributions of innate viral factors and acute-to-acute 
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transmission to the emergence of non-star-like phylogenies. If the most important contributor to 
these violations is intrinsic to the replication of HCV in general, or to certain strains of HCV in 
particular, then such behavior would be expected in transmission to both chimpanzees X355 and 
X331 because the sequences derived from the human donors 10081 and 10083 violated the 
predicted star-like phylogeny. However, if this pattern is primarily due to the context of acute-to-
acute transmission, then we might expect this pattern to exclusively manifest in the chimpanzee 
X331 where a sufficiently large inoculum was utilized to permit passage of multiple genomes. The 
data shows that diversification of virus in X355 adhered to the predictions made by the model of 
random diversification whereas diversification in X331 did not (Table 4.1). Furthermore, careful 
analysis of the likely provenance of each phylogenetic cluster detected in X331 showed that 13 
out of 25 clusters consisted of recipient sequences identical to donor sequences. While these 
data strongly support the role of acute-to-acute transmission in generating phylogenies that are 
not star-like, this does not rule out the possibility that factors intrinsic to the HCV life cycle can 
contribute to similar violations. Indeed, Figure 4.6 shows many examples of minor clusters of 
sequences found only in the recipient (e.g. phylogenetic cluster 3 - 5 and 10 - 16). 
In conclusion, we have demonstrated here that identification of T/F viruses based on a model of 
random diversification and achieved through phylogenetic inference correctly identifies the actual 
transmitted genomes in multiple transmission pairs. We also show that acute-to-acute infection of 
a chimpanzee with a substantial viral challenge recapitulates the complex phylogenetic structures 
previously noted in ~25% of recently infected individuals (155), and that the majority of 
phylogentic clusters found in the recipient were identical to sequences found in the donor. These 
data provide empirical evidence for the correct identification of actual transmitted via inference of 
T/F genomes with a model of random viral diversification. 
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Materials and Methods 
 Samples. All human samples were obtained with informed consent and in adherence to 
the Declaration of Helsinki. Human-to-human transmission samples were acquired from the New 
York Acute Hepatitis C Surveillance Network. Regular source plasma donors were the sources 
for acute samples 110069 (SeraCare Life Sciences, Inc.), 10081 (ZeptoMetrix, Inc.), and 10083 
(ZeptoMetrix, Inc.). Chimpanzees used in the transmission experiments were housed in an 
Association for Assessment and Accreditation of Laboratory Animal Care-accredited facility and 
were collected during a recent study as previously described (33). Serum asparate 
aminotransferase (ALT) levels were quantified with a Unicel DxC 600 general chemistry clinical 
system with a range from 21 to 55 U/L considered to be normal. Plasma vRNA load for human-to-
human transmission subjects CCI and CGI were determined with the COBAS AmpliPrep TNAI Kit 
and COBAS Taqman HCV test v2.0 (Roche Diagnostics) as previously described (84). vRNA 
load for human-to-chimp transmission subjects 10081, X355, 10083, and X331 determined with 
the COBAS Amplicor HCV Monitor Test v2.0 (Roche Diagnostics) as described (80, 84). The 
week 10 low viral load sample from chimpanzee X331 was additionally assayed with a 
Transcription-Mediated-Amplification-Driven assay (134). 
 Single genome amplification and sequencing of 5' half, 3' half, and poly-U/UC 
genome segments. Viral RNA was isolated from plasma using the Qiagen BioRobot EZ1 
Workstation and EZ1 Virus Mini Kit v2.0 (Qiagen). Eluted RNA isolated from plasma or 
synthesized and was subjected to reverse transcription with SuperScript III M-MLV reverse 
transcriptase (Life Technologies). RNA template was mixed with 0.25 µM antisense primer and 
0.5 mM of each dNTP and heated to 65°C for 5 minutes followed by icing for 1 minute. 1 x 
SuperScript III buffer, 0.5 mM dithiotreitol, 2 units/µL RNaseOUT Recombinant Ribonuclease 
Inhibitor (Life Technologies), and 10 units/µL SuperScript III enzyme were added and the mixture 
incubated at 50°C for 75 minutes. The enzyme was heat inactivated for 15 minutes at 70°C. 0.1 
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units/µL Ribonuclease H (Life technologies) was added and incubated for 20 minutes at 37°C 
followed by storage at -80°C. 
 cDNA was brought to limiting dilution in 96-well plates and subjected to nested or hemi-
nested PCR using the Platinum Taq DNA polymerase High Fidelity kit (Life Technologies). 20 µL 
volumes were prepared containing diluted cDNA, 1 x Platinum Taq Buffer, 2mM Mg SO4, 0.2 mM 
of each dNTP, 0.2 µM forward and reverse primer, and 0.025 units/µL of Platinum Taq 
polymerase enzyme. These reactions were subjected to a first round of amplification with the 
following parameters: an initial cycle at 94°C for 2 minutes; 35 cycles of denaturation at 94°C for 
15 seconds, annealing at 58°C for 30 seconds, elongation at 68°C for 5 minutes, 30 seconds; 
and a final extension step at 68°C for 10 minutes. Subsequently, 1 µL of the product from the first 
round was transferred to a second round PCR reaction mixture containing the second round 
primers. 
 The primers used for subject 110069 were: reverse transcription primer 5' - 
GCGGCCGCTATTGGAGTGAGTTTGAG - 3' (9201←9226); 1st round 5'- 
AGCACGAATCCTAAACCTCAAAGAAAAA -3' (345→372) and antisense primer 5'- 
CCGGAGTGTTTATCCCAACCTTCAT - 3' (9374←9398); 2nd round primer 5'- 
TCAAAGAAAAACCAAACGTAACACCAACCG - 3' (362→391) and antisense primer 5'- 
GCGGCCGCTATTGGAGTGAGTTTGAG - 3' (9201←9226). For subjects BGI, CCI, 10081, 
X355, 10083, and X331 the primers were: reverse transcription: 5' - 
TATTGTATCCCACTGATGAAGTTCCACAT - 3' (5634←5662); 1st round 5'- 
ACCCGRCTTTGGTATTTGACATCACC -3' (2983→3008) and antisense primer 5'- 
TATTGTATCCCACTGATGAAGTTCCACAT - 3' (5634←5662); 2nd round primer 5'- 
AAAGTGCCCTACTTYGTGCGCGT - 3' (3063→3085) and antisense primer 5'- 
AGGGCCTTCTGCTTGAACTGCTC - 3' (5517←5539). For subjects BGI and CCI the primers 
were: reverse transcription: 5' - GGTGCTCGTGACGACCTCCAGGTC - 3' (5295←5318); 1st 
round 5'- ATGAGCACGAATCCTAAACCTCAAAGA -3' (342→368) and antisense primer 5'- 
GCACTCTTCCATCTCATCGAACTC - 3' (5451←5474); 2nd round primer 5'- 
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TCAAAGAAAAACCAAACGTAACACCAACCG - 3' (362→391) and antisense primer 5'- 
GGTGCTCGTGACGACCTCCAGGTC - 3' (5295←5318). Nucleotide locations listed are based 
off the AF009606 position. Nucleotide locations listed are based off the AF009606 position. 
 PCR conditions for the second round were identical to those of the first except that 45 
cycles were performed. Following PCR, amplicons were run on 1% agarose TAE gels and 
amplicons containing the expected size were submitted for subsequent direct sequencing. PCR 
reactions were Sanger sequenced using the BigDye Direct Cycle Sequencing Kit (Applied 
Biosytems) and ABI 3730xl genetic analyzer (Applied Biosytems) as recommended by the 
manufacturers. 
 Sequence alignment and phylogenetic analysis. Sequences for each amplicon were 
assembled with Sequencher 5.0 (Gene Codes) and chromatograms inspected for mixed 
templates. Sequences where multiple peaks or mixed bases were present were excluded from 
further analysis. Sequence alignments were generated with Clustal W (308) and inspected with 
MacClade 4.08 (macclade.org). Lineage diversity analysis was performed with the DIVEIN 
analysis suite (57) Maximum-likelihood phylogenetic trees were generated using PhyML (98). 
Phylogenies were visualized with FigTree v1.4.2 (tree.bio.ed.ac.uk/software/figtree/). Highlighter 
plots (hcv.lanl.gov/content/sequence/HIGHLIGHT/highlighter.html) were generated to support the 
phylogenetic characterization. Sequences from donor and recipient pairs were analyzed for 
diversification that adhered to a star-like phylogeny with accumulation of mutations occurring 
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 Hepatitis C virus (HCV) infection is characterized by persistent replication of a complex 
mixture of viruses termed a “quasispecies.” Transmission is generally associated with a stringent 
population bottleneck characterized by infection by limited numbers of “transmitted/founder” (T/F) 
viruses. Characterization of T/F genomes of human immunodeficiency virus type-1 (HIV-1) has 
been integral to studies of transmission, immunopathogenesis, and vaccine development. Here, 
we describe the identification of complete T/F genomes of HCV by single genome sequencing of 
plasma viral RNA from acutely infected subjects. 2,726 single genome-derived amplicons 
comprising 10,623,169 bp from 18 acute and 11 chronically infected subjects were analyzed. 
Acute sequences diversified essentially randomly except for the poly(U/UC) tract, which was 
subject to polymerase slippage. Fourteen acute subjects were productively infected by more than 
one genetically distinct virus, permitting assessment of recombination between replicating 
genomes. No evidence of recombination was found among 1,589 sequences analyzed. Envelope 
sequences of T/F genomes lacked transmission signatures that could distinguish them from 
chronic viruses. Among chronic subjects, higher nucleotide substitution rates were observed in 
the poly(U/UC) tract than in envelope hypervariable region 1. Fourteen full-length molecular 
clones with variable poly(U/UC) sequences corresponding to seven genotype 1a, 1b, 3a, and 4a 
T/F viruses were generated. Like most unadapted HCV clones, T/F genomes did not replicate 
efficiently in Huh 7.5 cells, indicating that additional cellular factors or viral adaptations are 
necessary for in vitro replication. Full-length T/F HCV genomes and their progeny provide unique 




Hepatitis C virus (HCV) infects 2% - 3% of the world’s population and exhibits extraordinary 
genetic diversity. This diversity is mirrored by HIV-1, where characterization of 
transmitted/founder (T/F) genomes has been instrumental in studies of virus transmission, 
immunopathogenesis and vaccine development. Here, we show that despite major differences in 
genome organization, replication strategy and natural history, HCV (like HIV-1) diversifies 
essentially randomly early in infection, and as a consequence, sequences of actual T/F viruses 
can be identified. This allowed us to capture by molecular cloning, full-length HCV genomes that 
are responsible for infecting the first hepatocytes and eliciting the initial immune responses, 
weeks before these events could be directly analyzed in human subjects. These findings 
represent an enabling experimental strategy, not only for HCV and HIV-1 research, but also for 
other RNA viruses of medical importance including West Nile, Chikungunya, Venezuelan 





 Hepatitis C virus (HCV) is a positive strand RNA virus in the Hepacivirus genus of the 
Flaviviridiae family and an important blood-borne pathogen (161, 235). HCV infects an estimated 
2% to 3% of the world population, and it is a major cause of hepatitis, cirrhosis, and 
hepatocellular carcinoma (8). HCV replicates with an error-prone RNA-dependent RNA 
polymerase and persists as a diverse quasispecies in infected individuals (66). The virus also 
demonstrates remarkable diversity at a global level, with at least seven major genotypes that 
differ by approximately 30% at the nucleotide level (280, 283). 
 In contrast to the generally high intra-host diversity of HCV in chronic infection, virus 
transmission is associated with a significant population genetic bottleneck (32, 155, 325). 
Previous studies based on SGS of acute infection plasma viral RNA revealed that HCV generally 
exhibits early random diversification, thereby allowing for a precise phylogenetic inference and 
enumeration of T/F sequence lineages based on partial genome sequences (155, 238). 
Extension of this strategy to span the complete genome represents a different strategy for 
characterizing complete HCV genomes compared with previous studies, which used population 
sequencing of plasma vRNA to generate a consensus of the circulating quasispecies (90, 135, 
147, 336). The T/F strategy is notable for identifying actual genomes that are responsible for 
transmission and productive clinical infection, and that by inference encode all of the essential 
viral elements necessary and sufficient for productive infection of human liver cells in vivo. 
Moreover, T/F viruses and their progeny represent the initial targets of host immune defenses. 
 Consensus sequence based approaches to clone representative HCV genomes have 
been used to generate complete genomes for genotypes 1 to 4. Clones developed using this 
approach contain intact viral open reading frames (ORFs), and introduction of these clones into 
chimpanzees led to productive infection (90, 135, 147, 336). There is a relative paucity of full-
length genotype 3 and 4 genomes, which are of interest because of their distinct clinical profile 
(genotype 3) (113) and their extraordinarily high prevalence in Egypt (genotype 4) (297). The first 
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complete genotype 3 sequences were reported for genotype 3g, 3h, 3i, and 3k isolates in 2011 
(153, 171), and for genotypes 3a and 4a in 2013 (127). Other consensus-based genotype 3a and 
4a genomes lack the terminal 3' untranslated region (UTR) but have been complemented with 3' 
UTR sequences from homologous or heterologous genotypes to successfully generate 
subgenomic replicons (253, 254) and molecular clones that are infectious in chimpanzees (90). 
Despite the success of consensus clones in supporting virus replication in vivo, only JFH-1 (and 
its derivatives) and other highly adapted virus strains (324, 339, 342), replicate efficiently in in 
vitro tissue culture systems. 
 The precise molecular identification of T/F genomes by SGS is a recently developed 
strategy for studying the transmission and early immunopathogenesis of RNA virus infections. It 
was first developed for human immunodeficiency virus type 1 (HIV-1) (128, 257) and validated 
with simian immunodeficiency virus (SIV) (129). The identification of T/F HIV-1 and SIV genomes 
has become a central feature of studies aimed at characterizing viral transmission, natural 
history, immunopathogenesis, and candidate vaccines. (11, 88, 154, 244, 245, 258, 289, 318). 
Such studies revealed that in HIV-1 infection, transmission generally resulted from acquisition of 
a single virus, that multiplicity of infection varied with clinicoepidemiological infection risk, and that 
T/F genomes replicated preferentially in CD4 T cells (11, 154). In addition, T/F HIV-1 viruses 
exhibited distinctive patterns of coreceptor utilization, neutralization sensitivity, potential N-linked 
glycosylation (PNG) distribution, dendritic cell interaction, envelope content, and sensitivity to 
type I interferon (58, 69, 154, 202, 211, 223, 258). HIV-1 and SIV vaccine studies in humans and 
animal models used T/F analyses to detect sieving of the virus quasispecies at transmission or 
shortly thereafter and may indicate vaccine-mediated antiviral activity (244-246, 289). These 
findings in HIV-1 infection provide a strong scientific rationale for analyzing T/F genomes of HCV 
as a means to probe transmission, virus biology, and viral-host interactions relevant to vaccine 
development. 
 HCV has distinctive features in its RNA sequence, genome organization, life cycle, 
replication strategy and early evolution as compared with HIV-1 and SIV that could pose 
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challenges for inferring full-length T/F genomes. This includes a highly ordered secondary RNA 
structure (316), 5’ and 3’ termini lacking repeated elements, a 3’ terminus that consists of a 
poly(U/UC) tract of variable length preceding a highly conserved 98-nucleotide X-tail (136, 301), 
a prolonged infected cell lifespan associated with the accumulation of as many as 40 replication 
complexes per cell (40, 230), non-uniform evolution across the genome (32, 67, 142, 200), and 
reports of selective sweeps, population bottlenecks, shifts in viral lineage predominance or 
compartmentalized infection early after infection (66, 142, 285). To account for these challenges, 
we developed two complementary mathematical models to explore early HCV evolution (155) 
and an experimental strategy based on SGS (128, 155, 257) of acute infection plasma vRNA 
sequences to amplify large overlapping internal segments of the viral genome, followed by 
adapter-primed 5’ and 3’ terminal amplifications and a “bridging” SGS method that incorporated a 
molecular cloning step to span the poly(U/UC) tract. This strategy allowed us to generate 14 full-
length molecular clones containing variable length poly(U/UC) tracts corresponding to seven 
distinct T/F genomes representing genotypes 1a, 1b, 3a and 4a and to perform a comparative 




 Single genome sequencing of acute and chronic infection plasma vRNA. Serially 
collected plasma specimens from 18 acutely infected plasma donors and 11 chronically infected 
control subjects were used as sample material for SGS (Tables 5.1 and 5.2). The acute infection 
samples were seroconversion panels used in the development and validation of clinical 
diagnostic tests (Zeptometrix, Inc. and SeraCare Life Sciences, Inc.). The individuals who 
contributed these plasma specimens were qualified for plasma donation and had been screened 
extensively for findings of risk factors associated with the acquisition of HCV infection. Despite 
these efforts, they were found in the course of once or twice weekly plasma donations to become 
HCV RNA positive. Viral load, anti-HCV antibody kinetic data, and sample time-point selection 
used for generation of full-length genome sequences and clones in the present study are shown 
in Figure 5.1. Because plasma samples were de-identified and study subjects had previously 
denied risk factors for HCV infection, it was not possible to further assess risk behaviors that 
might have been associated with viral acquisition or monitor subsequent disease progression in 
these individuals. Chronically infected subjects were from clinical outpatient services at the 
University of Alabama at Birmingham. All subjects were treatment-naïve for anti-HCV 
therapeutics for the duration of the sampling period. 
 SGS was initially performed on 5’ half genomes from acute and chronic samples in order 
to identify and enumerate T/F HCV sequence lineages (Table 5.1). Figure 5.2A shows a 
representative maximum-likelihood phylogenetic tree and Highlighter plot for 5’ half genome 
sequences from subject 105431, revealing two discrete genotype 4a lineages. The inferred T/F 
genomes of these two lineages differed by 0.35% nucleotides (17/4,906 bases) whereas 
sequence diversity within each T/F lineage was exceedingly low with a mean of 0.017% diversity 
(range, 0.000 to 0.082%). This pattern of extremely limited early viral sequence variation within 
discrete viral lineages was typical of all acutely infected subjects and adhered to a model of 
random early diversification that exhibited near star-like phylogeny. These low diversity sequence 
lineages coalesced to distinct, unambiguous T/F genomes. In all, we studied 18 subjects with 
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acute HCV infection including 14 who were productively infected by more than one genetically 
distinguishable virus. The average interlineage nucleotide diversity among these subjects 
infected by more than one T/F virus ranged from 0.123 to 6.188%, which is typical of the 
spectrum of diversity found in chronically infected subjects. Figure 5.2B shows the strategy 
utilized to infer full-length T/F genomes from overlapping amplicons consisting of 5' UTR, 5' and 
3' half genome, poly(U/UC) tract, and X-tail fragments. In all cases, diversification in regions of 
the HCV 5’ UTR and open reading frames (ORFs) conformed to a model of random 
diversification from discrete genomes. These results for complete viral genomes substantially 
extend our earlier findings based on quarter genome analyses of some of these same study 
subjects (155). Importantly, additional T/F lineages were not identified as overlapping genome 
segments were amplified and sequenced using different sets of primers targeting different 
portions of the viral genome, indicating that primer-dependent selective amplification was not a 
confounder. In chronically infected subjects, HCV sequences were heterogeneous (range 
0.062% to 3.934% diversity) and did not show evidence of the low-diversity lineages typical of 
acute infection. An important feature of SGS is that it precludes artifactual in vitro recombination 
between genetically distinct target genomes due to Taq polymerase template switching (128, 
257, 258). This enabled us to look across the viral genomes of subjects infected by more than 
one T/F virus for evidence of in vivo recombination. Among 1,589 sequences and 6,960,866 
nucleotides analyzed by Highlighter plot inspection and the GARD (137) and Recco (183) 




Table 5.1 Viral sequence characteristics in acute and chronic infection. a Percent 
divergence scores for all regions except the poly(U/UC) were determined by multiple pairwise 
alignment analysis using the DIVEIN software suite. b T/F estimates are based on combined 
quarter- and half-genome analysis. cNA, not applicable.
Infection 
status 





nucleotide diversity (%)a 
No. T/F 
genomesb 
Acute 10002 1a 5’ half 31 0.104 13 
 10012 1a 5’ half 129 0.035 3 
 10017 1a 5’ half 192 0.037 4 
 10020 1a 5’ half 64 0.046 10 
















 10024 1a 5’ half 112 0.025 6 
















 10029 1a 5’ half 201 0.037 9 
 10062 1a 5’ half 140 0.025 3 
 105686 1a 5’ half 23 0.055 2 
 106889 1a 5’ half 87 0.024 >30 
















 6213 1a 5’ half 41 0.000 3 
 6222 1a 5’ half 17 0.082 4 
































 10003 3a 5’ half 133 0.031 >30 












































 LAST90001 1a 5’ half 19 0.730 NA 





















 WHRO3882 1a 5’ half 22 0.504 NA 
 WIMI4025 
 







 WIMI90003 1a 5’ half 28 1.013 NA 
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TABLE S1 Sample origin and characteristics of single-genome amplification fragments used for analyses.
Range (%) Mean (%) Median (%) Range (%) Mean (%) Median (%)




4,905 31 0.000 - 0.286 0.104 0.061 0.225 - 3.20 2.04 2.80






4,882 129 0.000 - 0.144 0.035 0.041 2.54 - 3.43 3.02 3.03








4,889 192 0.000 - 0.185 0.037 0.041 0.061 - 1.41 1.14 1.26




4,905 64 0.000 - 0.143 0.046 0.041 0.020 - 0.266 0.123 0.122
5’ UTR 9/13/98 8.70E5 773 6 0.000 0.000 0.000




4,878 96 0.000 - 0.082 0.027 0.020









483 46 NAf NA NA
X-tail 9/13/98 8.70E5 93 4 0.000 0.000 0.000




4,882 112 0.000 - 0.123 0.025 0.000 0.479 - 1.41 0.994 1.29
5’ UTR 3/31/98 7.77E5 437 5 0.000 0.000 0.000




4,882 92 0.000 - 0.144 0.044 0.041









491 22 NA NA NA
X-tail 3/31/98 7.77E5 93 5 0.000 -1.53 0.460 0.000






4,876 201 0.000 - 0.185 0.037 0.041 0.247 - 3.16 2.27 2.92






4,858 140 0.000 - 0.165 0.025 0.021 0.393 - 0.809 0.651 0.663
105686b 1a 2 5’ half 9/21/07 8.53E5 4,902 23 0.000 - 0.163 0.055 0.041 0.512 - 0.698 0.584 0.574
106889b 1a >30 5’ half 7/8/08 3.27E5 4,902 87 0.000 - 0.082 0.024 0.020 0.041 - 1.03 0.551 0.656
5’ UTR 7/8/09 3.37E6 390 8 0.000 0.000 0.000 0.000 0.000 0.000
5’ half 7/6/09 4.13E5 4,903 88 0.000 - 0.102 0.021 0.020 0.204 - 0.760 0.499 0.615
3’ half 7/8/09 3.37E6 4,513 22 0.000 - 0.097 0.035 0.024 0.024 - 0.317 0.171 0.146








498 33 NA NA NA NA NA NA
X-tail 7/6/09 4.13E5 93 12 0.000 0.000 0.000 0.000 0.000 0.000
6213a 1a 3 5’ half 2/22/96 1.82E5 4,905 41 0.000 - 0.001 0.000 0.000 3.10 - 6.68 6.19 6.51
6222a 1a 4 5’ half 9/27/96 4.02E5 4,903 17 0.020 - 0.204 0.082 0.082 0.266 - 0.574 0.406 0.389
5’ UTR 7/6/98 1.18E6 536 10 0.000 - 0.564 0.250 0.187




4,865 124 0.000 - 0.103 0.020 0.021







478 38 NA NA NA
X-tail 7/14/98 2.30E6 93 11 0.000 - 1.29 0.235 0.000
5’ UTR 3/18/98 1.62E6 802 8 0.000 - 0.125 0.031 0.000






4,912 157 0.000 - 0.122 0.034 0.041







732 45 NA NA NA
X-tail 3/18/98 1.62E6 92 4 0.000 0.000 0.000






4,917 133 0.000 - 0.102 0.031 0.020 0.041 - 0.429 0.160 0.163
5’ UTR 9/12/07 4.12E6 668 40 0.000 - 0.300 0.026 0.000 0.300 - 0.451 0.314 0.300
5’ half 9/12/07 4.12E6 4,906 59 0.000 - 0.082 0.017 0.020 0.348 - 0.430 0.374 0.368







398 69 NA NA NA NA § NA § NA §
X-tail 9/12/07 4.12E6 92 15 0.000 0.000 0.000 1.042 - 1.234 1.18 1.23
5’ half 3/19/09 4.00E6 4,877 43 0.062 - 2.52 1.25 0.640
Poly(U/UC) 3/19/09 4.00E6 370 8 NA NA NA
5’ half 10/3/08 1.83E6 4,881 22 0.145 - 2.20 1.01 0.498
Poly(U/UC) 10/3/08 1.83E6 460 14 NA NA NA
5' half 7/31/07 2.85E6 4,888 21 0.246 - 2.43 1.56 1.49
Poly(U/UC) 7/31/07 2.85E6 403 9 NA NA NA
5' half 4/22/09 1.30E6 4,887 13 0.123 - 2.04 0.929 0.825
Poly(U/UC) 4/22/09 1.30E6 383 23 NA NA NA
LAST90001c 1a NA 5’ half 1/25/11 2.40E6 4,839 19 0.083 - 1.51 0.730 0.228 NA NA NA
5' half 9/2/08 1.44E6 4,902 18 0.082 - 1.32 0.879 0.946
Poly(U/UC) 9/2/08 1.44E6 404 9 NA NA NA
5' half 9/16/09 1.00E6 4,904 29 0.245 - 3.31 1.09 0.636
Poly(U/UC) 9/16/09 1.00E6 482 13 NA NA NA
5' half 5/11/09 6.40E6 4,903 44 0.102 - 3.08 1.71 2.46
Poly(U/UC) 5/11/09 6.40E6 467 10 NA NA NA
WHRO3882c 1a NA 5’ half 11/2/05 1.46E5 4,899 22 0.123 - 1.01 0.504 0.328 NA NA NA
5' half 10/3/08 7.69E6 4,887 36 0.122 - 3.93 1.32 1.24
Poly(U/UC) 10/3/08 7.69E6 502 16 NA NA NA
WIMI90003c 1a NA 5’ half 1/25/11 2.08E+06 4,839 28 0.145 - 2.20 1.01 0.498 NA NA NA
NAChronic ARJA6267c 1a NA NA NA
NA NA
9055a 3a 1 NA NA NA












Intralineage  nucleotide diversity e Interlineage  nucleotide diversity e
10021a 1a NA NA NA
NA
110069b 1a 4
10025a 1a 1 NA NA
1a NA
105431b 4a 2


















WIMI4025c 1a NA NA NA NA
NAWEPA5774c 1a NA
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Table 5.2 Sample origin and characteristics of single-genome amplification fragments 
used for analyses. a ZM-SP, Zeptometrix seroconversion panel. b SC-SP, SeraCare 
seroconversion panel. c UAB-C, University of Alabama at Birmingham, Center for AIDS Research 
Network of Integrated Clinical Systems. d T/F estimates are based on combined quarter- and half-
genome analysis. e Percent divergence scores for all regions, except the Poly(U/UC) tracts, were 
determined by DIVEIN multiple pairwise alignment analysis. Needleman-Wunsch pairwise 
dynamic programming was used for Poly(U/UC) comparisons, and the results are presented in 
Figure 5.9 and in Table 5.3. f NA, not applicable. 
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Figure 5.1. Plasma viral RNA and anti-HCV antibody kinetics in acutely infected subjects. 
Kinetics of viral RNA (red line) and anti-HCV antibody (blue line) are depicted. The red dashed 
line is the lower limit of sensitivity of the viral RNA assay. Circled time points are samples that 
were used to generate full or partial genomes for genetic analysis and molecular clone 
construction. 





















































































































































































































































































































































Figure 5.2. Identification of two full-length T/F viral genomes in acutely infected subject 
105431. (A) The viral diversity found in subject 105431 is depicted for the 5’ half-genome 
fragment by a maximum-likelihood phylogenetic tree and highlighter plot. (B) The HCV genome is 
depicted with gene organization and major RNA secondary structures on the top followed by the 
amplification strategy for generating full-length HCV genomes in light yellow. Adaptors added to 
the 5' and 3' termini are depicted in orange. Highlighter plots for each region shown below 
demonstrate that a high degree of homology is maintained throughout the genomes within the T/F 
lineages, which are distinguished by large sets of shared polymorphisms. 
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 Genomic organization and phylogenetic analysis of T/F sequences. Full-genome 
sequencing of each T/F genome revealed intact ORFs. Figure 5.3 depicts a maximum-likelihood 
tree of these sequences together with representative globally circulating strains corresponding to 
the major HCV genotypes. The T/F genomes from subjects 10021, 10025, and 110069 were all 
genotype 1a viruses whereas that from subject 10051 was a subtype 1b virus. Subject 9055 was 
infected with a genotype 3a T/F virus and 105431 with genotype 4a T/F viruses. The T/F from 
10051 was most closely related to the consensus clone Con1 from Germany at 92.8% nucleotide 
identity (170). 10021 was most closely related to isolate AX663428 from a patient in France with 
94.9% identity while 10025 and 110069 were most closely related to isolate HEC278830 
sequenced from a British patient with 93.2% and 93.1% identity, respectively (140). The two 
genotype 4a T/F viruses from subject 105431 demonstrated close phylogenetic linkage, with the 
next most closely related virus being isolate 01-09 from the United States with 94.2% nucleotide 
identity (312). Genotype 3a T/F 9055 was most closely related to the Japanese isolate TYMM at 
91.6% nucleotide identity (335). These results indicate that the T/F sequences generated were 
well distributed throughout the phylogeny of HCV and its globally circulating genotypes.  
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Figure 5.3. T/F genomes are representative of three of the major HCV genotypes found 
globally. The maximum-likelihood nucleotide tree is based on the full ORFs with T/F genomes 
identified in this study highlighted in red. GenBank accession numbers are shown with the names 
of the strains or clones shown in parentheses. Bootstrap values are included for bootstraps >70% 































































































































































































Potential N-linked glycosylation site analysis of T/F versus chronic envelope 
glycoproteins. In HIV-1 infection, T/F viruses generally have fewer potential N-linked 
glycosylation (PNG) sites compared with viruses sampled in chronic infection (58, 211, 223), with 
N-linked glycans playing a protective role against antibody neutralization (194, 329). In HCV 
infection, a study in chimeric immunodeficient mice transplanted with human hepatocytes 
reported a distinctive amino acid signature pattern in envelope (198T, 448D, 474Y, 570D/A) 
including one E2 PNG site that was associated with selective HCV transmission (30). Our data 
set included T/F HCV envelope sequences from 18 acutely infected humans and a corresponding 
set from 11 chronically infected patients. Figure 5.4 depicts the percentage of PNG motifs found 
throughout the E1 and E2 proteins for 274 chronic and 51 T/F genotype 1a envelope sequences. 
No significant differences in PNG sites between T/F and chronic HCV genomes were observed 






Figure. 5.4. Potential N-linked Glycan sites are highly conserved between acute T/F lineage 
sequences and chronic sequences. AA position is based on the H77 AF009606 reference 


























































 Hypervariation in the 3' poly(U/UC) tract. The HCV 3’ UTR consists of a variable 
region containing two stem loops (340), a poly(U/UC) tract of varying length, a transitional region 
with a higher concentration of non-U nucleotides, and the highly conserved 98 nucleotide X-tail 
(136, 298, 301). Reverse transcription, amplification, and sequencing of long homopolymer tracts 
is technically challenging because of the potential for polymerase slippage (101, 144, 231, 241). 
In longitudinal acute samples for subjects 10021, 10025, 110069, 10051, 9055, and 105431 and 
from single samples for chronically infected subjects ARJA6267, BLMI6862, JOTO6422, 
KNPH3730, ROMI6847, SLRO5563, WEPA5774, and WIMI4025, we observed striking variability 
in sequence lengths of poly(U/UC) sequences within and among all subjects (Figures 5.5–5.7). In 
contrast, there was virtually no length variation in any of 3,652,088 nucleotides corresponding to 
the remaining ~98% of the genome exclusive of the poly(U/UC) tract. In acutely infected subjects, 
viral sequences with the longest poly(U/UC) tracts exhibited the greatest variation in sequence 
length and this was concentrated in the homopoly(U) stretches (Figures 5.5B, 5.6B, 5.6C). These 
sequence sets were characterized by a longer maximum poly(U/UC) tract length (112-162 
nucleotides), longer maximum homopoly(U) tract lengths (36-115 nucleotides), and a smaller 
average proportion on non-U nucleotides as a percentage of the poly(U/UC) tract (10%). In 
subjects with shorter poly(U/UC) tracts, the length variability in homopoly(U) stretches was 
reduced (Figures 5.5A, 5.6A, 5.6D). In these latter sequence sets, the maximum poly(U/UC) tract 
length was 66-95 nucleotides, the maximum homopoly(U) tract length was 23-47 nucleotides, 
and the average proportion of non-U nucleotides interspersed in the poly(U/UC) tract was 13%. 
In subjects 10021, 10025, 10051, 9055, and 105431, we analyzed multiple early time points to 
look for progressive loss or gain of homopoly(U) sequences during early infection (Figures 5.5A, 
5.5B, and 5.6). Within each subject, we could identify no such pattern and similar poly(U/UC) 





Figure 5.5. Length variation in the HCV poly(U/UC) tract. Varying degrees of length and 
sequence variation in the poly-U/UC tract in acute infection subjects 10051 (A) and 10025 (B) 
and in chronic infection subject BLMI6862 (C). See also Figures 5.6 and 5.7. 
! !" #" $" %" &" '" (" )" *" !"" !!" !#" !$" !%"
T G A A C G G G G A G C T A A G C A C T C C A G G C C A A T A G G C C A T C C T G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T C C - T T T T T T T T T T T T T T T A T T T T C T T C T T T G G T G G
T G A A C G G G G A G C T A A G C A C T C C A G G C C A A T A G G C C A T C C T G - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T T T T T G - - - - - - T T T T T T T T T T T T T T T T C T T T T T C C - - - - - - - T T T T T T T T T A T T T T C T T C T T T G G T G G
T G A A C G G G G A G C T A A G C A C T C C A G G C C A A T A G G C C A T C C T G - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T T T T T T G - - - - - - T T T T T T T T T T T T T T T T C T T T T T C C - - - - - - - T T T T T T T T T A T T T T C T T C T T T G G T G G
T G A A C G G G G A G C T A A G C A C T C C A G G C C A A T A G G C C A T C C T G - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T G - - - - - - - - T T T T T T T T T T T T T T C T T T T T C C - - - - - T T T T T T T T T T T A T T T T C T T C T T T G G T G G
T G A A C G G G G A G C T A A G C A C T C C A G G C C A A T A G G C C A T C C T G - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T T T G - - - - - - T T T T T T T T T T T T T T T T C T T T T T C C - - - - - T T T T T T T T T T T A T T T T C T T C T T T G G T G G
T G A A C G G G G A G C T A A G C A C T C C A G G C C A A T A G G C C A T C C T G - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T T T T T T G - - - - - - - - - T T T T T T T T T T T T T C T T T T T C C - - - - T T T T T T T T T T T T A T T T T C T T C T T T G G T G G
T G A A C G G G G A G C T A A G C A C T C C A G G C C A A T A G G C C A T C C T G - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T T T T T T T G - - - - - - - - T T T T T T T T T T T T T T C T T T T T C C - - - - T T T T T T T T T T T T A T T T T C T T C T T T G G T G G
T G A A C G G G G A G C T A A G C A C T C C A G G C C A A T A G G C C A T C C T G - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T T T T G - - - - - - T T T T T T T T T T T T T T T T C T T T T T C C - - - - T T T T T T T T T T T T A T T T T C T T C T T T G G T G G
T G A A C G G G G A G C T A A G C A C T C C A G G C C A A T A G G C C A T C C T G - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T G - - - T T T T T T T T T T T T T T A T T T T C T T T T T C C - - - T T T T T T T T T T T T T A T T T T C T T C T T T G G T G G
T G A A C G G G G A G C T A A G C A C T C C A G G C C A A T A G G C C A T C C T G - - - - - - T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T G - - - - - - T T T T T T T T T T T T T T T T C T T T T T C C - T T T T T T T T T T T T T T T A T T T T C T T C T T T G G T G G
T G A A C G G G G A G C T A A G C A C T C C A G G C C A A T A G G C C A T C C T G - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T T T T T T G - - - - - T T T T T T T T T T T T T T T T T C T T T T T C C - T T T T T T T T T T T T T T T A T T T T C T T C T T T G G T G G
T G A A C G G G G A G C T A A G C A C T C C A G G C C A A T A G G C C A T C C T G - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T T T T G - - - - - - - - C T T T T T T T T T T T T T C T T T T T C C T T T T T T T T T T T T T T T T A T T T T C T T C T T T G G T G G
T G A A C G G G G A G C T A A G C A C T C C A G G C C A A T A G G C C A T C C T G - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T G - - - - - - - T T T T T T T T T T T T T T T C T T T T T C C T T T T T T T T T T T T T T T T A T T T T C T T C T T T G G T G G
T G A A C G G G G A G C T A A G C A C T C C A G G C C A A T A G G C C A T C C T G - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T C T T T T T C C T T T T T T T T T T T T T T T T A T T T T C T T C T T T G G T G G
T G A A C G G G G A G C T A A G C A C T C C A G G C C A A T A G G C C A T C C T G - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T T T T T T G - - - - - - - - - - T T T T T T T T T T T T C T T T T T C C - - - - - - T T T T T T T T T T A T T T T C T T C T T T G G T G G
T G A A C G G G G A G C T A A G C A C T C C A G G C C A A T A G G C C A T C C T G - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T T T T G - - - - - - T T T T T T T T T T T T T T T T C T T T T T C C - - - - - T T T T T T T T T T T A T T T T C T T C T T T G G T G G
T G A A C G G G G A G C T A A G C A C T C C A G G C C A A T A G G C C A T C C T G T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T G - - - - - - T T T T T T T T T T T T T T T T C T T T T T C C - - - - - T T T T T T T T T T T A T T T T C T T C T T T G G T G G
T G A A C G G G G A G C T A A G C A C T C C A G G C C A A T A G G C C A T C C T G - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T G - - - - - - - T T T T T T T T T T T T T T T C T T T T T C C - - - - T T T T T T T T T T T T A T T T T C T T C T T T G G T G G
T G A A C G G G G A G C T A A G C A C T C C A G G C C A A T A G G C C A T C C T G - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T T T G - - - - - - - T T T T T T T T T T T T T T T C T T T T T C C - - - T T T T T T T T T T T T T A T T T T C T T C T T T G G T G G
T G A A C G G G G A G C T A A G C A C T C C A G G C C A A T A G G C C A T C C T G - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T T G - - - - - T T T T T T T T T T T T T T T T T C T T T T T C C - - - T T T T T T T T T T T T T A T T T T C T T C T T T G G T G G
T G A A C G G G G A G C T A A G C A C T C C A G G C C A A T A G G C C A T C C T G - - - - - - T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T G - - - - - - - - - T T T T T T T T T T T T T C T T T T T C C - - T T T T T T T T T T T T T T A T T T T C T T C T T T G G T G G
T G A A C G G G G A G C T A A G C A C T C C A G G C C A A T A G G C C A T C C T G - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T G - - - - - - - - T T T T T T T T T T T T T C C T T T T T C C - - T T T T T T T T T T T T T T A T T T T C T T C T T T G G T G G
T G A A C G G G G A G C T A A G C A C T C C A G G C C A A T A G G C C A T C C T G - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T G - - - - - - T T T T T T T T T T T T T T T T C T T T T T C C - - T T T T T T T T T T T T T T A T T T T C T T C T T T G G T G G
T G A A C G G G G A G C T A A G C A C T C C A G G C C A A T A G G C C A T C C T G - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T T T T T T G - - - - - T T T T T T T T T T T T T T T T T C T T T T T C C - T T T T T T T T T T T T T T T A T T T T C T T C T T T G G T G G
T G A A C G G G G A G C T A A G C A C T C C A G G C C A A T A G G C C A T C C T G - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T G - - - - - - - - - T T T T T T T T T T T T T C T T T T T C C T T T T T T T T T T T T T T T T A T T T T C T T C T T T G G T G G
T G A A C G G G G A G C T A A G C A C T C C A G G C C A A T A G G C C A T C C T G - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T T T T T T G - - - - T T T T T T T T T T T T T T T T T T C T T T T T C C T T T T T T T T T T T T T T T T A T T T T C T T C T T T G G T G G
T G A A C G G G G A G C T A A G C A C T C C A G G C C A A T A G G C C A T C C T G - - - - - - T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T G - - - T T T T T T T T T T T T T T T T T T T T T T T T T C C - - - T T T T T T T T T T T T T A T T T T C T T C T T T G G T G G
T G A A C G G G G A G C T A A G C A C T C C A G G C C A A T A G G C C A T C C T G - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T T G - - - - T T T T T T T T T T T T T T T T T T C T T T T T C C - - - - - T T T T T T T T T T T A T T T T C T T C T T T G G T G G
T G A A C G G G G A G C T A A G C A C T C C A G G C C A A T A G G C C A T C C T G - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T T G - - - - - - T T T T T T T T T T T T T T T T C T T T T T C C - - - - T T T T T T T T T T T T A T T T T C T T C T T T G G T G G
T G A A C G G G G A G C T A A G C A C T C C A G G C C A A T A G G C C A T C C T G - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T G - - - - - - - T T T T T T T T T T T T T T T C T T T T T C C - - - T T T T T T T T T T T T T A T T T T C T T C T T T G G T G G
T G A A C G G G G A G C T A A G C A C T C C A G G C C A A T A G G C C A T C C T G - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T T T G - - - T T T T T T T T T T T T T T T T T T T C T T T T T C C - - - T T T T T T T T T T T T T A T T T T C T T C T T T G G T G G
T G A A C G G G G A G C T A A G C A C T C C A G G C C A A T A G G C C A T C C T G - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T G - - T T T T T T T T T T T T T T T T T T T T C T T T T T C C - - - T T T T T T T T T T T T T A T T T T C T T C T T T G G T G G
T G A A C G G G G A G C T A A G C A C T C C A G G C C A A T A G G C C A T C C T G - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T G - - - - - - T T T T T T T T T T T T T T T T C T T T T T C C - - T T T T T T T T T T T T T T A T T T T C T T C T T T G G T G G
T G A A C G G G G A G C T A A G C A C T C C A G G C C A A T A G G C C A T C C T G - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T T T T T G - - - - - - T T T T T T T T T T T T T T T C C T T T T T C C - - T T T T T T T T T T T T T T A T T T T C T T C T T T G G T G G
T G A A C G G G G A G C T A A G C A C T C C A G G C C A A T A G G C C A T C C T G - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T G T T T T T T T T T T T T T T T T T T T T T T C T T T T T C C - - T T T T T T T T T T T T T T A T T T T C T T C T T T G G T G G
T G A A C G G G G A G C T A A G C G C T C C A G G C C A A T A G G C C A T C C T G - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T T G - - - - - T T T T T T T T T T T T T T T T T C T T T T T C C - T T T T T T T T T T T T T T T A T T T T C T T C T T T G G T G G
T G A A C G G G G A G C T A A G C A C T C C A G G C C A A T A G G C C A T C C T G - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T T T G - - - - - T T T T T T T T T T T T T T T T T C T T T T T C C - T T T T T T T T T T T T T T T A T T T T C T T C T T T G G T G G




! !" #" $" %" &" '" (" )" *" !"" !!" !#" !$" !%" !&" !&)
T G A A G G T T A G G G T A A A C A C T C C G G C C T C T T A G G T C A T T T T C T G - T T T T T T T T T T T T T T T T T T T C C C T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T C C - - - - - - - - T T T T T T T T T C T C - - - - - T T T T T T T T T T T T T T T A T T T T C T T T A A T G G T G G
T G A A G G T T A G G G T A A A C A C T C C G G C C T C T T A G G C C A T T T T C T G T T T T T T T T T T T T T T T T T T T T C T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T C C - - - - - T T T T T T T T T T T C C T C - - - - T T T T T T T T T T T T T T T T A T T T T C T T T A A T G G T G G
T G A A G G T T A G G G T A A A C A C T C C G G C C T C T T A G G C C A T T T T C T G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T A T T T T C T T T G A T G G T G G
T G A A G G T T A G G G T A A A C A C T C C G G C C T C T T A G G C C A T T T T C T G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T A T T T T C T T T G A T G G T G G
T G A A G G T T A G G G T A A A C A C T C C G G C C T C T T A G G C C A T T T T C T G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T C C - - - - T T T T T T T T T T T T T C T C - - - - - - - - - T T T T T T T T T T T A T T T T C T T T A A T G G T G G
T G A A G G T T A G G G T A A A C A C T C C G G C C T C T T A G G C C A T T T T C T G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T C C - - - - - - - T T T T T T T T T C C T C - - - - - - - - - T T T T T T T T T T T A T T T T C T T T A A T G G T G G
T G A A G G T T A G G G T A A A C A C T C C G G C C T C T T A G G C C A T T T T C T G - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T C C - - - - T T T T T T T T T T T T T C T C - - - - - - - T T T T T T T T T T T T T A T T T T C T T T A A T G G T G G
T G A A G G T T A G G G T A A A C A C T C C G G C C T C T T A G G C C A T T T T C T G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T C C - - - - - - T T T T T T T T T T T C T C - - - - - - T T T T T T T T T T T T T T A T T T T C T T T A A T G G T G G
T G A A G G T T A G G G T A A A C A C T C C G G C C T C T T A G G C C A T T T T C T G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T C T T T T T T T T T T T T T T T T T T T T C - - - - - T T T T T T T T T T T T T T T A T T T T C T T T A A T G G T G G
T G A A G G T T A G G G T A A A C A C T C C G G C C T C T T A G G C C A T T T T C T G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T A T T T T C T T T G A T G G T G G
T G A A G G T T A G G G T A A A C A C T C C G G C C T C T T A G G C C A T T T T C T G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T A T T T T C T T T A A T G G T G G
T G A A G G T T A G G G T A A A C A C T C C G G C C T C T T A G G C C A T T T T C - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T C T C - - T T T T T T T T T T T T T T T T T T A T T T T C T T T A A T G G T G G
T G A A G G T T A G G G T A A A C A C T C C G G C C T C T T A G G C C A T T T T C T G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T C C - - - - - - - - T T T T T T T T T C T C - - - - - - T T T T T T T T T T T T T T A T T T T C T T T A A T G G T G G
T G A A G G T T A G G G T A A A C A C T C C G G C C T C T T A G G C C A T T T T C T G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T C C - - - - - T T T T T T T T T T T T C T C - - - - - T T T T T T T T T T T T T T T A T T T T C T T T A A T G G T G G
T G A A G G T T A G G G T A A A C A C T C C G G C C T C T T A G G C C A T T T T C T G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T C C - - - - T T T T T T T T T T T T C C T C - - - T T T T T T T T T T T T T T T T T A T T T T C T T T A A T G G T G G
T G A A G G T T A G G G T A A A C A C T C C G G C C T C T T A G G C C A T T T T C T G - - - - - - - - T T T T T T T T T T T T C C C - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T C C C - - - - - - T T T T T T T T T T C T C - - - - - - - - - - T T T T T T T T T T A T T T T C T T T A A T G G T G G
T G A A G G T T A G G G T A A A C A C T C C G G C C T C T T A G G C C A T T T T C T G - - - - T T T T T T T T T T T T T T T T C C - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T C C - - - - - - - - T T T T T T T T T C T C - - - - - - - - - - T T T T T T T T T T A T T T T C T T T A A T G G T G G
T G A A G G T T A G G G T A A A C A C T C C G G C C T C T T A G G C C A T T T T C T G - - - - - - - T T T T T T T T T T T T T C C - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T C - - - - - - - - T T T T T T T T T C T C - - - - - - - - - T T T T T T T T T T T A T T T T C T T T A A T G G T G G
T G A A G G T T A G G G T A A A C A C T C C G G C C T C T T A G G C C A T T T T C T G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T A T T T T C T T T A A T G G T G G
T G A A G G T T A G G G T A A A C A C T C C G G C C T C T T A G G C C A T T T T C T G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T C C - - - - T T T T T T T T T T T T C C T C - - - T T T T T T T T T T T T T T T T T A T T T T C T T T A A T G G T G G
T G A A G G T T A G G G T A A A C A C T C C G G C C T C T T A G G C C A T T T T C T G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T C C - - - - T T T T T T T T T T T T C C T C T T T T T T T T T T T T T T T T T T T T A T T T T C T T T A A T G G T G G





! !" #" $" %" &" '" (" )" *!
T A G G C C A T T T T C C G G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T C T C C T T T A A T G G T G G
T A G G C C A T T T T C T G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T C T C T T T A A T G G T G G
T A G G C C A T T C T C T G - - - - - - - - - - - - - - - - - - - - - - - T T T T T T G T T T T T T T T T T C C T T T T T T T C T C T C T T T T G T T T T T T T T T T A A T G G T G G
T A G G C C A T T C T C T G - - - - - - - - - - - - - - - - - - - - - T T T T T T T G T T T T T T T T T T T T T T G T T T T T C C T T T T T T T T T T C C T T C T T T A A T G G T G G
T A G G C C A T T C T C T G - - - - - - - - - - - - - - - - - - - - - T T T T T T T G T T T T T T T T T T T T T G T T T T T C C T T T T T T T T T T T C C T T C T T T A A T G G T G G
T A G G C C A T T T T C T G - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T G T T T T T T T T C C T T T C T T T T G T T T T T T T T T T T C T T C T T T A A T G G T G G
T A G G C C A T T T T C T G - - - - - - - - - - - - - - - - - T T T T T T T C T T T T T T T T T T T T T T T G T T T T T C C T C T C T T T T T T T T T T T C T T C T T A A T G G T G G
T A G G C C A T T T T C C G - - - - - - - - - - - - - - T T T T T T T T T G T T T T T T T T T T T C T T T T T T T T T T C C T T T C T T T T T T T T T T C T T C T T T A A T G G T G G
T A G G T C A T T T T C T G - - - - - - - T T T T T T T G T T T T T T T T G T T T T T T T T T T T T T T C C T T T C C T T T T T T T T T T T T T T T T C C T T C T T T A A T G G T G G
T A G G C C A T T T T C T G - - - - - T T T T T T T T G T T T T T T T T T C C T T T T T T T T T T T C C T T T C T T T T G T T T T T T T T T T T T T T T C T T C T T T A A T G G T G G
T A G G C C A T T T T C T G - - - - - T T T T T T T T T T T T T C C T T T T G G T T T T T T T T T T T T C T T C T T T T G T T T T T T T T T T T T T T T C T T C T T T A A T G G T G G
T A G G T C A T T T T C C G - - - T T T T T C T T T T T T T T T T T G T T T T T C T T T T T T T T T T T C C T T T C T T T T T T T T T T T T T T G T T C C T T C T T T A A T G G T G G
T A G G C C A T T T T C T G - - T T T T T T T T T T T T T T G T T T T T T T T G G T T T T T T T T T T T T T C C T T T T T T T T C C T T T T T T T T T C C T T C T T T A A T G G T G G
T A G G C C A T T T T C T G T T T T T T T T T T G T T T T T T T T C C T T T T T C T T T T T T T T T T T T c T T C T T T T G T T T T T T T T T T T T T C C T T C T T T A A T G G T G G
+
& ' ' ' ' ' ' ' ' ' & ' ' ' ' ' ' ' ' ' && ' ' ' ' ' ' ' ' ' & ' ' ' ' ' ' ' ' '& ' ' ' ' ' ' ' ' ' & ' ' ' ' ' ' ' ' '& ' ' ' ' ' ' ' ' ' & ' ' ' ' ' ' ' ' '& ' ' ' ' ' ' ' ' ' & ' ' ' ' ' ' ' ' '& ' ' ' ' ' ' ' ' ' & ' ' ' ' ' ' ' ' '& ' ' ' ' ' ' ' ' ' & ' ' ' ' ' ' ' ' '
& ' ' ' ' ' ' ' ' ' & ' ' ' ' ' ' ' '& ' ' ' ' ' ' ' ' '& ' ' ' ' ' ' ' ' ' & ' ' ' ' ' ' ' ' '& ' ' ' ' ' ' ' ' '& ' ' ' ' ' ' ' ' ' & ' ' ' ' ' ' ' ' '& ' ' ' ' ' ' ' ' '& ' ' ' ' ' ' ' ' ' & ' ' ' ' ' ' ' ' '& ' ' ' ' ' ' ' ' '& ' ' ' ' ' ' ' ' ' & ' ' ' ' ' ' ' ' '& ' ' ' ' ' ' ' ' '& ' ' ' ' ' ' ' ' '
& ' ' ' ' ' ' ' ' ' & '& ' ' ' ' ' ' ' ' '& ' ' ' ' ' ' ' ' ' & ' ' ' ' ' ' ' ' '& ' ' ' ' ' ' ' ' '& ' ' ' ' ' ' ' ' ' & ' ' ' ' ' ' ' ' '& ' ' ' ' ' ' ' ' '& ' ' ' ' ' ' ' ' '











































Figure 5.6. Poly(U/UC) tract sequence variation in acute infection subjects. Poly(U/UC) tract 
sequences for acute infection subjects (A) 10021, (B) 110069, (C) 9055, and (D) 105431. Serial 
samples are color-coded with the corresponding viral kinetics presented on the left.
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T G A A G G T T G G G G T A A A C A C T C C G G C C C C T T A G G C C A T T T C C T G - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T A C C C T T T T T T C T C - - - - - T T T T T T T T T T T T T T C C T T C T T C T T T A A T G G T G G
T G A A G G T T G G G G T A A A C A C T C C G G C C C C T T A G G C C A T T T C C T G - - - - - T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T A C C C T T T T T T C T C - - - - T T T T T T T T T T T T T T T C C T T C T T C T T T A A T G G T G G
T G A A G G T T G G G G T A A A C A C T C C G G C C C C T T A G G C C A T T T C C T G - - - - - T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T A C C C T T T T T T C T C - - - - T T T T T T T T T T T T T T T C C T T C T T C T T T A A T G G T G G
T G A A G G T T G G G G T A A A C A C T C C G G C C C C T T A G G C C A T T T C C T G T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T A C C C T T T T T T C T C - - T T T T T T T T T T T T T T T T T C C T T C T T C T T T A A T G G T G G
T G A A G G T T G G G G T A A A C A C T C C G G C C C C T T A G G C C A T T T C C T G - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T A C C C T T T T T T C T C T C T T T T T T T T T T T T T T T T T - C T T C T T C T T T A A T G G T G G
T G A A G G T T G G G G T A A A C A C T C C G G C C C C T T A G G C C A T T T C C T G - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T A C C C T T T T T T C T C - - - - - - - T T T T T T T T T T T T C C T T C T T C T T T A A T G G T G G
T G A A G G T T G G G G T A A A C A C T C C G G C C C C T T A G G C C A T T T C C T G - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T A C C C T T T T T T C T C - - - - - - T T T T T T T T T T T T T C C T T C T T C T T T A A T G G T G G
T G A A G G T T G G G G T A A A C A C T C C G G C C C C T T A G G C C A T T T C C T G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T C C T T C T T C T T T A A T G G T G G
T G A A G G T T G G G G T A A A C A C T C C G G C C C C T T A G G C C A T T T C C T G - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T T A C C C T T T T T T C T C - - - - - - - - - - T T T T T T T T T C C T T C T T C T T T A A T G G T G G
T G A A G G T T G G G G T A A A C A C T C C G G C C C C T T A G G C C A T T T C C T G - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T C T T T A C C C T T T T T T C T C - - - - - - - T T T T T T T T T T T T C C T T C T T C T T T A A T G G T G G
T G A A G G T T G G G G T A A A C A C T C C G G C C C C T T A G G C C A T T T C C T G - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T T T T A C C C T T T T T T C T C - - - - - - - T T T T T T T T T T T T C C T T C T T C T T T A A T G G T G G
T G A A G G T T G G G G T A A A C A C T C C G G C C C C T T A G G C C A T T T C C T G - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T A C C C T T T T T T T T C - - - - - - T T T T T T T T T T T T T C C T T C T T C T T T A A T G G T G G
T G A A G G T T G G G G T A A A C A C T C C G G C C C C T T A G G C C A T T T C C T G - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T T A C C C T T T T T T C T C - - - - - - T T T T T T T T T T T T T C C T T C T T C T T T A A T G G T G G
T G A A G G T T G G G G T A A A C A C T C C G G C C C C T T A G G C C A T T T C C T G - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T T T A C C C T T T T T T C T C - - - - - - T T T T T T T T T T T T T C C T T C T T C T T T A A T G G T G G
T G A A G G T T G G G G T A A A C A C T C C G G C C C C T T A G G C C A T T T C C T G - - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T A C C C T T T T T T C T C - - - - - T T T T T T T T T T T T T T - C T T C T T C T T T A A T G G T G G
T G A A G G T T G G G G T A A A C A C T C C G G C C C C T T A G G C C A T T T C C T G - - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T A C C C - T T T T T C T C - - - - - T T T T T T T T T T T T T T C C T T C T T C T T T A A T G G T G G
T G A A G G T T G G G G T A A A C A C T C C G G C C C C T T A G G C C A T T T C C T G - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T A C C C T T T T T T C T C - - - - - T T T T T T T T T T T T T T C C C T C T T C T T T A A T G G T G G
T G A A G G T T G G G G T A A A C A C T C C G G C C C C T T A G G C C A T T T C C T G - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T A C C C T T T T T T C T C - - - - - T T T T T T T T T T T T T T C C T T C T T C T T T A A T G G T G G
T G A A G G T T G G G G T A A A C A C T C C G G C C C C T T A G G C C A T T T C C T G - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T T T A C C C T T T T T T C T C - - - - - T T T T T T T T T T T T T T C T T T C T T C T T T A A T G G T G G
T G A A G G T T G G G G T A A A C A C T C C G G C C C C T T A G G C C A T T T C C T G - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T T T T A C C C T T T T T C C C C - - - - - T T T T T T T T T T T T T T C C T T C T T C T T T A A T G G T G G
T G A A G G T T G G G G T A A A C A C T C C G G C C C C T T A G G C C A T T T C C T G - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T T T T T - C C C T T T T T T C T C - - - - - T T T T T T T T T T T T T T C C T T C T T C T T T A A T G G T G G
T G A A G G T T G G G G T A A A C A C T C C G G C C C C T T A G G C C A T T T C C T G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T A C C C T T T T T C C T C - - - - T T T T T T T T T T T T T T T C C T T C T T C T T T A A T G G T G G
T G A A G G T T G G G G T A A A C A C T C C G G C C C C T T A G G C C A T T T C C T G - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T A C C C - T T T T T C T C - - - - T T T T T T T T T T T T T T T C C T T C T T C T T T A A T G G T G G
T G A A G G T T G G G G T A A A C A C T C C G G C C C C T T A G G C C A T T T C C T G - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T A C C C T T T T T T C T C - - - - T T T T T T T T T T T T T T T C C T T C T T C T T T A A T G G T G G
T G A A G G T T G G G G T A A A C A C T C C G G C C C C T T A G G C C A T T T C C T G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T C C T T C T T C T T T A A T G G T G G
T G A A G G T T G G G G T A A A C A C T C C G G C C C C T T A G G C C A T T T C C T G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T A C C C T T T T T T C T C - - T T T T T T T T T T T T T T T T T C C T T C T T C T T T A A T G G T G G
T G A A G G T T G G G G T A A A C A C T C C G G C C C C T T A G G C C A T T T C C T G - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T A C C C - - T T T T C T C - - T T T T T T T T T T T T T T T T T C C C T C T T C T T T A A T G G T G G
T G A A G G T T G G G G T A A A C A C T C C G G C C C C T T A G G C C A T T T C C T G - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T A C C C T T T T T T C T C - - - - - - - - T T T T T T T T T T T C C T T C T T C T T T A A T G G T G G
T G A A G G T T G G G G T A A A C A C T C C G G C C C C T T A G G C C A T T T C C T G - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T C T T T T T T T T T T T T T T T A C C C T T T T T T C T C - - - - - - - - T T T T T T T T T T T C C T T C T T C T T T A A T G G T G G
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T G A A G G T T G G G G T A A A C A C T C C G G C C C C T T A G G C C A T T T C C T G - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T C T T T T T A C C C T T T T T T C T C C - - - - - - T T T T T T T T T T T T C C T T C T T C T T T A A T G G T G G
T G A A G G T T G G G G T A A A C A C T C C G G C C C C T T A G G C C A T T T C C T G - - - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T A C C C T T T T T T C T C - - - - - - T T T T T T T T T T T T T C C T T C T T C T T T A A T G G T G G
T G A A G G T T G G G G T A A A C A C T C C G G C C C C T T A G G C C A T T T C C T G - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T C T T T T T A C C C T T T T T T C T C - - - - - - T T T T T T T T T T T T T C C T T C T T C T T T A A T A G T G G
T G A A G G T T G G G G T A A A C A C T C C G G C C C C T T A G G C C A T T T C C T G - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T A T T T T T T T T T A C C C T T T T T T C T C - - - - - - T T T T T T T T T T T T T C C T T C T T C T T T A A T G G T G G
T G A A G G T T G G G G T A A A C A C T C C G G C C C C T T A G G C C A T T T C C T G - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T T T A C C C T T T T T T C T C - - - - - T T T T T T T T T T T T T T C C T T C T T C T T T A A T G G T G G
T G A A G G T T G G G G T A A A C A C T C C G G C C C C T T A G G C C A T T T C C T G - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T A C C C T T T T T T C T C - - - - T T T T T T T T C T T T T T T C C T T C T T C T T T A A T G G T G G
T G A A G G T T G G G G T A A A C A C T C C G G C C C C T T A G G C C A T T T C C T G - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T A C C C T T T T T T C T C - - - - T T T T T T T T T T T T T T T C C T T C T T C T T T A A T G G T G G
T G A A G G T T G G G G T A A A C A C T C C G G C C C C T T A G G C C A T T T C C T G - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T A C C C T T T T T T C T C - - - - T T T T T T T T T T T T T T T C C T T C T T C T T T A A T G G T G G
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Figure 5.7. Poly(U/UC) tract sequence variation from chronic infection subjects. Poly(U/UC) 
tract sequences for chronic infection subjects (A) SLRO5563, (B) WEPA5774, (C) WIMI4025, (D) 
ARJA6267, (E) JOTO6422, (F) KNPH3730, (G) ROMI6847.
! !" #" $" %" &" '" (" )" *" !"" !!" !#"!#%
T A G G C C A T T A T C T G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T C C T T T C T T - A C T G G T G G
T A G G C C A T T - - C T G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T C C T T T C T C T T T C C T C T C C T T T T T C C T T C T T T - A A T G G T G G
T A G G C C A T T A T C T G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T G T T T T T T T T T T T C C T T T C T T T C T T T T C C T T T C T T C A C T G G T G G
T A G G C C A T T T - C T G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T T T T C C C T C T T T C T T T T T T T T T T C C T T C C T T - A A T G G T G G
T A G G C C A T T T T C T G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T C T T T T T T T T T T T C T T T C C T T C T T T T T T T T T T T C C T T C C T T - A A T G G T G G
T A G G T C A T T T T C T G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T G T T T T T T T T G T T T T T T T T T T T T C C T T T C C T T T T T T T T T T T T T C C T T C T T T - A A T G G T G G
T A G G C C A T T T - C T G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T T G T T T T T T T T T T C C T T T C C T T C T T T T T T T T T T C C T T C C T T - A A T G G T G G
T A G G C C A T T T - C T G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T T T T C C T T T T T C T T C C T T T T T T T T T T T T T T T T T T T T T T C C T T C T T T - A A T G G T G G
T A G G C C A T T T - C C G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T C C T T T T T T T T T T T T T T T T T T C C T T T C C T T C T T C T T T T T T T T T T T T T T T T T T C C T T C C T T - A A T G G T G G
T A G G C C A T T A T C T G T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T C C T T T T C C T T T C T T C A C T G G T G G
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T A G G C C G T T T C - - T G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T C T T T C C T T T C C T T T T T C T T T T T T C C C T T C T T T A A T G G T G G
T A G G C C G T T T C - - T G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T C C T T T C C T T T T C T T T T C T T T T T T T C C T T C T T T A A T G G T G G
T A G G C C G T T T C - - T G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T C T C T T T C C T T C C T T T T T T T C T T C T T T T T T C C T T C T T T A A T G G T G G
T A G G C C G T T T C - - T G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T C C C T T T T T C T T T C C T T T T T C T T T T T T T C C C T T C T T T A A T G G T G G
T A G G C C G T T T C - - T G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T T C C C T T T T T T T T T T C C T T T T C T T T C C T T T T T T T T T T T C C T T C T T T A A T G G T G G
T A G G C C G T T T C - - T G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T C C T T T T T T T T T T C C T T T T C C T T T C C T T T T T C T T T T T T T T T T T C T T C T T T A A T G G T G G
T A G G C C A T T T C C G T G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T T T T T T T T T T T T T T C C T T T T T T T T T C T T T T T T T T T T T C C T T T C C T T T T T T T T T T C C C T T T C T T T A A T G G T G G
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 Variation in the length of the poly(U/UC) tract in viral genomes emanating from single T/F 
genomes could result from slippage of the HCV RdRp in vivo or slippage by any of the 
polymerases used in the amplification and sequencing steps in vitro. HCV RdRp is highly 
processive (16, 169) and tightly grips the template RNA (3, 197). In contrast, the Moloney murine 
leukemia virus (MMLV) reverse transcriptase (RT) and T. aquaticus (Taq) polymerase enzymes 
used to generate and amplify cDNA from vRNA are prone to slippage and template switching 
(175, 203, 218, 321), likely due to inherent structure-function relationships of the enzymes (54, 
158, 187, 273, 295). Additionally, both MMLV and Taq enzymes are particularly error-prone in 
homopolymer tracts (26, 101, 131, 273). To evaluate potential sources of the variability that we 
observed in poly(U/UC) sequences, we analyzed each step in the analysis of vRNA sequences 
individually. We found that the E. coli enzymes involved in plasmid replication during subcloning 
did not introduce frequent variation in the poly(U/UC) tract: the vast majority (96.6%) of bacterial 
colonies that had been transformed with a plasmid containing a known homopoly(U) tract 
nucleotides did not introduce a single change into the homopolymer tract of the cultured plasmid 
(Figure 5.8A). Amplification by Taq polymerase potentially contributed more to the observed 
variation in poly(U/UC) sequences than did the E. coli DNA polymerase but had a minor over-all 
effect on the median length of poly(U/UC) tracts: Amplification of a molecularly cloned DNA 
construct with a known homopoly(U) sequence followed by plasmid subcloning and sequencing 
yielded a median length that was 99.4% of the expected length but 83.3% of the poly(U/UC) tract 
sequences contained additions, deletions, or substitutions (Figure 5.8B). To evaluate the impact 
of the MMLV RT infidelity on the length and sequence variation observed in the poly(U/UC) tract, 
we chemically synthesized homologous 40 nucleotide RNA oligomers that differed only by the 
substitution of two cytidine residues within the 40-nucleotide homopoly(U) tract (Figures 5.8C - 
5.8F). This was done to test directly MMLV polymerase slippage and the hypothesis that non-U 
nucleotides within a homopoly(U) tract would diminish its frequency.  
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 The two RNA templates were subjected to reverse transcription, subcloning and SGS. 
Among colonies derived from the 40-nucleotide homopoly(U) RNA template, we observed wide 
variation in the length of the amplified homopoly(U) sequences that resulted in a trend towards 
truncation of the homopoly(U) tract. 96.9% of the sequences contained differences from the input 
RNA template and the median tract length was 80% of the expected length (Figure 5.8C). 
Conversely, there was less variation in the median length of the homopoly(U) tract in products 
sequenced from the RNA template that contained two cytidine residues (Figure 5.8D). The 
median length of the homopoly(U) tracts was 97.5% of the expected length. The difference in 
sequence lengths generated from the two otherwise identical homopoly(U) RNA templates was 
highly significant (p<0.0001).  
 Altogether, these findings indicate that MMLV RT step is most error prone with regard to 
processivity and template slippage, that slippage most often results in shortening of sequences, 
and that RT slippage is potentially the primary contributor to the length variation that we observed 
in the poly(U/UC) region. However, these findings also highlighted other changes in the 
poly(U/UC) tract that could not be attributed to RT slippage and that were most notable in chronic 
HCV sequences (Figures 5.5, 5.7). This included the interspersion of numerous C and G 
substitutions in the homopoly(U) region and variation in the transitional region. In order to 
quantify and compare this variation in sequences from acute and chronic subjects, we subjected 
a 45 nucleotide region of the poly(UC) tract region immediately 5’ of the X-tail to Needleman-
Wunsch pairwise analysis. We compared variation in this region to that in the highly conserved 
CD81 binding domain I (CD81 BDI) (207) and hypervariable region 1 (HVR1) of the envelope 
gene E2 (126) (Figure 5.9 and Table 5.3). Acute infection sequences did not differ significantly in 
diversity among the poly(U/UC), HVR1, and CD81 BDI regions in this analysis, consistent with 
the recent evolution of these sequences from discrete T/F genomes. However, among chronic 
infection sequences, the HVR1 (77.2 to 95.1% similarity score) and poly(UC) (66.6 to 90.7% 
similarity score) sequences exhibited significantly greater diversity than CD81 BDI sequences 
(95.5 to 100% similarity score; p<0.001 for each comparison). Surprisingly, chronic poly(UC) 
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sequences exhibited even greater mean diversity (66.6 to 90.7% similarity score) than chronic 
HVR1 sequences (77.2 to 95.1% similarity score, p<0.001), a region that has been previously 
described as harboring the highest within-host variation (93). 
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Figure 5.8. Contributions of E. coli, Taq polymerase and MMLV reverse transcriptase to 
poly(U/UC) tract variation. (A) DNA from a molecular clone containing a 41-nucleotide 
homopoly(U) tract (input) was used to transform E. coli. 60 colonies were sequenced revealing 
rare deletions and no nucleotide substitutions. (B) Plasmid DNA containing an 87-nucleotide 
homopoly(U) tract was endpoint diluted and subjected to 45 PCR cycles of amplification, cloned 
into a plasmid, transfected into E. coli, and 36 colonies analyzed, revealing contributions of Taq 
polymerase slippage to poly(U/UC) length variation. (C) Reverse transcription, single genome 
amplification, and subcloning were performed on input synthetic RNA molecules containing a 40-
nucleotide homopoly(U) tract, revealing substantial poly(U/UC) length variation, more so than in 
panels A, B or D. (D) Reverse transcription, single genome amplification, and subcloning were 
performed on input synthetic RNA molecules containing a 30-nucleotide homopoly(U) tract. (E) 
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Electrospray ionization mass spectrometry (ESI-MS) demonstrates that the synthetic RNA used 
as input in panel C are homogeneous in length with the expected molecular weight for RNA 
oligonucleotide UC1 (predicted 25,019.4; observed 25,019.3). (F) The synthetic RNA used as 
input in panel D is similarly homogeneous in length and with the expected molecular weight for 




Figure 5.9 Nucleotide sequence similarity scores of the poly(UC) tract, Env E2 
hypervariable region and CD81 binding domain I in acute and chronic infection. The y-axis 
denotes the mean percent similarity score from Needleman-Wunsch pairwise analysis of 
genomic regions corresponding to the CD81 binding domain I (AF009606 position 1,491 - 1,530), 
the E2 hypervariable region (AF009606 position 1,575 - 1,614), and a 45 nucleotide portion of the 
poly(U/UC) tract immediately 5' of the X-tail (AF009606 position 9504 - 9548). Means and 





































Table 5.3 Poly(UC) tract hypervariation as revealed by Needleman-Wunsch pairwise 
analysis. Needleman-Wunsch similarity scores are presented as a percentage of the maximum 
possible score. a The short poly(U/UC) fragment denotes the first 45 nucleotides immediately 5’ of 
the X-tail. b The long poly(U/UC) fragment denotes the first 60 nucleotides immediately 5’ of the 
X-tail. c In the case of subjects 105431 and ARJA6267, the poly(U/UC) tract was not sufficiently 
long for a 60- or 65-nt analysis. NA, not applicable. 
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 Analysis of 3' UTR sequence motifs. For detailed analysis of the 3' UTR, we aligned 
this region from the seven full-length T/F genomes we inferred along with representative HCV 
sequences from the Los Alamos HCV database (Figure 5.10). The variable region immediately 5’ 
of the poly(U/UC) tract showed sequence patterns shared within genotypes but not between 
genotypes. This region is predicted to form two stem loop structures that play a role in the viral 
replication cycle (75, 340). Small insertions and deletions in this region are well tolerated in vitro 
and in vivo but large deletions have a significant impact on optimal RNA replication (75, 337, 
340). Consistent with previous reports, genotype 3a sequences had an abbreviated variable 
region approximately 50% shorter than that of genotypes 1a, 1b, 2a, and 4a. Nevertheless, a 
short island of conservation constituting the predicted 3' miR-122 binding motif 'ACACUCC' (122) 
is preserved immediately 5’ of the gap in the 3a genomes. The homopoly(U) tracts of the 
genotype 4a viruses sequenced in this study were shorter than those for the other genotypes 
studied. The length of the homopoly(U) and poly(U/UC) are known to have an important impact 
on viral replication in vitro. Minimal lengths of >16 nt (343) for the homopoly(U) and 
approximately >40 nt for the poly(U/UC) (75, 340) have been reported in vitro. The length of the 
poly(U/UC) tract is also known to play a critical role in permitting robust viral replication in vivo 
with the longer poly(U/UC) structures generally favored over shorter structures (135). The X-tails 
of T/F viruses were highly conserved within and between genotypes with the exception of a short 
polymorphic region spanning nucleotide 9620 to 9623 that is predicted to be located at the tip of 
the X-tail stem-loop 1 (136) and would not be expected to alter the RNA folding structure of these 
regions (115). These data indicate that the variable region sequences 5' of the poly(U/UC) tract of 
genotypes 1, 3, and 4 genomes are conserved within, but not between, genotypes while the X-tail 





Figure 5.10. T/F genotypes 1a, 1b, 3a, and 4a 3' UTR sequences compared with 
representative HCV reference sequences. The numbering on the top corresponds to the H77 
AF009606 genome. Asterisks indicate positions with nucleotide identity. Dashes indicate 
deletions. The 5’ codon represents the stop codon at the end of the NS5B gene. T/F genomes 
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 Construction and analysis of T/F molecular clones. Excluding the poly(U/UC) region, 
the sequences of seven T/F genomes corresponding to genotypes 1a, 1b, 3a, and 4a from six 
subjects could be inferred unambiguously. These sequences were chemically synthesized and 
subcloned into plasmids together with poly(U/UC) sequences representing the spectrum of 
variation evident in the sequences from multiple early time points (Figure 5.11). Plasmids 
contained a 5' T7 promoter and 3' linearization restriction site to facilitate in vitro transcription. 
Plasmids containing HCV genomic clones were grown large scale and sequence confirmed. T/F 
molecular clones were used to generate vRNA for studies of innate immune signaling, with 
findings reported in the accompanying paper (192) and elsewhere (83). vRNAs expressed from 
these clones were also tested for translation and replication competence by electroporation into 
Huh 7.5 cells stably expressing an HCV replication dependent fluorescence relocalization 
reporter (121). 
 Expression of functional HCV NS3/4A protein in these cells results in the nuclear 
localization of otherwise mitochondrial-tethered RFP. Viral protein expression was assessed 48 h 
after electroporation by monitoring the translocation of the RFP and by flow cytometry for NS5A 
protein expression. Figure 5.12 shows that electroporation of Huh 7.5 cells with vRNA from the 
replication competent molecular clone JFH-1 yielded significant numbers of cells positive for 
NS5A (p<0.0001) and NS3/4A (p<0.01) expression compared with cells treated with the HCV 
polymerase inhibitor 2'CMA (35) or with mock infected cells. In contrast, Huh 7.5 cells 
electroporated with T/F vRNA corresponding to HCV genotypes 1a, 3a, or 4a showed no 
evidence of virus replication. Additional attempts at launching other T/F molecular clones (Fig. 
S6) in Huh 7.5 cells under varying conditions yielded similarly negative results. Moreover, efforts 
to launch these clones in primary fetal hepatoblasts (6) and stem cell derived differentiated 
hepatocyte-like cells (204) were largely unsuccessful; low levels of NS3/4A activity were 
observed particularly for T/F clone 10051TF.UC1 but successful passage of virus was not 
achieved (unpublished observations). These data suggest that similar to other unadapted HCV 
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clones (90, 342), T/F molecular clones cannot replicate efficiently in the existing cell culture 
systems and that additional cellular factors or viral adaptations will be necessary to achieve 
robust in vitro replication.  
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Figure 5.11. Full-length T/F HCV molecular clones. (A-G) All clones include a 5’ T7 
transcription site and 3’ linearization site for use in generating viral RNA in vitro. Restriction sites 
used to concatenate the full genomes are labeled in green and the restriction sites used to 
introduce the genomes into the vectors are labeled in red. In cases where the terminal restriction 
site and the RNA run-off sites are different, the run-off site is labeled in blue. (F) The distinctive 
poly(U/UC) tracts for each molecular clone are listed with the corresponding accession number 
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Figure 5.12. Comparative launch of T/F and JFH-1 vRNA in Huh-7.5 cells. Huh-7.5 cells were 
electroporated with in vitro transcribed RNA from pJFH-1 and T/F molecular clones 
110069TF1.UC1, 9055.UC1, 105431TF2.UC1. NS5A expression, determined by flow cytometry, 
is represented in white and light grey bars. NS3/4A activity, determined by translocation of the 
MAVS-NLS-RFP signal, is presented in the dark grey bars. Error bars represent the standard 
































































 Previously, we described a conceptual and mathematical model of early HCV sequence 
diversification that allowed for an unambiguous identification of T/F genomes based on an 
analysis of quarter or half genome sequences (155). This work in HCV was adapted from earlier 
studies in HIV-1 that included both partial and full-length genome analyses as well as an 
empirical validation of this experimental strategy in the SIV-infected Indian rhesus macaque 
model (128, 129, 151, 163, 257, 258). Because of differences in the primary and secondary RNA 
sequence, genome organization, life cycle, kinetics of target cell turnover, sequence evolution 
and immunopathogenesis of HCV versus HIV-1 infection, it was not obvious a priori whether HCV 
diversification across the complete genome would exhibit essentially random diversification early 
in infection, which is a prerequisite for inferring T/F genomes. Indeed, some models suggested 
that violations to the Poisson distribution of near-random mutations might be more common in 
HCV than in HIV-1 (155) due to differences in viral replication strategies. Furthermore, viral 
recombination (50, 76, 87), compartmentalized infection (33, 66, 84), early selective sweeps (32, 
285), population bottlenecking, shifts in predominant virus populations (142, 285), or non-uniform 
evolution across the genome (32, 67, 142, 200) might all obscure virus lineages evolving from 
discrete T/F genomes. In this study, we found that none of these potential complexities obscured 
a precise and unambiguous inference of T/F genomes. Only polymerase slippage, presumably 
due primarily to reverse transcriptase infidelity in the cDNA synthesis step, complicated the 
identification of T/F genomes. We thus were able to infer full-length T/F genome sequences 
corresponding to all structural genes and 5’ and 3’ regulatory sequences exclusive of the 
poly(U/UC) tract from six subjects shortly after the first appearance of plasma viremia (Figures 
5.1 and 5.2). The rapid, exponential rise in plasma virus load, with a comparable increase in 
numbers of productively infected hepatocytes and viral replication complexes likely explains the 
essentially random diversification that we observed throughout the viral genome. In a separate 
study where we characterized T/F HCV genomes in human-to-human and human-to-chimpanzee 
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linked transmission pairs, we confirmed that T/F genomes inferred from early viral sequence 
coalesced to actual transmitted viral genomes found in the donor subjects (See Chapter 4). 
 While it was not the original focus of our study, we had a unique opportunity to look with 
great sensitivity and specificity for viral recombination in subjects acutely infected by more than 
one genetically distinct virus. The SGS strategy for generating long amplicons and sequences (5 
to 9kb) is particularly useful in this regard because it is based on Taq polymerase amplification of 
end point diluted, single cDNA molecules, which obviates the appearance of Taq polymerase 
mediated recombination events in finished sequences (128, 257, 258). Based on this powerful 
technique and an examination of 1,589 partial or full-length sequences from 14 subjects infected 
with multiple genetically distinct T/F viruses, we failed to identify even one recombinant 
sequence. This stands in contrast to acute infection by genetically distinct genomes of HIV-1 
where most of the circulating HIV-1 sequences are recombinants by 6 weeks of infection (11, 
128, 154). This suggests that while HCV recombination is a theoretical concern (76, 269), it is 
exceedingly uncommon in the setting of acute and early infection. Altogether, the data reported 
here and previously (155, 238) reach the important conclusion that in most cases of acute HCV 
infection, discrete T/F viral genomes can be unambiguously identified and their early evolution 
mapped precisely. This permits the identification of viral genes and expressed proteins that are 
well suited for transmission and early replication. This in turn allows for comprehensive proteome-
wide mapping of selective changes on the evolving viral quasispecies resulting from innate or 
adaptive immune pressures or drug therapy, and it enables a genetic analysis of virus sieving that 
could result from prior vaccination with candidate immunogens (14). It further allows for an 
analysis of viral superinfection in the setting of pre-existing immunity to HCV. 
 Variation in T/F E1 and E2 envelope glycoproteins has been hypothesized to contribute 
to selective transmission of HCV viruses and the observed population bottleneck (30). Both E1 
and E2 are heavily glycosylated and these glycans are essential for appropriate protein folding 
(85) and receptor engagement (184). This glycosylation is highly conserved among published 
HCV sequences, (86) and plays a role in determining viral neutralization sensitivity (103). Brown 
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and colleagues recently reported an envelope signature pattern associated with HCV 
transmission in human hepatocyte engrafted immunocompromised mice. This motif consisted of 
four amino acid changes (198T, 448D, 474Y, 570D/A) including an ablated PNG site at position 
448 that distinguished transmitted viruses from the vast majority of viruses in the inoculum. This 
mutation further altered the entry phenotype of HCV pseudoparticles, consistent with the notion 
the altered PNG profile contributed to selective virus transmission (30). Our findings comparing 
51 HCV T/F genome sequences and their evolved progeny with chronic HCV sequences of the 
same genotype (1a) failed to confirm this signature of HCV transmission fitness in acutely 
infected humans (Figure 5.4). 
 Another region of the HCV genome that represents a target of the immune response is 
the poly(U/UC) tract of the 3’ UTR. The 3’ UTR is of importance because it plays a critical role in 
the viral life cycle (75, 340, 343) and is the principal pathogen-associated molecular pattern 
(PAMP) that stimulates the retinoic acid-inducible gene 1 (RIG-I)-dependent innate response to 
HCV RNA (256, 267). The HCV poly(U/UC) tract and X-tail is notably difficult to amplify and 
sequence as reported in the original descriptions of the HCV 3’ UTR (135, 136). It continues to be 
a challenge for generating full-length HCV sequences. In this study we found notable length 
variation in the poly(U/UC) tract even in the setting of acute infection. We thus examined the likely 
causes of this length variation. HCV RdRp is highly processive (16, 169), and thus it seemed 
likely that one of the steps in the in vitro synthesis or amplification of HCV cDNA was a more 
likely cause of poly(U) length variability observed. Not unexpectedly, we found that the MMLV RT 
was the principal source of poly(U) length variation (Figs. S5C and S5D). Retroviral RTs exhibit 
an "open" configuration that loosely wraps around the RNA/DNA hybrid permitting homologous 
recombination, an essential property of the viral life cycle (54, 157, 231). Template switching and 
slippage due to the RT has been well documented in homopolymer tracts (26, 101, 131). Taq 
polymerase also exhibits a relatively "open" configuration (158), allowing for slippage on 
homopolymer tracks, which we showed contributes part of the length variation that we observed. 
We found that introduction of as few as two tandem cytosine residues in a homopoly(U) tract of 
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40 nt in length could substantially anchor the RT and Taq polymerases and limit polymerase 
slippage. In turn, this likely accounts for the fidelity that we observed in poly(UC) sequences 
adjacent to homopoly(U) sequences. Given these findings (Figs. 3, S3, S4, S5), we concluded 
that the longer poly(U/UC) tracts that we observed were more likely to be reflective of T/F 
sequences in vivo than were shorter poly(U/UC) tracts. 
 For HIV-1, in addition to anchoring viral immunopathogenesis and vaccine studies to 
unambiguous T/F proteomes, the identification of T/F HIV-1 genomes has been an enabling 
strategy for elucidating unique biological properties of those viruses responsible for transmission 
and productive clinical infection. For HCV, we hypothesized that the same could be true. We thus 
attempted to launch the replication of T/F HCV genomes in the Huh 7.5 cells, which support the 
replication of JFH-1 and its derivatives but not other primary virus strains. We reasoned that T/F 
genomes, which reached high viral titers in humans in vivo within weeks of infection (Figure 5.1), 
might be better suited for replication in Huh 7.5 cells, which have defective RIG-I and TLR3-
mediated cell-intrinsic innate signaling pathways (156, 293), than were consensus clones derived 
from plasma of chronic infection HCV patients. Unfortunately, this was not the case. While JFH-1 
exhibited robust replication in Huh 7.5 cells (Figure 5.12), T/F genomes did not. 
  We obtained similar results with primary human fetal hepatoblasts and human embryonic 
derived differentiated liver cells: both supported robust replication of JFH-1 but not T/F genomes 
(unpublished data). This observation is consistent with previous reports for unadapted genomes 
from various genotypes (90, 221, 342) and suggests that the development of cell culture systems 
that more closely reflect the liver microenvironment or cell culture adaptation of T/F molecular 
clones may be required for their in vitro propagation (102, 182). In the meantime, the 
experimental strategy outlined here can be used to study the immunopathogenesis of HCV and 
structure-function properties of T/F HCV genes and their encoded proteins. Importantly, the 
approaches described in this study to characterize virus transmission can be extended to other 




Materials and Methods 
 Samples. All samples were obtained with informed consent and according to the 
Declaration of Helsinki. Acute samples were obtained from regular source plasma donors via 
Zeptometrix, Inc. and SeraCare Life Sciences, Inc. (Table 5.1, Table 5.2). Samples from 
chronically HCV-infected subjects were obtained from the University of Alabama at Birmingham 
Center for AIDS Research Network of Integrated Clinical Systems. In all cases vRNA load was 
determined by isolating total nucleic acid using the COBAS AmpliPrep TNAI Kit and COBAS 
Taqman HCV test v2.0 (Roche Diagnostics). This assay has a dynamic range of 43 - 6.9 x 107 
IU/mL. Samples obtained from Zeptometrix were also tested for anti-HCV antibody using the 
Murex Anti-HCV assay (Abbott Diagnostic Division) with positivity defined as a signal to cutoff 
ratio of >0.84. SeraCare samples were tested for anti-HCV antibodies with the HCV Ortho ELISA 
v3.0 assay (Ortho-Clinical Diagnostics) with positivity defined as a signal to cutoff ratio of >0.72. 
 Single genome amplification and sequencing of 5' half, 3' half, and poly-U/UC 
genome segments. Viral RNA was isolated from plasma using the Qiagen BioRobot EZ1 
Workstation and EZ1 Virus Mini Kit v2.0 (Qiagen). Eluted RNA isolated from plasma or 
synthesized and was subjected to reverse transcription with SuperScript III M-MLV reverse 
transcriptase (Life Technologies). RNA template was mixed with 0.25 µM antisense primer (Table 
5.4) and 0.5 mM of each dNTP and heated to 65°C for 5 minutes followed by icing for 1 minute. 1 
x SuperScript III buffer, 0.5 mM dithiotreitol, 2 units/µL RNaseOUT Recombinant Ribonuclease 
Inhibitor (Life Technologies), and 10 units/µL SuperScript III enzyme were added and the mixture 
incubated at 50°C for 75 minutes. The enzyme was heat inactivated for 15 minutes at 70°C. 0.1 
units/µL Ribonuclease H (Life technologies) was added and incubated for 20 minutes at 37°C 
followed by storage at -80°C. 
 cDNA was brought to limiting dilution in 96-well plates and subjected to nested or hemi-
nested PCR using the Platinum Taq DNA polymerase High Fidelity kit (Life Technologies). 20 µL 
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volumes were prepared containing diluted cDNA, 1 x Platinum Taq Buffer, 2mM Mg SO4, 0.2 mM 
of each dNTP, 0.2 µM forward and reverse primer for each respective segment (Table 5.4), and 
0.025 units/µL of Platinum Taq polymerase enzyme. These reactions were subjected to a first 
round of amplification with the following parameters: an initial cycle at 94°C for 2 minutes; 35 
cycles of denaturation at 94°C for 15 seconds, annealing at 58°C for 30 seconds, elongation at 
68°C for 5 minutes, 30 seconds; and a final extension step at 68°C for 10 minutes. Subsequently, 
1 µL of the product from the first round was transferred to a second round PCR reaction mixture 
containing the second round primers (Table 5.4). PCR conditions for the second round were 
identical to those of the first except that 45 cycles were performed. Following PCR, amplicons 
were run on 1% agarose TAE gels and amplicons containing the expected size were submitted 
for subsequent direct sequencing. PCR reactions were Sanger sequenced using the BigDye 
Direct Cycle Sequencing Kit (Applied Biosytems) and ABI 3730xl genetic analyzer (Applied 
Biosytems) as recommended by the manufacturers. 
 HCV 3’ poly-U/UC tracts were converted into cDNA using the same approach as 
described for the 5' and 3' half genomes with the only alteration being a necessary decrease in 
reverse transcription incubation temperature to 43°C. Following generation of cDNA, single 
genome amplification was performed identically as the procedure above except the PCR 
elongation step was shortened to 1 minute 15 seconds and the final elongation step to 3 minutes. 
Unlike the 5’ UTR, 5’ half genome, and 3’ half genome regions, poly-U/UC tract amplicons were 
subcloned using the pGEM-T Easy Vector System (Promega) as recommended by the 
manufacturer. Plasmid-containing colonies were expanded and their plasmid DNA purified using 
the QIAprep Miniprep Kit (Qiagen). These clones were submitted for sequencing using the M13F-
20 and M13R-20 primers (Table 5.4). 
 Single genome amplification of 5' UTR and 3' UTR structures. cDNA for 5’ UTR 
regions was generated using the FirstChoice RLM-RACE Kit (Life Technologies) largely as 
recommended by the manufacturers. The only alteration to the protocol was that Calf Intestine 
Alkaline Phosphatase treatment was not utilized. Briefly, template RNA was treated with Tobacco 
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Acid Pyrophosphatase at 37°C for 1 h followed by ligation of the 5’ RACE adaptor (Table 5.4) by 
T4 RNA ligase at 37°C for 1 hour. Reverse transcription was performed by incubating the ligated 
RNA at 42°C for 1 hour in the presence of M-MLV reverse transcriptase and random decamers 
as described in the manufacturer protocol. Following generation of cDNA, single genome 
amplification was performed identically as described above. The only change to the procedure 
was to decrease the PCR elongation step to 2 minutes and the final elongation step to 4 minutes. 
 The terminal 3’ UTR X-tail structure was isolated using 3’ RACE in a manner similar to as 
previously described (Kolokohva and Rice Xtail). vRNA samples were combined with 0.5 µM of 
the 5’ phosphated, 3’ dideoxynucleotide terminated  RNA or RNA-DNA hybrid molecules 
(Eurofins Genomics) in Table 5.4, 1 x RNA ligase buffer (New England Biolabs), 1 mM ATP, and 
0.4 units/µL of T4 RNA Ligase (New England Biolabs) and incubated at 37°C for 1 hour and 35 
minutes. Following this ligation step, cDNA synthesis was performed using the ligand-specific 
primers listed in Table 5.4 according the method described above. PCR amplification was 
performed identically except that the PCR elongation time was decreased to 1 minute, the final 
elongation step was decreased to 2 minutes, and amplicons were run on 2% agarose gels for 
quality analysis. Similar to the poly-U/UC tract, these amplicons were also subcloned prior to 
sequencing. 
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TABLE S3: Oligonucleotide primers used to amplify and sequence viral genome fragments. 
 
1a Reverse Transcription primers 
Oligonucleotide Sequence AF009606 
position 
5’ UTR Random Decamers NA 



























1a Amplification Primers 











5UTR-F1 GCTGATGGCGATGAAT NA 
5UTR-F2 GCTGGCTTTGATGAA NA 
1aU5UTR_R2 AAGATTCCCTGTTGCATAGTTCA R: 826!848 
1aU5UTR_R1 TACTCGAGTTAGGGCAATCATT R: 954!975 






1aCORE-F2-362 TCAAAGAAAAACCAAACGTAACACCAACCG F: 362"391 
1aNS4A-R1 GCACTCTTCCATCTCATCGAACTC R: 5451!5474 
1aNS3-R2v2 GGTGCTCGTGACGACCTCGAGGTC R: 5295!5318 






1aNS3.F2 CATCGTGGGACCAGATGTGGAAG F: 5146"5168 
1aNS5B.R1 TCATCGGTTGGGGAGGAGGTAGAT R: 9354!9377 







1aNTRF2 AATAGGGTGGCCGCATGCCTCAGAAAACTTG F: 9048"9078 
U3tailR3 CATGCGGCTCACGGACCTT R: 9587!9605 







1a3'raceF1 TTCTTCTTTAATGGTGGCTCCAT F: 9537"9559 
1a3'raceF2 TTAATGGTGGCTCCATCTTA F: 9544"9563 
3termi-R1 AGAGTCATGTCACTAGCGAGCACAGATGG NA 




























































1b Reverse Transcription Primers 
Oligonucleotide Sequence AF009606 
position 
5’ UTR Random Decamers NA 



























1b Amplification Primers 











5UTR-F1 GCTGATGGCGATGAAT NA 
5UTR-F2 GCTGGCTTTGATGAA NA 
1bU5UTR_R2 AGCGGAAACTGGGATGGTCAAACA R: 891!914 
1bU5UTR_R3 CAAACAGGACAGCAAAGCCAAAAG R: 873!896 






1bCORE-F2-362 TCAAAGAAAAACCAAACGTAACACCAACCG F: 362"391 
1bNS4A-R1 GCACTCTTCCATCTCATCGAACTC R: 5451!5474 
1bNS3-R2 GGTGCTCGTGACGACCTCCAGGTC R: 5295!5318 






1bNS3.F2 TCCTCGGTCCTGTGTGAGTGCTATGA  F: 4878"4899 
1bNS5B.R1 TCATCGATTGGGGAGCAGGTAGAT R: 9354!9377 







1bNTRF2 AATAGGGTGGCTTCATGCCTCAGAAAACTTG F: 9048"9078 
U3tailR3 CATGCGGCTCACGGACCTT R: 9587!9605 







1b3'raceF1 TTCTTCTTTGGTGGCTCCAT F: 9540"9559 
1b3'raceF2 TCTTTGGTGGCTCCATCTTA F: 9541"9563 
3termi-R1 AGAGTCATGTCACTAGCGAGCACAGATGG NA 






















































3a Reverse Transcription Primers 
Oligonucleotide Sequence AF009606 position 
5’ UTR Random Decamers NA 



























3a Amplification Primers 










5’RACE-F1 GCTGATGGCGATGAATGAACACTG NA 
5’RACE-F2 CGCGGATCCGAACACTGCGTTTGCTGGCTTTGATG NA 
3a5'-R1-841 GAGCAACCGGGCAAGTTC R: 842!859 
3a5'-R2-803 CCCGTCTTCAAGGGCCCTCAC R: 802!824 






3aCOR-F2-362 TCAAAGAAAAACCAAAAGAAACACCATCCG F: 362"391 
3aNS3-R2v2-5287 TTACTTCCAGATCAGCTGACA R: 5287!5307 






3aNS3-F2-4651 CTGACGCCCTCATGACTGGAT F: 4651"4671 







3aF8817 AACTCCTGGTTGGGCAACATCATCA F: 8790"8810 








XF9550-22 GTGGCTCCATCTTAGCCCTAGT Rev:9550"9571 
3’RACE-R1 GTCACAAGTAAGTAGCGGTAGTCG NA 





























































Table 5.4 Oligonucleotide primers used to amplify and sequence viral genome fragments. 
Primers used to generate cDNA, amplify genome fragments, and sequence partial or complete 
genomes are listed with the corresponding AF009606 location where applicable.
 
4a Reverse Transcription Primers 
Oligonucleotide 
 
Sequence AF009606 position 
5' UTR Random Decamers  



























4a Amplification Primers 
Oligonucleotide 
 









5’RACE-F1 GCTGATGGCGATGAATGAACACTG NA 
5’RACE-F2 CGCGGATCCGAACACTGCGTTTGCTGGCTTTGATG NA 
4aR4-2-732 GATGTATCCCATGAGGTCGGC R: 732!752 
4aR4-670 CCTCCGCCGGGGATCAT R: 670!686 






4aCOR-F2-362 TCAAAGAAAAACCAAACGTAACACCAACCG F: 362"391 
4aNS3-R2v2-5299 ACGTGCTCGTCACTACCTCGA R: 5299!5319 






4aNS3-F2-F4681 ACTTTGACTCAGTGATAGACTGCAA F: 4681"4707 







4aF9090 TTGAGAGCGTGGAGACATCG F: 9090"9109 








XF9550-22 GTGGCTCCATCTTAGCCCTAGT R: 9550"9571 
3’RACE-R1 GTCACAAGTAAGTAGCGGTAGTCG NA 





































 Sequence alignment and phylogenetic analysis. Sequences for each amplicon were 
assembled and assessed for quality with Sequencher 5.0 (Gene Codes). Each chromatogram 
was inspected to look for mixed templates. Sequences where multiple peaks or mixed bases 
were present were excluded from further analysis because they potentially reflected cases where 
multiple cDNA templates were present despite cDNA dilution. Sequence alignments were 
generated with Clustal W (308). These sequences were then manually checked and realigned 
where necessary using MacClade 4.08 (macclade.org). Percent identity values determined using 
Geneious v4.8.3 (Biomatters, Ltd.). Lineage diversity analysis was performed with the DIVEIN 
analysis suite (57). Maximum-likelihood phylogenetic trees were generated using PhyML (98) and 
visualized using FigTree v1.4.2 (tree.bio.ed.ac.uk/software/figtree/). The Highlighter sequence 
visualization tool (hcv.lanl.gov/content/sequence/HIGHLIGHT/highlighter.html) was also used to 
match overlapping partial-length HCV genome fragments by conserved polymorphisms in cases 
where multiple T/F lineages were observed in single patients. Recombination was additionally 
probed through the use of the GARD (137) and Recco (183) recombination identification tools. In 
the case of sequences from early time points that were used to generate the full T/F genomes, 
single T/F lineages were defined as phylogenetic clusters containing <1 mutations per 1,250 
bases, a 0.0008% difference, and containing shared polymorphisms in overlapping regions in 
cases where multiple T/Fs were present. This assessment is based on agent-based mathematical 
modeling of the viral life-cycle in the setting of acute infection that been described previously 
(155, 238). 
 Potential N-linked glycosylation site analysis. The E1 and E2 region of HCV from the 
full panel of chronic and T/F sequences were subjected to PNG analysis using the N-GlycoSite 
online tool (hcv.lanl.gov/content/sequence/GLYCOSITE/glycosite.html) with the AF009606 H77 
sequence as a reference (280). The frequency of glycosylation for each site was calculated for 
each subject and the difference between acute and chronic frequencies was assessed by multiple 
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Mann-Whitney tests and the Bonferroni method to account for multiple comparisons (P values 
<0.0026 were considered significant). 
 Poly(UC) tract similarity scoring analysis. Similarity scores for the poly(UC) or 
transitional region immediately 5’ of the conserved X-tail ‘GGTGG’ motif (corresponding to 
position 9504 to 9548 for AF009606) were generated using the EMBOSS Needleman-Wunsch 
pairwise sequence alignment tool (http://variome.bic.nus.edu.sg/cgi-bin/emboss/needleall/) with 
the DNAfull cost matrix. Polymerase-associated truncations due to polymerase slippage were 
described in this study as heavily concentrated in HCV homopoly(U) sequences and apparent 
homopoly(U) tract deletions were excluded from similarity score analyses. The HVR1 and 
CD81BD regions corresponding to AF009606 position 1,491 to 1,530 and 1,575 to 1,614, 
respectively, were analyzed using the same process. Percent similarity scores were natural log 
transformed. Differences in variation in either acute or chronic data sets were investigated using 
one-way analysis of variance (ANOVA). Differences in variation within the CD81 BDI, HVR1, and 
poly(UC) region between acute and chronic data sets were analyzed using independent t test 
comparisons. The Bonferroni method was used to account for multiple comparisons (P values 
<0.0083 were considered significant). In cases were homopoly(U) or poly(U/UC) tract lengths are 
compared based on percent scores, natural log transformation followed by two-tailed unpaired t 
tests were used for statistical analysis. 
 Molecular clone construction and RNA transcription. Fourteen molecular clones 
corresponding to seven separate transmitted founder viruses were chemically synthesized (Blue 
Heron Biotech) in four or five sequential fragments with a 5' T7 promoter, a 3' in vitro transcription 
run-off site, and terminal 5' and 3' restriction sites to facilitate cloning into the pBR322 or pCR-XL-
TOPO vectors (Figure 5.11). Plasmid DNA stock was grown in MAX Efficiency Stbl2 cells (Life 
Technologies) and DNA purified with the Purelink Maxiprep (Life Technologies) according to the 
manufacturer's specifications. Plasmids were linearized using the restriction enzymes described 
in Figure 5.11 (New England BioLabs) and phenol-chloroform purified. vRNA was transcribed 
using the T7 RiboMAX Express Large Scale RNA Production System (Promega) and purified 
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using the RNeasy Mini Kit (Qiagen). RNA quality was assessed by agarose gel electrophoresis 
and quantified with the Qubit Assay Kit (Life Technologies). 
 Cell culture, electroporation, and analysis for HCV protein expression. Cells were 
grown in DMEM media (Life Technologies) containing 10% Fetal Bovine Serum, 10mM HEPES 
buffer (Life Technologies), 200mM GlutaMAX I (Life Technologies), and 100 U/mL Penicillin/Strep 
solution (Life Technologies). 5ug of vRNA was electroporated into 3 million Huh-7.5 cells using an 
ECM 830 electroporator (Harvard Apparatus), BTX 0.2 cm cuvettes (Harvard Apparatus), and 
BTXpress Electro Solution (Harvard Apparatus). Instrument settings were 820V, Pulse length 99 
microseconds, 5 pulses, and an interval of 1.1 seconds. The MAVS-based NS3/4A reporter 
system was visualized on a DMRE fluorescence microscope (Leica Microscopy). Cells were 
prepared for flow cytometry 48 hours to 7 days after electroporation. Briefly, cells were trypsinized 
and fixed with 2% paraformaldehyde for 20 minutes at room temperature, then washed and 
permeabilized with 0.1% saponin-PBS. Cells were incubated for 1 hour with the anti-NS5A IgG2a 
antibody 9E10 at a 1:2,000 concentration in 3% FBS-0.1% saponin-PBS, washed, and stained 
with Goat Anti-mouse APC conjugated secondary antibody (Life Technologies) for 1 h. Flow 
cytometry performed using a FACSAria II (BD Biosciences) instrument and analyzed using 
FlowJo 10 (Tree Star, Inc.). Results were statistically assessed using one-way ANOVA with 
Bonferroni multiple comparison tests. 
 Statistical analysis. Statistics were performed using the SPSS software suite (IBM 
Corporation) and Prism 5.0d (GraphPad Software). For specific methods, see the respective 
explanations above. 
 Nucleotide sequence accession numbers. The GenBank/EMBL/DDBJ accession 
numbers for the full nucleotide sequences of the transmitted/founder viruses are as follows: 
subject 10021 is KM043272-KM043273; subject 10025, KM043272-KM043273; subject 10025, 
KM043274-KM043277; subject 110069, KM043278-KM043279; subject 9055, KM043280-
	  194	  
KM43281; subject 105431, KM043282-KM043284; subject 10051, KM043285; additional acute 
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CHAPTER 6: SUMMARY AND FUTURE DIRECTIONS 
 
 
Mark B. Stoddard 
 






The objectives of the previous studies were to describe early HCV transmission and evolution in 
humans using a molecular approach, to determine whether HCV diversification adhered 
sufficiently closely to the models of HIV-1 diversification to permit adaptation of these 
approaches, to use these approaches to identify and study T/F genes and genomes, and to 
generate molecular clones reflective of HCV full-length, unadapted T/F viruses for future studies. 
Chapter 2 describes how SGS was first applied to generate partial genome length fragments 
ranging from 2.5 to 5 kb in length. Phylogentic analysis revealed that 13 out of 17 subjects were 
infected with discrete lineages with mutations accumulating in a Poisson distribution and forming 
star-like phylogenies (Table 2.1). The range of T/Fs identified was from 1 to >30 and the median 
number of T/F viruses was 4 (Table 2.1). 4 out of 17 cases did not fit this description, violating the 
predicted Poisson distribution and the star-like phylogeny. One of these cases represented the 
transmission of a large number of viruses all of which carried mutations in the NS3 protease gene 
that confer high resistance to the recently developed protease inhibitors Boceprevir and 
Telaprevir. In the other three cases, the phylogenetic pattern resembles that seen in HIV-1 acute-
to-acute transmission. Chapter 2 also presents two models of early HCV diversification: (1) the 
HIV-1 model of stringent bottle-necking and early random diversification and (2) a refinement of 
the HIV-1 model that takes into account the long-lived nature of HCV replication complexes and 
host cells (Figure 2.3). The specific prediction made by the second model is that progeny of HCV 
transmitted viruses might be expected to have as many as 3-fold more stochastically shared 
mutations sequenced from patient plasma and therefore might be more likely to violate the model 
of star-like phylogeny. Whether acute-to-acute transmission patterns could be recapitulated, and 
whether cases of spontaneous violation of intra-lineage star-like phylogenies could be detected in 
paired transmission subjects was further addressed in chapter 4. This study demonstrated the 
proof-of-concept that HCV diversification did typically occur according to a pattern sufficiently 
similar to that observed in HIV-1 and SIV to suggest that identification of T/F genes was possible 
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and that potentially full-length genomes could be identified by extending and adapting this 
approach. 
In chapter 3 the sequencing data generated by experiments from chapter 2 were utilized to 
construct and validate a mathematical model that correlated several metrics of viral replication 
(specifically turnover of replication complexes, turnover of infected cells, the probability for viral 
RNA to be exported in a virion, the probability that this virion would then be either cleared or 
infect a new cell, the maximal number of infected cells, the fraction of lethal mutations, the time 
required for infected cells to begin producing virions, and the mutation rate of the viral RdRp in 
vivo). By using this mathematical approach to predict viral load kinetic curves and the numbers of 
mutations expected over time, and cross-checking these predictions against the actual viral 
kinetics (Figure 3.1) and the accumulation of mutations over time (Figure 3.2), new estimates for 
the mutation rate of HCV in vivo (2.1 to 5.9x10-5) and replication complex half-life (t1/2= 5 to 15 
days) could be made (Table 3.1, Figure 3.4). The predicted mutation rate was notably smaller 
than previously published predictions, but was further validated by applying the previously used 
methods to reach very similar estimates with the SGS-derived data set. 
In chapter 4, we empirically demonstrated that the model of random diversification of viral 
genomes is capable of correctly inferring transmitted HCV genomes. Furthermore, we 
recapitulated and characterized the violations of the star-like phylogeny described in chapter 2 
that occurred in ~25% of acute infection cases. Specifically, we showed that much of the 
phylogenetic complexity that responsible for these deviations from the star-like phylogeny could 
be recapitulated by the acute-to-acute transmission of a substantial viral inoculum to a new host 
(Figures 4.4 to 4.6). 
The experiments outlined in chapter 5 demonstrated that T/F analysis can be successfully 
extended to the entirety of the HCV genome to infer full-length T/F genomes (Figure 5.2). 
Diversification is largely random throughout the genome with the surprising exception of the 
poly(U/UC) region. This variation was largely introduced by reverse transcriptase during 
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experimentation (Figures 5.3, 5.9, 5.11) but this region was also found to be possibly be highly 
tolerant to variation and/or subjected to multiple selective forces since it is hypervariable in 
chronic infection sequences (Figures 5.3, 5.10). Molecular clones of the inferred full-length HCV 
genomes were synthesized. Consistent with previous efforts with clinical isolates or unadapted 
molecular clones (90, 221, 342), efforts to launch viral replication proved that these genomes did 
not replicate readily in the most important in vitro model, Huh7.5 hepatoma cells, and further 
efforts in fetal hepatoblasts and stem-cell derived hepatocyte-like cells did not yield a system 
where infectious virions could be generated. 
In summary, the work presented has revealed novel insights into the molecular basis of HCV 
transmission and early diversification; findings relevant to our understanding of HCV natural 
history, immunopathogenesis, treatment and prevention. At the same time, these findings and the 
techniques and reagents generated over the course of these studies, are enabling with respect to 
futures studies of HCV biology, therapeutic and vaccine development. The Future Directions 
section below describes some of this work that is already underway as well as other studies that 





 This dissertation work aimed to test the hypothesis that T/F HCV genomes – those 
genomes responsible for transmission and productive clinical infection – could be unambiguously 
identified by SGS and phylogenetic analysis within the context of a mathematical model of 
random diversification. The findings presented above, are strongly supportive of this hypothesis 
and by the empirical evidence presented in chapter 4. Additional research directions enabled by 
these T/F studies are described below. 
 Molecular characterization of the adaptive immune response to HCV. While the 
experiments outlined in chapters 2 to 5 describe early HCV evolution in the newly infected host, 
future work using SGS to follow viral evolution and diversification during and after the emergence 
of the adaptive immune system could illuminate mechanisms of viral immune evasion and 
persistence. This is analogous to studies in HIV-1, where viral evolution has been carefully 
studied to characterize the breadth and kinetics of selection in viral genomes and to investigate 
the driving selective pressures that shape this evolution (258). Importantly, the work described 
above describes how SGS studies might be performed for complete or partial genomes whereas 
previous studies have typically focused on evolution in relatively small regions, such as the 
hypervariable region of the HCV glycoproteins (67, 68). 
 Define the Early Innate and Cell-Intrinsic Responses to HCV T/F Genomes. T/F 
genomes and their immediate progeny are the first genomes to interact with host hepatocytes, 
liver endothelial cells, and immune cells such as plasmacytoid dendritic cells and monocytes. The 
experiments described in Chapter 5 showed that the primary PAMP associated with the RIG-I-
dependent innate response to HCV RNA (256) was either highly tolerant to the accumulation of 
multiple structures or highly susceptible to positive selection (or both) since it was hypervariable 
in chronic infection sequences (Figures 5.3, 5.10). The work described above also includes the 
generation of a panel of T/F virus clones representing genotypes 1, 3, and 4 with a range of 
poly(U/UC) tracts for use in studies of cell-intrinsic innate responses to HCV (Figure 5.12). Some 
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investigations based on these efforts are currently under way, or have recently been performed to 
study the immunopathological response to RNAs transcribed from these T/F clones. For example, 
Giugliano, et. al. (83) showed that liver sinusoidal endothelial cells, which are the cells most likely 
to initially take up and sense viral particles in the liver, responded in a robust fashion to RNA 
transcribed from these genomes. Specifically, these endothelial cells internalized the viral RNA 
and translated the genomic RNAs despite not supporting viral replication. This was followed by 
transcription of multiple IFNs and IFN-stimulated genes. Supernatants taken from sinusoidal 
endothelial cells inhibited the replication of the JFH-1 strain in Huh 7.5 cells and induced 
expression of antiviral genes in primary human hepatocytes. These results highlight the important 
role that liver endothelial cells may play in responding to in early HCV infection. 
 In another study by Mitchell and colleagues (192), significant differences in the potency 
and nature of the innate responses to RNAs generated from T/F molecular clones were detected 
in cultured hepatocyes and immortalized cell lines. Additionally, these were found to correlate 
with respect to the genotypes of the T/F genomes with genotype 3 RNAs stimulating an 
enhanced pro-inflammatory profile as compared to that of genotype 1 and 4 T/F RNAs. The cell-
intrinsic response to genotype 3 RNAs included enhanced expression of RIG-1, STAT1, and 
TLR3. Intriguingly, these findings may provide a mechanistic explanation for the unique clinical 
characteristics of genotype 3 infections including a higher rate of spontaneous clearance (152), 
and a strong association with accelerated cirrhosis and hepatocellular carcinoma (24, 89, 124, 
227). 
Development of In vitro Systems For Studying the Biological Properties of T/F Genomes. 
Experiments described in chapter 5 and depicted in Figure 5.6 show that T/F genomes are not 
capable of efficiently replicating in the most important and commonly used cell culture system 
available for HCV research (288). While generating a cell-culture system for studying HCV T/F 
genomes or genes represents a very significant challenge, it may also afford a unique opportunity 
to test genomes that are known to be replication competent in vivo. This is because the T/F 
genomes described here have been generated using SGS techniques that afford a higher degree 
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of precision than that possible using bulk-PCR based molecular cloning approaches (257). 
Therefore, it is possible to have a higher degree of confidence that they do indeed reflect the 
actual genomes of viruses and should contain all of the viral genetic components both necessary 
and sufficient for viral replication. Future studies can build on this by pursuing two major angles: 
(1) investigating viral adaptation in subgenomic replicon systems to the Huh 7.5 system, and (2) 
studying the cellular components required for supporting replication of unadapted subgenomic 
replicons and full-length molecular clones. 
The subgenomic replicon system was the first scientifically replicated, robust in vitro cell culture 
system available for the study of HCV (170). An important characteristic of this system is that 
selectable markers, including drug resistance or fluorescent proteins, may be added to the viral 
sequence to facilitate selection and detection of replication and that this is the case with even 
poorly adapted molecular clones (195). Previous efforts to generate full-length, replication 
competent, non-JFH1 molecular clones have relied on identifying multiple co-adaptive replication 
enhancing mutations (REMs) and testing different combinations in otherwise unadapted 
backbones. For example, a replication-competent adapted clone was generated for H77 by 
testing a variety of adaptive mutations and introducing five REMs into a single clone (341, 342). 
In order to apply this technique to T/F genomes, the nonstructural proteins would need to be 
transferred to a vector (preferably one that carries other functional HCV subgenomic replicons), a 
fluorescent protein (such as mCherry RFP protein) placed in-frame with NS5A (195), and an 
initial REM inserted into the genome. The S2204I mutation in the NS5A protein would be the 
most promising first REM to introduce since it has been shown to be co-synergistic with a number 
of other adaptive mutations in genotype 1a, 1b, and 3a systems (22, 94, 145, 146, 168, 341). 
After generating the molecular constructs, RNA would be synthesized and transfected into Huh 
7.5 cells. Cell sorting for fluorescent protein positive cells would permit the quantification and 
isolation of cells supporting replicons in a high-throughput manner. After culture in selective 
antibiotic (this would further purify for cells containing replicons), cells could be lysed, vRNA 
isolated, and sequencing for HCV genes performed via SGS. This study would permit the 
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identification of potentially large numbers of REMs for T/Fs for genotypes 1a, 3a, and 4a that 
could subsequently be introduced into full-length genomes in an effort to generate full-length, 
cell-culture adapted molecular clones. This approach would require a substantial dedication of 
time and effort and might not yield the desired result (this being to produce adapted T/F 
molecular clones capable of further adapting in cell culture) since multiple REMs would likely be 
required and they would need to be identified and tested in an empiric fashion. Another possible 
drawback of this approach would be that by definition it would involve altering the biological 
properties of T/F genomes. In essence, it would involve adding mutations that would either have 
no effect – or a paradoxically negative effect – on replication activity in vivo (31, 219, 255, 264). 
Therefore data generated using this approach arguably would not be generalizable to the 
behavior of actual T/F viruses in vivo. 
An alternative approach, that could have the additional strength of potentially generating a more 
broadly useful HCV cell culture system, would be to use the T/F molecular clones to identify 
cellular factors associated with supporting unadapted molecular clones or subgenomic replicons 
in vitro. In the past, interest in developing in vitro models for HCV has led to efforts to establish 
cell lines with increased permissivity to subgenomic replicons, JFH-1, or chimeric HCV molecular 
clones, and patient derived-isolates (198). A method commonly used to generate these cell lines 
has been to serially expand and passage cell populations, select cells that support HCV 
replicons, expand and cure these sublines with anti-viral inhibitors, and analyze these for 
enhanced support of JFH-1 replication. For example, several Huh 7 sublines including Huh 7.5, 
Huh 7.5.1, Huh 7-lunet, and Huh 7-lunet-57C have been established with this method (21, 23, 
138, 243, 346). Importantly, heterokaryon studies with Huh 7.5 cells demonstrated that replication 
blocks in human non-hepatic (eg. 293T, HeLa) and mouse hepatic (eg. Hep56.1D) cell lines are 
not due to dominant restriction factors (74); this suggests that host factors that enhance 
permissivity to HCV replication may play an important role. Future studies might apply this 
knowledge and leverage T/F molecular clones to study HCV replication-enhancing modification of 
Huh 7.5 cells via high-throughput targeted gene up-regulation or non-specific mutagenesis. 
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Indeed, an analogous approach has recently employed by Mohsan Saeed, Ph.D. and Charles 
Rice, Ph.D. to generate a Huh 7.5 derivative that is capable of efficiently supporting subgenomic 
replicons without detectable adaptation (M. Saeed, C. Rice, unpublished communication). This 
was achieved by constitutively expressing a membrane trafficking protein identified in a high-
throughput lentivirus-based gene up-regulation screen. While these cells do not appear to 
support full-length unadapted clones to the same degree as subgenomic replicons (M. Saeed, C. 
Rice, unpublished communication), this study nonetheless represents an important proof-of-
concept for future efforts to generate a system capable of supporting HCV T/F clones. 
A first step that would increase to odds for success would be to construct fluorescent protein 
expressing T/F subgenomic replicons as described above since these replicons would be more 
likely to persist in vitro and replication could be more easily measured. A lentivirus-based system 
similar to that described by Saeed and Rice could be one platform for up-regulating cellular 
factors. Lentiviral ORF expression libraries have been developed for this purpose (338) and are 
commercially available (59). Initial phenotypic testing would be performed by sorting for cells 
expressing markers (e.g. RFP) generated by the T/F subgenomic replicons and this would be 
followed by curing these cells with anti-viral DAAs and studying cells with the desired cellular 
phenotype(s). 
An alternative approach to using a lentiviral upregulation screen could be to use a mutagenesis 
screen such as the sleeping beauty (SB) transposon system (4). A non-specific mutagenesis 
screen could permit simultaneously screen for a large number of cellualr factors in very large 
batches of cells without having to generate and handle large numbers of lentiviral stocks. While 
simple knockout screening studies in Huh 7.5 cells would expect to be hampered by the diploid 
nature of these cells, the primary objective would be to randomly up-regulate cellular factors that 
might play a role in enhancing permissivity (74) while still maintaining the capacity for partially 
downregulation of other cellular factors (15, 56, 64). SB has several desirable properties relevant 
for non-specific mutagenesis studies in Huh 7.5 cells: it demonstrates near-random insertional 
selection (18), it may be titrated to control the expected number of insertions per cell in a 
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transfected population (91), it has been used to stably insert genes into Huh 7 cell lines 
previously (281), it has been used for both upregulation mutagenesis (281) and simultaneous up- 
and down-regulation mutagenesis studies in diploid cell mammalian systems (64), and integration 
site analysis could be used to investigate potential mechanisms of phenotypic alterations (18). 
Specific constructs that have desirable properties for mutagensis studies in Huh 7.5 cells include 
the T2/Onc2 (64) or GFP-TORE-SV40 (55) transposons along with the SB transposase SB100X 
(4). Phenotypic testing and further study of modified cells would be achieved in the same fashion 
as described above for the lentivirus screening method, with the caveat that determining the 
nature of the cellular alterations introduced by the transposon would also need to be achieved. 
In conclusion, the work presented in chapters 2 through 5 applied a novel molecular SGS 
approach to substantially enhance current understanding of HCV transmission and 
diversification. Future efforts should build on this work by further expanding our understanding of 
early HCV evolution, analyzing the innate or cell-intrinsic response to T/F genomes, and seeking 
to study the biological properties of T/F viruses by adapting either the viral genomes or the Huh 
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